Heterocyclic compounds as NRAS inhibitors

WO2024167922A3PCT designated stage expired Publication Date: 2024-11-14BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/014619
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-07
Filing Date
2024-02-06
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for RAS G12D-mediated diseases, particularly NRAS G12D-mediated diseases, have been limited in effectiveness due to challenges in targeting mutant RAS proteins, with existing therapies showing toxicity issues and limited impact on RAS-driven cancers.

Method used

Development of specific heterocyclic compounds, such as those described in Formulas I, II, III, and IV, which are designed to inhibit NRAS G12D function by directly targeting the mutant protein, offering a new approach for treating NRAS G12D-mediated diseases.

Benefits of technology

These compounds effectively inhibit NRAS G12D function, providing a potential therapeutic option for diseases driven by NRAS G12D mutations, such as cancer, by modulating the biochemical output and cell proliferation associated with NRAS G12D activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

Disclosed herein are compounds, and salts thereof, which inhibit targeted NRAS mutants, pharmaceutical formulations, and methods of treatment of NRAS-mediated diseases, such as certain cancers.
Need to check novelty before this filing date? Find Prior Art

Description

HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS

[0001] This application claims the benefit of priority of United States provisional application no.63 / 483,603, filed February 07, 2023, the contents of which are incorporated by reference as if written herein in their entirety.

[0002] RAS proteins serve a critical role in cell proliferation as they regulate signal transduction received from extracellular stimuli to downstream pathways such as MAPK, PI3K-AKT and Ral-GDS. These pathways are involved in cellular events such as cell cycle, cell differentiation and cell survival. Dysregulation in RAS signaling is most often associated with activating mutations in the RAS protein typically found at codons 12,13 and 61. Such activating mutations break down the cycling between active (GTP-bound) and inactive (GDP-bound) RAS leading to cancer.

[0003] Approximately 20% of all human cancers present with mutations in RAS proteins. KRAS mutations are responsible for 75% of these cases and are predominantly found in PDAC, colorectal cancer and adenocarcinoma, followed by NRAS (17%) in hematopoietic cancers and malignant melanoma and HRAS (7%) in head and neck squamous cell carcinomas and bladder tumors. NRAS mutant-driven acute myeloid leukemia (AML) accounts for 11–30% of all AML patients.44% of occurring mutation in AML is observed at codon 12 (NRAS G12D represents 30%) followed by codon 13 and 61. In contrast, in melanoma, NRAS mutations are predominantly observed at codon 61 and to a lesser extent at codons 12 and 13.

[0004] Targeting RAS mutant cancers has been historically challenging. After the initial failed attempts to prevent KRAS attachment and activation in the membrane by using farnesyl transferase inhibitors, focus has shifted to upstream and downstream targets in the RAS signaling pathway. Inhibition of RTKs (receptor tyrosine kinases), SHP2 and SOS, all found upstream of RAS, has shown limited impact on RAS driven cancers, while regulation of downstream proteins such as MEK, RAF and PI3K are often plagued by toxicity issues. However, it has been discovered that directly targeting the mutant RAS proteins offers new possibilities for inhibiting the main oncogene. The direct targeting of KRAS G12C mutant tumors has been demonstrated in the clinic to be an effective mode of treatment of NSCLC (non-small cell lung cancer), resulting in the FDA approval of sotorasib. Others have shown that KRAS G12D mutant cancers can also be targeted with non-covalent inhibitors, with the non-conserved KRAS residue H95 theorized to play a significant role in binding selectivity.

[0005] Despite the significant attention focused on targeting RAS mutants, there exists a need for compounds and methods for the treatment of RAS G12D-mediated diseases, specifically NRAS G12D-mediated diseases. The present disclosure fulfills these and other needs, as evident in reference to the following disclosure. SUMMARY

[0006] Provided is a compound of Formula I,or a salt thereof, wherein J1is chosen from N and CH; R1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl; A is chosen from -OCH2-, -OCH2CH2-, -OC(CH3)CH-, and a bond; X is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R4is chosen from H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, alkoxy, amino, - C(O)OR10, alkylthio, and halo, wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, alkoxy, amino, and alkylthio may be optionally substituted with one or more R5; each R5is independently chosen from alkyl, aryl, haloalkoxy, amino, alkyl sulfonyl, -C(O)OR10, heterocycloalkyl, hydroxyl, alkoxy, oxo, cyano, and halo; R6is chosen from H, alkyl, acyl, and heterocycloalkylalkyl; R7is chosen from alkyl, cycloalkyl, alkynyl, and cyano, wherein alkyl, cycloalkyl, and alkynyl may be optionally substituted with one or more R9;each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; each R9is independently chosen from alkyl, amino, alkyl sulfonyl, hydroxyl, alkoxy, and halo; R10is chosen from H and C1-6alkyl; and n is chosen from 0, 1, or 2.

[0007] Also provided is a compound of Formula II,or a salt thereof, wherein J1is chosen from N and CR6; J2is chosen from N and CR7; X is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R1is chosen from -OH, alkoxy, and amino; R2is alkyl; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl; R4is chosen from H, halo, alkyl, alkoxy, and benzyloxy; R5is chosen from H and halo; R6is chosen from H, cyano, halo, and alkyl; R7is chosen from H and halo; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; and n is chosen from 0, 1, or 2.

[0008] Also provided is a compound of Formula III,or a salt thereof, wherein J1is chosen from N and CCl; Z is chosen from benzothiophene, tetrahydrobenzothiophene, pyridinyl, benzoindazolyl, quinolinyl, and isoquinolinyl, any of which may be optionally substituted by one or more groups chosen from alkyl, alkynyl, amino, hydroxyl, cyano, haloalkyl, and halo; ORR1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl;A is chosen from -OCH2-, -OCH2CH2-, -OC(CH3)CH-, heterocycloalkyl, and a bond; X is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R4is chosen from H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, heteroaryloxy, alkoxy, amino, alkylamino, dialkylamino, -C(O)OR10, alkylthio, and halo, wherein alkyl,alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, heteroaryloxy, alkoxy, amino, and alkylthio may be optionally substituted with one or more R5; OR A, R4, and R7combine to form a 5- membered heterocycloalkyl optionally substituted with one or more R5; each R5is independently chosen from alkyl, cycloalkyl, aryl, haloalkoxy, haloalkenyl, amino, alkylamino, dialkylamino, hydroxyalkylamino, alkyl sulfonyl, - C(O)OR10, heterocycloalkyl, hydroxyl, alkoxy, oxo, cyano, and halo, or two R5may combine to form a cycloalkyl or heterocycloalkyl; R6is chosen from H, alkyl, acyl, and heterocycloalkylalkyl; R7is chosen from alkyl, cycloalkyl, alkynyl, halo, amino, and cyano, wherein alkyl, cycloalkyl, and alkynyl may be optionally substituted with one or more R9; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; each R9is independently chosen from deuterium, alkyl, amino, alkyl sulfonyl, hydroxyl, alkoxy, cyano, and halo; R10is chosen from H and C1-6alkyl; R11is halo; OR R7and R11may combine to form a 6-membered heterocycloalkyl; each R12is independently chosen from halo and alkynyl; n is chosen from 0, 1, and 2; and m is chosen from 1 and 2.

[0009] Also provided is a compound of Formula IV,or a salt thereof, wherein J1is chosen from N and CR6; J2is chosen from N and CR7; Q is chosenZ is chosen fromX is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R1is chosen from -OH, alkoxy, and amino; R2is alkyl; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl; R4is chosen from H, halo, alkyl, alkoxy, and benzyloxy; R5is chosen from H and halo; R6is chosen from H, cyano, halo, and alkyl; R7is chosen from H and halo; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; and n is chosen from 0, 1, or 2.

[0010] Also provided is a compound disclosed herein, or a pharmaceutically acceptable salt thereof.

[0011] Also provided is a pharmaceutical formulation comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

[0012] Also provided is a method for treating a disease or condition that benefits from or is treatable by inhibition of NRAS G12D, comprising the administration of a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

[0013] Also provided are methods of inhibiting at least one NRAS G12D function comprising the step of contacting NRAS G12D with a compound as described herein, or a pharmaceutically acceptable salt thereof. The cell phenotype, cell proliferation, activity of NRAS G12D, change in biochemical output produced by active NRAS G12D, expression of NRAS G12D, or binding of NRAS G12D with a natural binding partner may be monitored. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.

[0014] Also provided are methods of treatment of an NRAS G12D-mediated disease comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

[0015] Also provided is a method of inhibition of NRAS G12D comprising contacting NRAS G12D with a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0016] Also provided is a method of modulation of an NRAS G12D-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0017] These and other aspects of the invention will be apparent upon reference to the following detailed description. DETAILED DESCRIPTION

[0018] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

[0019] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.

[0020] Reference throughout this specification to “one embodiment” or “an embodiment” or “some embodiments” or “a certain embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” or “in some embodiments” or “in a certain embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0021] Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise.

[0022] When ranges of values are disclosed, and the notation “from n1 … to n2” or “between n1… and n2” is used, where n1and n2are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 µM (micromolar),” which is intended to include 1 µM, 3 µM, and everything in between to any number of significant figures (e.g., 1.255 µM, 2.1 µM, 2.9999 µM, etc.).

[0023] As used herein, “about” means ± 20% of the stated value, and includes more specifically values of ± 10%, ± 5%, ± 2% and ± 1% of the stated value.

[0024] The term “acyl,” as used herein, refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon. An “acetyl” group refers to a –C(O)CH3 group. An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group.

[0025] The term “alkenyl,” as used herein, refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In some embodiments, alkenyl will comprise from 2 to 6 carbon atoms. The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(-CH=CH-),(-C::C-)].

[0026] The term “alkoxy”, and, interchangeably, “(alkyl)oxy”, as used herein, refers to an alkyl radical attached to a molecule by oxygen.

[0027] The term “alkyl,” as used herein, refers to a straight-chain or branched-chain saturated, hydrocarbon radical containing from 1 to 20 carbon atoms. In some embodiments, alkyl will comprise from 1 to 10 carbon atoms. In some embodiments, alkyl will comprise from 1 to 8 carbon atoms.

[0028] The term “alkyl sulfonyl", as used herein, refers to a -S(O)2R group, wherein R is alkyl.

[0029] The term “alkylthio,” as used herein, refers to an alkyl thioether (R–S–) radical wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized.

[0030] The term “alkynyl,” as used herein, refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms

[0031] The terms “amido” and “carbamoyl,” as used herein, refer to an amino group as described below attached to the parent molecular moiety through a carbonyl group, or vice versa. The term “C-amido” as used herein, refers to a -C(O)N(RR’) group, wherein R and R’ are independently chosen from hydrogen, alkyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, . Additionally, R and R’ may combine with the amino nitrogen atom to form heterocycloalkyl. The term “N-amido” as used herein, refers to a RC(O)N(R’)- group, wherein R and R’ are independently chosen from hydrogen, alkyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, .

[0032] The term “amino,” as used herein, refers to -NRR’, wherein R and R’are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl. Additionally, R and R’ may combine with the amino nitrogen atom to form heterocycloalkyl.

[0033] The term "aryl," as used herein, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together.

[0034] The term “aryloxy,” as used herein, refers to an aryl group attached to the parent molecular moiety through an oxygen atom.

[0035] The term “carbonyl,” as used herein, is a -C(O)- group.

[0036] The term “cyano,” as used herein, refers to -CN.

[0037] The term “cycloalkoxy,” as used herein, refers to a cycloalkyl group attached to the parent molecular moiety through an oxygen atom.

[0038] The term “cycloalkyl,” or, alternatively, “carbocycle,” as used herein, refers to a saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members. In some embodiments, cycloalkyl will comprise from 5 to 7 carbon atoms. In some embodiments, cycloalkyl will comprise a spirocyclic ring system. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, as well as the multicyclic (multicentered) saturated type.

[0039] The term “halo,” or “halogen,” as used herein, refers to fluorine, chlorine, bromine, or iodine.

[0040] The term “haloalkoxy,” as used herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.

[0041] The term “haloalkyl,” as used herein, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.

[0042] The term "heteroaryl," as used herein, refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from N, O, and S. In some embodiments, heteroaryl will comprise from 1 to 4 heteroatoms as ring members. In some embodiments, heteroaryl will comprise from 1 to 2 heteroatoms as ring members. In some embodiments, heteroaryl will comprise from 5 to 7 atoms. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings wherein heteroaryl rings are fused with other heteroaryl rings wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings.

[0043] The term “heteroaryloxy,” as used herein, refers to an heteroaryl group attached to the parent molecular moiety through an oxygen atom.

[0044] The term “heterocycloalkoxy,” as used herein, refers to a heterocycloalkyl group attached to the parent molecular moiety through an oxygen atom.

[0045] The terms “heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, refers to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) monocyclic; saturated, partially unsaturated, or fully unsaturated (but not fully aromatic) bridged; saturated, partially unsaturated, or fully unsaturated (but not fully aromatic) bicyclic; or saturated, partially unsaturated, or fully unsaturated (but not fully aromatic) tricyclic heterocyclic group containing at least one heteroatom as a ring member wherein each heteroatom may be independently chosen from nitrogen, oxygen, and sulfur.

[0046] In some embodiments, heterocycloalkyl will comprise a spirocyclic ring system. In some embodiments, heterocycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In some embodiments, heterocycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In some embodiments, heterocycloalkyl will comprise from 3 to 8 ring members in each ring. In some embodiments, heterocycloalkyl will comprise from 3 to 7 ring members in each ring. In some embodiments, heterocycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzofused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl or heteroaryl group, as defined herein, or an additional heterocycle group.

[0047] The terms “hydroxy” and, interchangeably, “hydroxyl,” as used herein, refers to - OH.

[0048] The term “oxo,” as used herein, refers to =O.

[0049] The term “spirocyclic ring system” refers to a polycyclic ring system comprising two rings such that a single atom is common to both rings.

[0050] Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.

[0051] Asymmetric centers exist in the compounds and pharmaceutically acceptable salts thereof, disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1-isomers, and mixtures thereof. Individual stereoisomers of compounds, and pharmaceutically acceptable salts thereof, can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds, and pharmaceutically acceptable salts thereof, of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds, and pharmaceutically acceptable salts thereof, disclosed herein may exist as geometric isomers. The present disclosure includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof.

[0052] Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms.

[0053] The term “bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. A bondmay be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.

[0054] The term “chlorinating agent,” as used herein, refers to a compound or salt that adds a chlorine atom or atoms to an organic compound in a chemical reaction.

[0055] The term “dehydrating agent,” as used herein, refers to a compound, salt, catalyst, or combination thereof that effects the net loss of one or more molecules of water to an organic compound in a chemical reaction.

[0056] The term “alkylating agent”, as used herein, refers to a compound that effects the net addition of an alkyl group to an organic compound in a chemical reaction.

[0057] The term “oxidizing agent”, as used herein, refers to a compound that effects the oxidation of an organic compound in a chemical reaction (also known as an “oxidation reaction” or an “oxidation”).

[0058] The term “reducing agent”, as used herein, refers to a compound that effects the reduction of an organic compound in a chemical reaction (also known as an “reduction reaction” or a “reduction”).

[0059] As used herein, "administering to a patient" refers to the process of introducing a composition or dosage form into the patient via an art-recognized means of introduction.

[0060] The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

[0061] The term "combination therapy" means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

[0062] The phrase "therapeutically effective" is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint. The precise therapeutically effective amount for a subject may depend upon, e.g.,the subject’s size and health, the nature and extent of the condition, the therapeutics or combination of therapeutics selected for administration, and other variables known to those of skill in the art. The effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician.

[0063] As used herein, the term “treat,” “treating”, or “treatment” means the administration of therapy to an individual who already manifests at least one symptom of a disease or condition or who has previously manifested at least one symptom of a disease or condition. For example, “treating” can include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition. For example, the term “treating” in reference to a disorder means a reduction in severity of one or more symptoms associated with that particular disorder. Therefore, treating a disorder does not necessarily mean a reduction in severity of all symptoms associated with a disorder and does not necessarily mean a complete reduction in the severity of one or more symptoms associated with a disorder.

[0064] The term “patient” is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.

[0065] Those skilled in the art will appreciate that the invention(s) described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention(s) includes all such variations and modifications. The invention(s) also includes all the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of steps or features unless specifically stated otherwise.

[0066] The present invention(s) is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally equivalent products, compositions, and methods are clearly within the scope of the invention(s), as described herein.

[0067] It is appreciated that certain features of the invention(s), which are, for clarity, described in the context of separate embodiments, can also be provided in combination in asingle embodiment. Conversely, various features of the invention(s), which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

[0068] Provided is a compound of Formula I,or a salt thereof, wherein J1is chosen from N and CH; R1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl; A is chosen from -OCH2-, -OCH2CH2-, -OC(CH3)CH-, and a bond; X is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R4is chosen from H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, alkoxy, amino, - C(O)OR10, alkylthio, and halo, wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, alkoxy, amino, and alkylthio may be optionally substituted with one or more R5; each R5is independently chosen from alkyl, aryl, haloalkoxy, amino, alkyl sulfonyl, -C(O)OR10, heterocycloalkyl, hydroxyl, alkoxy, oxo, cyano, and halo; R6is chosen from H, alkyl, acyl, and heterocycloalkylalkyl; R7is chosen from alkyl, cycloalkyl, alkynyl, and cyano, wherein alkyl, cycloalkyl, and alkynyl may be optionally substituted with one or more R9; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH;each R9is independently chosen from alkyl, amino, alkyl sulfonyl, hydroxyl, alkoxy, and halo; R10is chosen from H and C1-6alkyl; and n is chosen from 0, 1, or 2.

[0069] Also provided is a compound of Formula III,or a salt thereof, wherein J1is chosen from N and CCl; Z is chosen from benzothiophene, tetrahydrobenzothiophene, pyridinyl, benzoindazolyl, quinolinyl, and isoquinolinyl, any of which may be optionally substituted by one or more groups chosen from alkyl, alkynyl, amino, hydroxyl, cyano, haloalkyl, and halo; ORR1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl;A is chosen from -OCH2-, -OCH2CH2-, -OC(CH3)CH-, heterocycloalkyl, and a bond;X is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R4is chosen from H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, heteroaryloxy, alkoxy, amino, alkylamino, dialkylamino, -C(O)OR10, alkylthio, and halo, wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, heteroaryloxy, alkoxy, amino, and alkylthio may be optionally substituted with one or more R5; OR A, R4, and R7combine to form a 5- membered heterocycloalkyl optionally substituted with one or more R5; each R5is independently chosen from alkyl, cycloalkyl, aryl, haloalkoxy, haloalkenyl, amino, alkylamino, dialkylamino, hydroxyalkylamino, alkyl sulfonyl, - C(O)OR10, heterocycloalkyl, hydroxyl, alkoxy, oxo, cyano, and halo, or two R5may combine to form a cycloalkyl or heterocycloalkyl; R6is chosen from H, alkyl, acyl, and heterocycloalkylalkyl; R7is chosen from alkyl, cycloalkyl, alkynyl, halo, amino, and cyano, wherein alkyl, cycloalkyl, and alkynyl may be optionally substituted with one or more R9; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; each R9is independently chosen from deuterium, alkyl, amino, alkyl sulfonyl, hydroxyl, alkoxy, cyano, and halo; R10is chosen from H and C1-6alkyl; R11is halo; OR R7and R11may combine to form a 6-membered heterocycloalkyl; each R12is independently chosen from halo and alkynyl; n is chosen from 0, 1, and 2; and m is chosen from 1 and 2.

[0070] In some embodiments, the compound has structural Formula I,salt thereof.

[0071] In some embodiments, J1is CH.

[0072] In some embodiments, J1is N.

[0073] In some embodiments, J1is CCl.

[0074] In some embodiments, Z is chosen from benzothiophene, tetrahydrobenzothiophene, pyridinyl, benzoindazolyl, and isoquinolinyl, any of which may be optionally substituted by one, two, or three groups chosen from alkyl, alkynyl, amino, hydroxyl, cyano, haloalkyl, and halo.

[0075] In some embodiments, Z is chosen from benzothiophene and tetrahydrobenzothiophene, either of which may be optionally substituted by two or three groups chosen from fluoro, cyano, and amino.

[0076] In some embodiments, Z is pyridinyl optionally substituted by two or three groups chosen from alkyl, haloalkyl, and amino.

[0077] In some embodiments, Z is isoquinolinyl optionally substituted by three groups chosen from fluoro, alkynyl, hydroxyl, and amino.

[0078] In some embodiments, Z is chosen from 2-amino-3-cyano-7- fluorobenzo[b]thiophene, 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophene, 1H- benzo[f]indazolyl, 3-amino-8-ethynyl-7-fluoroisoquinolinyl, 6-methyl-5-(trifluoromethyl)2- aminopyridinyl, 4-methyl-5-(trifluoromethyl)2-aminopyridinyl, and 5-(trifluoromethyl)2- aminopyridinyl. [

[0080] In some embodiments, R2is H.

[0081] In some embodiments, R2is fluoro.

[0082] In some embodiments, each R12is independently chosen from fluoro, bromo, and alkynyl.

[0083] In some embodiments, m is 1.

[0084] In some embodiments, m is 2.

[0085] In some embodiments, m is 3.

[0086] In some embodiments, Z is chosen from 5-ethynyl-6-fluoronaphthalen-2-ol, 5- ethynyl-8-fluoronaphthalen-2-ol, 5-ethynylnaphthalen-2-ol, 5-bromo-6-fluoronaphthalen-2- ol, 5-bromonaphthalen-2-ol, and 2-amino-3-fluoronaphthalenyl.

[0087] In some embodiments, R3is H.

[0088] In some embodiments, R3is OCH3.

[0089] In some embodiments, J1is N, R2is H, and R3is H.

[0090] In some embodiments, R6is chosen from H and oxetanylmethyl.

[0091] In some embodiments, R6is H.

[0092] In some embodiments, A is -OCH2-.

[0093] In some embodiments, A is -OCH2CH2-.

[0094] In some embodiments, A is -OC(CH3)CH-.

[0095] In some embodiments, A is a bond.

[0096] In some embodiments, R4is chosen from H, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkoxy, 5- to 7-membered heteroaryl, cyano, fluoro, chloro, - C(O)OCH3, C1-5alkyl, C3-7cycloalkoxy, C-amido, N-amido, and C3-7cycloalkyl, wherein 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkoxy, 5- to 7-membered heteroaryl, C1-5alkyl, C3-7cycloalkoxy, C-amido, N-amido, and C3-7cycloalkyl may be substituted by one, two, or three R5.

[0097] In some embodiments, R4is chosen from H, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkoxy, 5- to 7-membered heteroaryl, cyano, fluoro, chloro, - C(O)OCH3, C1-5 alkyl, C2-6 alkynyl, C3-7 cycloalkoxy, C-amido, N-amido, and C3-7 cycloalkyl, wherein 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkoxy, 5- to 7-membered heteroaryl, C1-5 alkyl, C3-7 cycloalkoxy, C-amido, N- amido, and C3-7cycloalkyl may be optionally substituted by one, two, or three R5.

[0098] In some embodiments, R4is chosen from H, chloro, cyano, oxetanyl, and oxazolyl, wherein oxetanyl and oxazolyl may be optionally substituted by one or two R5.

[0099] In some embodiments, R4is chosen from H, methyl, propyl, butyl, isobutyl, isopentyl, chloro, cyano, cyclopropyl, cyclobutyl, ethynyl, azetidinyl, pyrrolidinyl, pyrrolyl,tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, pyridinyl, oxetanyl, and oxazolyl, wherein methyl, propyl, isopropyl, butyl, isobutyl, isopentyl, cyclopropyl, cyclobutyl, ethynyl, azetidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, imidazolyl, piperazinyl, piperidinyl, pyridinyl, oxetanyl and oxazolyl, any of which may be optionally substituted by one, two, or three R5.

[0100] In some embodiments, R4isoptionally substituted by one, two, or three R5.

[0101] In some embodiments, A, R4, and R7form a 5-membered heterocycloalkyl chosen from dihydropyrrole, dihydrofuran, either of which may be optionally substituted by one, two, or three R5.

[0102] In some embodiments, R5is chosen from methyl, phenyl, -NH2, -C(O)OCH3, cyano, trifluoroalkoxy, dimethylamino, morpholinyl, and fluoro.

[0103] In some embodiments, each R5is independently chosen from methyl, phenyl, pyridinyl, -NH2, -C(O)OCH3, -C(O)OCH2CH3, cyano, trifluoroalkoxy, fluoromethylene, dimethylamino, morpholinyl, oxo, hydroxyl, and fluoro, or two R5may combine to form cyclopropyl, oxetanyl, or 2-azaspiro[3.3]heptanyl.

[0104] In some embodiments, R7is chosen from C1-5alkyl, C3-7cycloalkyl, cyano, and alkynyl, wherein C1-5alkyl, C3-7cycloalkyl, and alkynyl may be optionally substituted by one or more R9.

[0105] In some embodiments, R7is chosen from C1-5alkyl, C3-7cycloalkyl, cyano, halo, amino, and C2-6 alkynyl, wherein C1-5 alkyl, C3-7 cycloalkyl, and C2-6 alkynyl may be optionally substituted by one, two, or three R9.

[0106] In some embodiments, R7is methyl, optionally substituted by one, two, or three R9.

[0107] In some embodiments, R7is methyl.

[0108] In some embodiments, R7is cyano.

[0109] In some embodiments, R7is cyclopropyl, optionally substituted by one or two R9.

[0110] In some embodiments, R7is alkynyl, optionally substituted by one R9.

[0111] In some embodiments, R7is ethynyl, optionally substituted by one R9.

[0112] In some embodiments, each R9is independently chosen from deuterium, hydroxyl and fluoro.

[0113] In some embodiments, R7is chosen from chloro, bromo, and iodo.

[0114] In some embodiments, R11is fluoro.

[0115] In some embodiments, R7and R11combine to form a pyran.

[0116] In some embodiments, n is 1.

[0117] In some embodiments, R8is hydroxyl.

[0118] In some embodiments, R8is methyl.

[0119] In some embodiments, R8is fluoro.

[0120] In some embodiments, R8is cyano.

[0121] In some embodiments, R8is -CH2OH.

[0122] In some embodiments, X is -CH2CH2-.

[0123] In some embodiments, X is -CH=CH-.

[0124] In some embodiments, X is -CH2-O-CH2-.

[0125] In some embodiments, Q is chosen from,

[0126] In some embodiments,

[0127] In some embodiments,

[0128] In some embodiments, R1is NH2.

[0129] In some embodiments, R10is H.

[0130] In some embodiments, R10is methyl.

[0131] In some embodiments, the compound is chosen fromH;[or a salt thereof, wherein J1is chosen from N and CR6; J2is chosen from N and CR7; X is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R1is chosen from -OH, alkoxy, and amino; R2is alkyl; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl; R4is chosen from H, halo, alkyl, alkoxy, and benzyloxy; R5is chosen from H and halo; R6is chosen from H, cyano, halo, and alkyl;R7is chosen from H and halo; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; and n is chosen from 0, 1, or 2.

[0133] Also provided is a compound of Formula IV,or a salt thereof, wherein J1is chosen from N and CR6; J2is chosen from N and CR7; Q is chosen fromZ is chosen fromX is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8; R1is chosen from -OH, alkoxy, and amino; R2is alkyl; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl; R4is chosen from H, halo, alkyl, alkoxy, and benzyloxy; R5is chosen from H and halo; R6is chosen from H, cyano, halo, and alkyl; R7is chosen from H and halo; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; andn is chosen from 0, 1, or 2.

[0134] In some embodiments, the compound has structural Formula II,salt thereof.

[0135] In some embodiments, J1is N.

[0136] In some embodiments, J1is CR6.

[0137] In some embodiments, R6is chosen from H, cyano, chloro, and methyl.

[0138] In some embodiments, R6is H.

[0139] In some embodiments, J2is N.

[0140] In some embodiments, J2is CR7.

[0141] In some embodiments, R7is chosen from H, fluoro, and bromo.

[0142] In some embodiments, Z is .

[0143] In some embodiments, R1is chosen from -OH, methoxy, and -NH2.

[0144] In some embodiments, R1is -OH.

[0145] In some embodiments, R2is methyl.

[0146] In some embodiments, R2is ethyl.

[0147] In some embodiments, R3is chosen from H, C3-6cycloalkoxy, C1-4alkoxy, methyl, chloro, and fluoro.

[0148] In some embodiments, R3is chosen from H, cyclobutoxy, cyclopropoxy, cyclopentoxy, methoxy, ethoxy, isopropoxy, isopropylthio, phenoxy, pyridinyloxy, trifluoromethoxy, methyl sulfonyl, methyl, chloro, and fluoro.

[0149] In some embodiments, R3is H.

[0150] In some embodiments, R4is chosen from H and fluoro.

[0151] In some embodiments, R5is chosen from H and fluoro.

[0152] In some embodiments, n is 0.[ [.

[0155] The compounds disclosed herein can exist as pharmaceutically acceptable salts. The present disclosure includes compounds listed herein in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non- pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).

[0156] The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate,pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present disclosure contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.

[0157] Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N'-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

[0158] While it may be possible for the compounds, and pharmaceutically acceptable salts thereof, of the subject disclosure to be administered as the raw chemical, it is also possible to present them as a pharmaceutical formulation.

[0159] Also provided is a pharmaceutical formulation comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound, or pharmaceutically acceptable salts thereof, of the subject disclosure or a pharmaceutically acceptable salt thereof ("active ingredient") with the carrier which constitutes one or moreaccessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

[0160] Preferred unit dosage formulations are those containing an effective dose, or an appropriate fraction thereof, of the active ingredient.

[0161] Compounds, or pharmaceutically acceptable salts thereof, may be administered at a dose of from 0.1 to 500 mg / kg per day. The dose range for adult humans is generally from 5 mg to 2 g / day. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

[0162] The compounds, or pharmaceutically acceptable salts thereof, can be administered in various modes. In some embodiments, the pharmaceutical formulation is formulated for oral administration.

[0163] In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the compounds herein, or pharmaceutically acceptable salt thereof, is hypertension, then it may be appropriate to administer an anti- hypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein, or pharmaceutically acceptable salts thereof, may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit of experienced by a patient may be increased by administering one of the compounds described herein, or pharmaceutically acceptable salts thereof, with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.

[0164] In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein, or a pharmaceutically acceptable salt thereof) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multipledoses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.

[0165] Also provided is a method for treating a disease or condition that benefits from or is treatable by inhibition of NRAS G12D, comprising the administration of a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

[0166] Also provided are methods of inhibiting at least one NRAS G12D function comprising the step of contacting NRAS G12D with a compound as described herein, or a pharmaceutically acceptable salt thereof. The cell phenotype, cell proliferation, activity of NRAS G12D, change in biochemical output produced by active NRAS G12D, expression of NRAS G12D, or binding of NRAS G12D with a natural binding partner may be monitored. Such methods may be modes of treatment of disease, biological assays, cellular assays, biochemical assays, or the like.

[0167] Also provided are methods of treatment of an NRAS G12D-mediated disease comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

[0168] Also provided is a method of inhibition of NRAS G12D comprising contacting NRAS G12D with a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0169] Also provided is a method of modulation of an NRAS G12D-mediated function in a subject comprising the administration of a therapeutically effective amount of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof.

[0170] In some embodiments, the NRAS G12D-mediated disease is cancer.

[0171] In some embodiments, the cancer is chosen from Melanoma, Malignant Solid Tumors, Colorectal Carcinoma, Non-Small Cell Lung Carcinoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Colorectal Adenocarcinoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Pancreatic Carcinoma, Cutaneous Melanoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Acute Lymphoblastic Leukemia, Thyroid Gland Carcinoma, Glioma, Neurofibromatosis, Poorly Differentiated Thyroid Gland Carcinoma, Myelodysplastic Syndrome With Excess Blasts, Juvenile Myelomonocytic Leukemia, Histiocytic And Dendritic Cell Neoplasm, Head And Neck Squamous Cell Carcinoma, Small Cell Lung Carcinoma, Low Grade Glioma, Squamous Cell Lung Carcinoma, Breast Carcinoma, Chronic Myelomonocytic Leukemia, Thyroid Gland Undifferentiated (Anaplastic) Carcinoma, Embryonal Rhabdomyosarcoma,Thyroid Gland Follicular Carcinoma, T-Cell Acute Lymphoblastic Leukemia, Mucosal Melanoma, Low Grade Ovarian Serous Adenocarcinoma, Thyroid Gland Papillary Carcinoma, Refractory Anemia With Excess Blasts, Myeloid Neoplasm, Myelodysplastic / Myeloproliferative Neoplasm, Rectal Carcinoma, Colon Carcinoma, Malignant Peripheral Nerve Sheath Tumor, Cholangiocarcinoma, Endometrial Carcinoma, Mantle Cell Lymphoma, Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome, Lymphoma, Neuronal And Mixed Neuronal-Glial Tumors, Ganglioglioma, Soft Tissue Sarcoma, Bladder Carcinoma, Esophageal Carcinoma, Sarcoma, Thymic Carcinoma, Lung Adenocarcinoma, Lung Carcinoma, Uveal Melanoma, Head And Neck Carcinoma, Diffuse Glioma, Squamous Cell Carcinoma, Chronic Myeloid Leukemia, Adenocarcinoma of the Gastroesophageal Junction, Glioblastoma, Neuroblastoma, Astrocytic Tumor, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Anaplastic Astrocytoma, Gastric Adenocarcinoma, Gastric Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, B-Cell Acute Lymphoblastic Leukemia, Double-Hit Lymphoma, Dysembryoplastic Neuroepithelial Tumor, Gangliocytoma, Low-Grade Neuroepithelial Tumor, Peripheral T-Cell Lymphoma, Pilocytic Astrocytoma, Pilomyxoid Astrocytoma, Rhabdoid Tumor, and Schwannoma.

[0172] Further embodiments include the embodiments disclosed in the following Schemes, which are not to be construed as limiting in any way. SCHEMES Scheme I

[0173] Referring to Scheme I, Step 1, to a solution of the compound of Formula 101 (Y = halogen) in a polar aprotic solvent, such as dimethylformamide, is added tert-butyl 2- cyanoacetate, a base, such as cesium carbonate, and a compound of R7-I. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1–5 h. The product, a compound of Formula 102, is isolated and purified using methods known in the art.

[0174] Referring to Scheme I, Step 2, to a solution of the compound of Formula 102 in an organic solvent, such as toluene, is added a strong acid, such as p-toluenesulfonic acid. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred between 2–4 h. The product, a compound of Formula 103, is isolated and purified using methods known in the art.

[0175] Referring to Scheme I, Step 3, to a solution of the compound of Formula 103 in a polar solvent, such as acetonitrile, is added a dehydrating agent, such as POCl3. The resulting mixture is stirred, optionally under elevated temperatures and pressures. In someembodiments, the mixture is stirred for 12–24 h. The product, a compound of Formula 104, is isolated and purified using methods known in the art.

[0176] Referring to Scheme I, Step 4, to a solution of the compound of Formula 104 in an organic solvent, such as methylene chloride, is added an oxidizing agent, such as a complex of urea and hydrogen peroxide. The mixture is stirred, optionally at ambient temperature. In some embodiments, the mixture is stirred for 2–4 h. The product is filtered and concentrated, then added to an organic solvent, such as a mixture of THF and dimethylformamide, along with an acid anhydride, such as trifluoroacetic acid anhydride. The mixture is stirred, optionally at ambient temperatures. In some embodiments, the mixture is stirred for 1–2 h. The product is isolated and purified using methods known in the art, then suspended in an organic solvent, such as chloroform, along with a strong base, such as silver carbonate, and an alkylating agent, such as methyl iodide. The mixture is stirred, optionally at ambient temperature. In some embodiments, the mixture is stirred for 2–4 h, then heated and stirred for an additional 12–18 h. The product, a compound of Formula 105, is isolated and purified using methods known in the art. If R3is H, Step 4 is omitted and the compound of Formula 104 is a compound of Formula 105.

[0177] Referring to Scheme I, Step 5, to a solution of a compound of Formula 105 in a polar solvent, such as dioxane, is added a non-nucleophilic base, such as diisopropylethylamine, and a compound of Formula 106. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1–3 h. The product, a compound of Formula 107, is isolated and purified using methods known in the art.

[0178] Referring to Scheme I, Step 6, to a solution of a compound of Formula 107 in a polar solvent, such as a mixture of THF and water, is added a base, such as potassium phosphate, a compound of Formula 108 (PG = protecting group, such as triisopropylsilyl; and R = alkyl, such as methyl, or hydrogen, or in combination with a second R group forms a heterocycloalkyl, such as pinacol borane), and a metal catalyst, such as XPhos Pd G4. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1–2 h. The product, a compound of Formula 109, is isolated and purified using methods known in the art.

[0179] Referring to Scheme I, Step 7, to a solution of a compound of Formula 109 in a polar aprotic solvent, such as dimethylformamide, is added a metal catalyst and a compound of X-A-R4, wherein X is any functionality capable of facilitating a metal-catalyzed cross- coupling, such as halogen or pinacol borane. The mixture is stirred, optionally at elevated temperature. In some embodiments, the mixture is stirred for 1–24 h. The product is isolatedand purified using methods known in the art, then subjected to any set of deprotection conditions known in the art. The product, a compound of Formula I, is isolated and purified using methods known in the art. Individual enantiomers can be separated by using methods known in the art, such as chiral chromatography. Scheme II

[0180] Referring to Scheme II, Steps 1–2, to a solution of diisopropylamine in a polar aprotic solvent, such as THF, in an inert atmosphere is added a strong base, such as n- butyllithium. A compound of Formula 201 (each X is independently chosen from halogen or hydrogen) is added and the mixture is stirred, optionally at low temperatures, such as -78°C.In some embodiments, the mixture is stirred for 0.5–1 h. The product is isolated and purified, then subjected to any Boc-deprotection conditions known in the art, such as HCl in dioxane. The product, a compound of Formula 202, is isolated and purified using methods known in the art.

[0181] Referring to Scheme II, Steps 3–4, the compound of Formula 202 is stirred in a chlorinating reagent, such as SOCl2. In some embodiments, the mixture is stirred for 2–4 h. The mixture is concentrated, then dissolved in a polar solvent, such as acetone, and added to a solution of NH4SCN in the same polar solvent. The resulting mixture is stirred for between 1–2 h at room temperature. The product is isolated, then methylated using any conditions known in the art, such as methyl iodide and sodium hydroxide in methanol. The product, a compound of Formula 203, is isolated and purified using methods known in the art.

[0182] Referring to Scheme II, Step 5, to a solution of the compound of Formula 203 in a polar aprotic solvent, such as dimethylacetamide, is added a compound of formula R3-M, wherein M is a metal. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 0.5–2 h. The product, a compound of Formula 204, is isolated and purified using methods known in the art.

[0183] Referring to Scheme II, Step 6, to a solution of the compound of Formula 204 in a polar aprotic solvent, such as acetonitrile, is added a dehydrating agent, such as POCl3, and a base, such as diisopropylethylamine. The resulting mixture is stirred, optionally under elevated temperatures. In some embodiments, the mixture is stirred under elevated temperatures for 1–2 h, then cooled. A compound of Formula 205 is added and stirred at ambient temperature for an additional 1–2 h. The product, a compound of Formula 206, is isolated and purified using methods known in the art.

[0184] Referring to Scheme II, Step 7, to a solution of a compound of Formula 206 in a polar solvent, such as a mixture of THF and water, is added a base, such as potassium phosphate, a compound of Formula 207 (PG = protecting group, such as triisopropylsilyl; and R = alkyl, such as methyl, or hydrogen, or in combination with a second R group forms a heterocycloalkyl, such as pinacol borane), and a metal catalyst, such as cataCXium® A Pd G4. The mixture is stirred, optionally at elevated temperature. In some embodiments, the mixture is stirred for 16–24 h. The product, a compound of Formula 208, is isolated and purified using methods known in the art.

[0185] Referring to Scheme II, Step 8, to a solution of the compound of Formula 208 in an organic solvent, such as methylene chloride, is added meta-chloroperoxybenzoic acid. The resulting mixture is stirred at ambient temperature. In some embodiments, the mixture isstirred for 1–2 h. The product, a compound of Formula 209, is isolated and purified using methods known in the art.

[0186] Referring to Scheme II, Step 9, to a solution of the compound of Formula 209 in a polar aprotic solvent, such as THF, is added a reducing agent, such as lithium bis(trimethylsilyl)amide. The mixture is stirred, optionally at a lowered temperature, such as 0°C. In some embodiments, the mixture is stirred for 0.5–1 h. The product, a compound of Formula 210, is isolated and purified using methods known in the art.

[0187] Referring to Scheme II, Step 10, to a solution of the compound of Formula 210 in a polar aprotic solvent, such as dimethylformamide, is added a base, such as cesium carbonate, and an alkylating agent, such as methyl iodide. The mixture is stirred at ambient temperature. In some embodiments, the mixture is stirred for 1–2 h. The product, a compound of Formula 211, is isolated and purified using methods known in the art.

[0188] Referring to Scheme II, Step 11, the compound of Formula 211 is treated using any method or methods of removing protecting groups known in the art. The final product, a compound of Formula II, is isolated and purified using methods known in the art. Individual enantiomers can be separated by using methods known in the art, such as chiral chromatography.

[0189] Referring to Scheme III, Step 1, to a solution of a compound of Formula 301 in a polar solvent, such as dioxane, is added a non-nucleophilic base, such as diisopropylethylamine, and a compound of Formula 302. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1–3 h. The product, a compound of Formula 303, is isolated and purified using methods known in the art.

[0190] Referring to Scheme III, Step 2, to a solution of a compound of Formula 303 in a polar solvent, such as a mixture of THF and water, is added a base, such as potassium phosphate, a compound of Formula 304 (R = alkyl, such as methyl, or hydrogen, or in combination with a second R group forms a heterocycloalkyl, such as pinacol borane), and a metal catalyst, such as XPhos Pd G4. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1–2 h. The product, a compound of Formula 305, is isolated and purified using methods known in the art.

[0191] Referring to Scheme III, Step 3, to a solution of a compound of Formula 305 in a polar aprotic solvent, such as dimethylformamide, is added a metal catalyst and a compound of X-A-R4, wherein X is any functionality capable of facilitating a metal-catalyzed cross- coupling, such as halogen or pinacol borane. The mixture is stirred, optionally at elevated temperature. In some embodiments, the mixture is stirred for 1–24 h. The product, a compound of Formula III, is isolated and purified using methods known in the art. Individual enantiomers can be separated by using methods known in the art, such as chiral chromatography. Scheme IV

[0192] Referring to Scheme IV, Step 1, to a solution of the compound of Formula 401 (Y = halogen) in a polar aprotic solvent, such as acetonitrile, is added a dehydrating agent, such as POCl3, and a base, such as diisopropylethylamine. The resulting mixture is stirred,optionally under elevated temperatures. In some embodiments, the mixture is stirred under elevated temperatures for 1–2 h, then cooled. A compound of Formula 402 is added and stirred at ambient temperature for an additional 1–2 h. The product, a compound of Formula 403, is isolated and purified using methods known in the art.

[0193] Referring to Scheme IV, Step 2, to a solution of a compound of Formula 403 in a polar solvent, such as a mixture of THF and water, is added a base, such as potassium phosphate, a compound of Formula 404 (R = alkyl, such as methyl, or hydrogen, or in combination with a second R group forms a heterocycloalkyl, such as pinacol borane), and a metal catalyst, such as cataCXium® A Pd G4. The mixture is stirred, optionally at elevated temperature. In some embodiments, the mixture is stirred for 16–24 h. The product, a compound of Formula 405, is isolated and purified using methods known in the art.

[0194] Referring to Scheme IV, Step 3, to a solution of the compound of Formula 405 in an organic solvent, such as methylene chloride, is added meta-chloroperoxybenzoic acid. The resulting mixture is stirred at ambient temperature. In some embodiments, the mixture is stirred for 1–2 h. The product, a compound of Formula 406, is isolated and purified using methods known in the art.

[0195] Referring to Scheme IV, Step 4, to a solution of the compound of Formula 406 in a polar aprotic solvent, such as THF, is added a reducing agent, such as lithium bis(trimethylsilyl)amide. The mixture is stirred, optionally at a lowered temperature, such as 0°C. In some embodiments, the mixture is stirred for 0.5–1 h. The product, a compound of Formula 407, is isolated and purified using methods known in the art.

[0196] Referring to Scheme IV, Step 5, to a solution of the compound of Formula 407 in a polar aprotic solvent, such as dimethylformamide, is added a base, such as cesium carbonate, and an alkylating agent, such as methyl iodide. The mixture is stirred at ambient temperature. In some embodiments, the mixture is stirred for 1–2 h. The product, a compound of Formula IV, is isolated and purified using methods known in the art. Individual enantiomers can be separated by using methods known in the art, such as chiral chromatography. Scheme V505 Formula III

[0197] Referring to Scheme V, Step 1, to a solution of a compound of Formula 501 and a compound of Formula 502 in a polar solvent, such as methanol, is added a Lewis acid, such as cesium acetate, and a rhodium catalyst, such as pentamethylcyclopentadienyl rhodium(III) chloride. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 16–24 h. The product, a compound of Formula 503, is isolated and purified using methods known in the art.

[0198] Referring to Scheme V, Step 2, to a solution of a compound of Formula 503 in a polar solvent, such as dioxane, is added a non-nucleophilic base, such as diisopropylethylamine, and a compound of Formula 504. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1–3 h. The product, a compound of Formula 505, is isolated and purified using methods known in the art.

[0199] Referring to Scheme V, Step 3, to a solution of a compound of Formula 505 in a polar solvent, such as a mixture of THF and water, is added a base, such as potassium phosphate, a compound of Formula 506 (R = alkyl, such as methyl, or hydrogen, or in combination with a second R group forms a heterocycloalkyl, such as pinacol borane), and a metal catalyst, such as XPhos Pd G4. The mixture is stirred, optionally at elevated temperatures. In some embodiments, the mixture is stirred for 1–2 h. The product, a compound of Formula III, is isolated and purified using methods known in the art.

[0200] Examples of embodiments of the present disclosure are provided in the following examples. The following examples are presented only by way of illustration and to assist one of ordinary skill in using the disclosure. The examples are not intended in any way to otherwise limit the scope of the disclosure.EXAMPLE 11-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5- fluoro-4-methyl-2,7-naphthyridine-3-carbonitrile

[0201] Ethyl 4,6-dichloro-5-fluoro-pyridine-3-carboxylate To a solution of 4, 6- dichloro-5-fluoro-pyridine-3-carboxylic acid (50 g, 238.11 mmol, 1 eq) in EtOH (1 L) was added SOCl2 (56.66 g, 476.21 mmol, 34.55 mL, 2 eq) dropwise at 80°C. Then the mixture was stirred at 65°C for 16 h. LCMS showed the starting material was consumed completely and a peak (91%) with the mass of ethyl 4,6-dichloro-5-fluoro-pyridine-3-carboxylate. The mixture was concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, eluent of 0~6% Ethyl acetate / Petroleum ether gradient @ 200 mL / min) to afford ethyl 4, 6-dichloro-5-fluoro- pyridine-3-carboxylate (51 g, 203.53 mmol, 85.48% yield, 95% purity) as colorless oil. MS (ES+) C8H6NCl2FO2requires:237, found: 238 [M+H]+.1H NMR (400 MHz, CDCl3) δ ppm 8.68 (s, 1 H), 4.45 (q, J = 7.13 Hz, 2 H), 1.43 (t, J = 7.19 Hz, 3 H).

[0202] Ethyl 4-(2-tert-butoxy-1-cyano-1-methyl-2-oxo-ethyl)-6-chloro-5-fluoro- pyridine-3-carboxylate To a solution of ethyl 4,6-dichloro-5-fluoro-pyridine-3- carboxylate (51 g, 214.25 mmol, 1 eq) and Cs2CO3 (209.42 g, 642.74 mmol, 3 eq) in DMF (750 mL) was added tert-butyl 2-cyanoacetate (39.32 g, 278.52 mmol, 39.84 mL, 1.3 eq) at 25°C. The mixture was then stirred at 25°C for 3 h. Then MeI (45.61 g, 321.37 mmol, 20.01mL, 1.5 eq) was added to the mixture at 25°C. Then the mixture was stirred at 100°C for 2 h. LCMS showed the ethyl 4-(2-tert-butoxy-1-cyano-2-oxo-ethyl)-6-chloro-5-fluoro-pyridine-3- carboxylate still remained and then MeI (45.61 g, 321.37 mmol, 20.01 mL, 1.5 eq) was added to the mixture at 25°C. Then the mixture was stirred at 100°C for another 2 h. TLC showed that the ethyl 4-(2-tert-butoxy-1-cyano-2-oxo-ethyl)-6-chloro-5-fluoro-pyridine-3- carboxylate was consumed completely. The mixture was filtered and the filtrate was quenched by brine (500 mL), then the aqueous phase was extracted with ethyl acetate (300 mL x 3). The combined organic phase was washed with brine (1000 mL x 3), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® Silica Flash Column, Eluent of ~6% ethyl acetate / Petroleum ether gradient @ 200 mL / min) to afford ethyl 4-(2-tert-butoxy-1- cyano-1-methyl-2-oxo-ethyl)-6-chloro-5-fluoro-pyridine-3-carboxylate (40.8 g, 98.35 mmol, 45.90% yield, 86% purity) as yellow oil. MS (ES+) C16H18N2ClO4F requires: 356, found: 357 [M+H]+.1H NMR (400 MHz, CDCl3) δ ppm 8.49 - 8.55 (m, 1 H), 4.38 (q, J = 7.25 Hz, 2 H), 2.04 (d, J = 2.75 Hz, 3 H), 1.42 (s, 9H), 1.35 (t, J = 7.13 Hz, 3 H).

[0203] 6-Chloro-5-fluoro-4-methyl-4H-2,7-naphthyridine-1,3-dione To a solution of ethyl 4-(2-tert-butoxy-1-cyano-1-methyl-2-oxo-ethyl) -6-chloro-5-fluoro- pyridine-3-carboxylate (40.8 g, 114.36 mmol, 1 eq) in toluene (300 mL) was added 4- methylbenzenesulfonic acid hydrate (21.75 g, 114.36 mmol, 1 eq). The mixture was then stirred at 110°C for 2 h. LCMS showed the starting material was consumed completely and a peak (19%) with the mass of 6-chloro-5-fluoro-4-methyl-4H-2, 7-naphthyridine-1, 3-dione. The mixture was quenched by sat. aq. KH2PO4 (400 mL) at 0°C. Then the mixture was stirred at 25°C for 5 min and filtered. The filtered cake was triturated with water (300 mL) and filtered. The filtered cake was diluted with water (300 mL) and MeCN (40 mL) and lyophilized to afford 6-chloro-5-fluoro-4-methyl-4H-2,7-naphthyridine-1,3-dione (12.5 g, 47.02 mmol, 41.12% yield, 86% purity) as a yellow solid. MS (ES+) C9H6N2ClO2F requires:228, found: 229 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ ppm 11.67 (s, 1 H), 8.78 - 8.86 (m, 1 H), 4.07 (q, J = 7.50 Hz, 1 H), 1.56 (d, J = 7.50 Hz, 3 H).

[0204] 1,3,6-Trichloro-5-fluoro-4-methyl-2,7-naphthyridine 8 batches: 6-chloro-5- fluoro-4-methyl-4H-2,7-naphthyridine-1,3-dione (1.5 g, 6.56 mmol, 1 eq) and POCl3 (6.04 g, 39.37 mmol, 3.66 mL, 6 eq) were taken up into a microwave tube in MeCN (12 mL). The sealed tube was heated at 110 °C for 12 h under microwave. LCMS showed the starting material was consumed completely and a peak (44%) with the mass of 1,3,6-trichloro-5- fluoro-4-methyl-2,7-naphthyridine. The mixture was quenched by water (500 mL) and extracted with ethyl acetate (300 mL x 3). The combined organic phase was washed with sat. aq. NaHCO3(500 mL x 2), dried with anhydrous Na2SO4, filtered and concentrates in vacuum. The aqueous phase was adjusted to pH = 7 by aq. NaOH (1M) and discarded. The residue of organic phase was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0~6% Ethyl acetate / Petroleum ether gradient @ 200 mL / min) to afford 1,3,6-trichloro-5-fluoro-4-methyl-2,7-naphthyridine (7.6 g, 28.34 mmol, 53.99% yield, 99% purity) as white solid. MS (ES+) C9H4N2Cl3F requires: 264, found: 265 [M+H]+.

[0205] Tert-butyl 3-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate To a solution of1,3,6-trichloro-5-fluoro-4- methyl-2,7-naphthyridine (2.2 g, 8.29 mmol, 1 eq) in dioxane (22 mL) was added DIEA (3.21 g, 24.86 mmol, 4.33 mL, 3 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.76 g, 8.29 mmol, 1 eq) at 25 °C, then the mixture was stirred at 110 °C for 16 h. LCMS showed a peak (100%) with the mass of tert-butyl 3-(3,6-dichloro-5-fluoro-4-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate. The mixture was concentrated and the crude product was triturated with ethyl acetate : petroleum ester = 1:1 (30 mL) at 25 °C for 10 min. The mixture was filtered and the filtered cake was dried undervacuum to afford tert-butyl 3-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (3.5 g, 7.93 mmol, 95.71% yield) as white solid. MS (ES+) C20H23Cl2FN4O2 requires: 440, found: 441 [M+H]+

[0206] Tert-butyl 3-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(3,6-dichloro-5- fluoro-4-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (2.7 g, 6.12 mmol, 1 eq), 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (3.14 g, 6.12 mmol, 1 eq) and K3PO4 (1.5 M, 12.24 mL, 3 eq) in dioxane (61.2 mL) was added XPhos Pd G4 (526.43 mg, 611.79 μmol, 0.1 eq) under N2 at 25 °C. Then the mixture was stirred at 90 °C for 16 h under N2. LCMS showed the tert-butyl 3-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate was consumed completely and a peak (27%) with the desired mass was formed. The mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~9% Ethyl acetate / Petroleum ether gradient @ 200 mL / min) and re-purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~9% Ethyl acetate / Petroleum ether gradient @ 200 mL / min) to afford tert-butyl 3-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (1.6 g, 1.44 mmol, 23.46% yield, 71% purity) as yellow oil. MS (ES+) C43H53N4ClF2O4Si requires:790, found:791 [M+H]+.

[0207] Tert-butyl 3-[3-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-[3-chloro-5-fluoro- 6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (900 mg, 1.14 mmol, 1 eq), Pd(dppf)Cl2 (249.62 mg, 341.15 μmol, 0.3 eq) and Zn(CN)2 (200.30 mg, 1.71 mmol, 108.27 μL, 1.5 eq) in DMF (15 mL) was added Zn (96.67 mg, 1.48 mmol, 1.3 eq) under N2 at 25 °C. Then the mixture was stirred at 100 °C for another 16 h. LCMS showed the starting material was consumed completely and a peak (58%) with the desired mass was formed. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phase was washed with brine (50 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 25 SepaFlash® Silica Flash Column, Eluent of 0~12% Ethyl acetate / Petroleum ether gradient @ 150 mL / min) to afford tert-butyl 3-[3-cyano-5-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (628 mg, 682.61 μmol, 60.03% yield, 85% purity) as a yellow oil, which was confirmed by LCMS. MS (ES+) C44H53N5F2O4Si requires:781, found:782 [M+H]+.

[0208] Tert-butyl 3-[3-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-5-fluoro-4-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-[3-cyano-5-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (578 mg, 739.13 μmol, 1 eq) in DMF (10 mL) was added CsF (336.83 mg, 2.22 mmol, 81.75 μL, 3 eq) at 25 °C. Then the mixture was stirred at 25 °C for 40 min. LCMS showed the tert-butyl 3-[3-cyano-5-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate was consumed completely and a peak (82%) with the desired mass was formed. The mixture was poured into ethyl acetate (50 mL) and washed with brine (50 mL x 2). Then the organic phase was dried with anhydrous Na2SO4, filtered, and the filtrate was concentrated in vacuum to afford tert-butyl 3-[3-cyano-6-[8- ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-4-methyl-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (627 mg, crude) as a yellow oil. MS (ES+) C35H33N5F2O4 requires:625, found:626 [M+H]+.

[0209] 1-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1- naphthyl)-5-fluoro-4-methyl-2,7-naphthyridine-3-carbonitrile To a solution of tert-butyl 3-[3-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-4-methyl-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (627 mg, 1.00 mmol, 1 eq) in DCM (15 mL) was added HCl / dioxane (4 M, 5.01 mL, 20 eq) at 25 °C. Then the mixture was stirred at 25 °C for 20 min. LCMS showed tert-butyl 3-[3-cyano-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-4-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate was consumed completely and a peak (87%) with the desired mass was formed. The mixture was adjusted pH to pH = 7 by cold sat. aq. NaHCO3 at 25 °C. Then the aqueous phase was extracted with ethyl acetate (20 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex Luna® C18150*25 mm* 10um;mobile phase: [water (FA) -ACN];B%: 20%-40%, 10 min) and lyophilized to afford 1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5-fluoro-4-methyl-2,7-naphthyridine-3-carbonitrile (138.4 mg, 262.36 μmol, 26.18% yield, 100% purity, FA) as a yellow solid. MS (ES+) C28H21N5F2O·CH2O2requires: 481, found:482 [M+H]+.1H NMR (400 MHz, CD3OD) δ ppm 9.35 (s, 1 H), 8.50 (s, 1 H), 7.89 (dd, J = 9.17, 5.75 Hz, 1 H), 7.39 (d, J = 2.57 Hz, 1 H), 7.35 (t, J = 8.93 Hz, 1 H), 7.27 (d, J = 2.45 Hz, 1 H), 4.16 (s, 2 H), 3.96 - 4.10 (m, 2 H), 3.63 (dd, J = 13.20, 4.16 Hz, 2 H), 3.28 - 3.30 (m, 1 H), 2.87 (d, J = 5.99 Hz, 3 H), 2.31 - 2.46 (m, 2 H), 2.09 - 2.26 (m, 2 H). EXAMPLE 24-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-6-chloro-4-fluoro-1-methoxy-5-methyl- 2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0210] 3,6,8-Trichloro-4-fluoro-5-methyl-2,7-naphthyridine 2-oxide To a cooled 0 °C solution of 1,3,6-trichloro-5-fluoro-4-methyl-2,7-naphthyridine (300 mg, 1.130 mmol) in DCM (5650 µL) was added urea--hydrogen peroxide (1 / 1) (319 mg, 3.39 mmol) and 2,2,2-trifluoroacetic anhydride (481 µL, 3.39 mmol). The resulting mixture was stirred at 25 °C for 2 h. H2O was added and the layers were separated. The aqueous phase was extracted with DCM (3 x), the combined organic layers were washed with sat. NaHCO3x2, washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure to give 3,6,8-trichloro-4-fluoro-5-methyl-2,7-naphthyridine 2-oxide (300 mg, 1.066 mmol, 94 % yield).1H NMR (600 MHz, CDCl3) δ 9.18 (d, J = 1.7 Hz, 1H), 2.83 (d, J = 5.2 Hz, 3H). LCMS(ES+) C9H4Cl3FN2O requires: 280, found 281 [M+H]+.

[0211] 3,6,8-Trichloro-4-fluoro-5-methyl-2,7-naphthyridin-1-ol To a suspension of 3,6,8-trichloro-4-fluoro-5-methyl-2,7-naphthyridine 2-oxide (318 mg, 1.130 mmol) in THF (2824 µL) and DMF (2824 µL) was added TFAA (479 µL, 3.39 mmol) dropwise and the resulting mixture was stirred at 25 °C for 1 h. The volatiles were removed under reduced pressure. Ice water was added and the precipitate was stirred for 15 min. The reaction mixture was diluted with DCM, H2O was added, and the layers were separated. The aqueous phase was extracted with DCM (2 x), the combined organic layers were washed with sat NaCl x3, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was adsorbed onto silica and purified via flash chromatography (0 - 100 % EtOAc in hexanes) to give 3,6,8-trichloro-4-fluoro-5-methyl-2,7-naphthyridin-1-ol (200 mg, 0.710 mmol, 62.9 % yield) as a purple solid.1H NMR (600 MHz, DMSO) δ 2.71 (d, J = 6.7 Hz, 3H). LCMS(ES+) C9H4Cl3FN2O requires: 280, found 281

[0212] 1,3,6-Trichloro-5-fluoro-8-methoxy-4-methyl-2,7-naphthyridine To a suspension of 3,6,8-trichloro-4-fluoro-5-methyl-2,7-naphthyridin-1-ol (100 mg, 0.355 mmol) in chloroform (1776 µL) was added silver carbonate (147 mg, 0.533 mmol) and MeI (33.3 µL, 0.533 mmol) and the resulting mixture was stirred at 25 °C for 2 h. The reaction was then heated to 50 °C overnight. To the solids were added TFA (2 mL) and stirred and then filtered. The filtrate was washed with MeOH until no more color appeared. The combined organics were concentrated. The residue was purified via silica gel chromatography (0 - 30 % EtOAc in hexanes) to give 1,3,6-trichloro-5-fluoro-8-methoxy-4-methyl-2,7-naphthyridine (10 mg, 0.034 mmol, 9.53 % yield) as a white crystalline solid.1H NMR (600 MHz, CDCl3) δ 4.14 (s, 3H), 2.80 (d, J = 6.5 Hz, 3H). LCMS(ES+) C10H6Cl3FN2O requires: 294, found 295 [M+H]+.

[0213] Tert-butyl (1R,5S)-3-(3,6-dichloro-5-fluoro-8-methoxy-4-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of 1,3,6- trichloro-5-fluoro-8-methoxy-4-methyl-2,7-naphthyridine (9 mg, 0.030 mmol) in 1,4- Dioxane (305 µL) was added tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (7.11 mg, 0.034 mmol) and DIEA (6.38 µL, 0.037 mmol) and the resulting mixture was stirred at 80 °C for 1.5 h. The volatiles were removed under reduced pressure. The residue was purified via silica gel chromatography (0 - 70 % EtOAc in hexanes) to give tert-butyl (1R,5S)-3-(3,6-dichloro-5-fluoro-8-methoxy-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (8 mg, 0.017 mmol, 55.7 % yield) as a colorless oil.1H NMR (500 MHz, CDCl3) δ 4.33 – 4.16 (m, 2H), 4.06 (s, 3H), 3.98 – 3.60 (m, 2H), 3.52 – 3.19 (m, 2H), 2.63 (d, J = 6.4 Hz, 3H), 1.83 (s, 4H), 1.50 (s, 9H). LCMS(ES+) C21H25Cl2FN4O3 requires: 470, found 471 [M+H]+.

[0214] Tert-butyl (1R,5S)-3-(3-chloro-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-8-methoxy-4-methyl-2,7-naphthyridin-1-yl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate A solution of tert-butyl (1R,5S)-3-(3,6- dichloro-5-fluoro-8-methoxy-4-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane- 8-carboxylate (21 mg, 0.045 mmol), potassium phosphate (28.4 mg, 0.134 mmol), and ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (22.84 mg, 0.045 mmol) in Water (223 µL) and THF (668 µL)was degassed with N2for 3 minutes. XPhos Pd G4 (3.84 mg, 4.46 μmol) was added and the mixture was degassed with N2for an additional minute. The reaction mixture was heated to 80 °C and stirred for 1 h. Sat. NH4Cl was added and the layers were separated. The aqueous phase was extracted with EtOAc (3 x), the combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S)-3-(3-chloro-5- fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-8- methoxy-4-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (11 mg, 0.013 mmol, 30.1 % yield) as a yellow oil. LCMS(ES+) C44H55ClF2N4O5Si requires: 820, found 821 [M+H]+.

[0215] 4-(8-((1R,5S)-3,8-Diazabicyclo[3.2.1]octan-3-yl)-6-chloro-4-fluoro-1-methoxy- 5-methyl-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol To a solution of tert-butyl (1R,5S)-3-(3-chloro-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-8-methoxy-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (11 mg, 0.013 mmol) in DCM (268 µL) was added HCl (100 µL, 0.402 mmol) and the resulting mixture was stirred at 25 °C for 2.5 h. The volatiles were removed under reduced pressure. The reaction mixture was diluted with EtOAc, sat. NaHCO3was added, and the layers were separated. The aqueous phase was extracted with EtOAc (3 x), the combined organic layers were washed with sat NaCl, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was dissolved in DMF (300 µL) and CsF (20.34 mg, 0.134 mmol) was added and stirred at 25 °C for 2 h. More CsF (20.34 mg, 0.134 mmol) was added and stirred overnight. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 30 - 70%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-6-chloro-4-fluoro-1-methoxy- 5-methyl-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (1 mg, 1.920 μmol, 14.33 % yield) as a yellow solid as the first eluting isomer.1H NMR (600 MHz, MeOD) δ 7.85 (dd,J = 9.2, 5.7 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.24 (d, J = 2.5 Hz, 1H), 4.20 – 4.13 (m, 2H), 4.07 (s, 3H), 3.56 – 3.43 (m, 2H), 3.28 (s, 1H), 2.67 (d, J = 6.5 Hz, 3H), 2.43 – 2.26 (m, 2H), 2.17 – 2.07 (m, 2H), 1.35 – 1.26 (m, 4H). LCMS(ES+) C28H23ClF2N4O2 requires: 520, found 521 [M+H]+. EXAMPLE 3N-(1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1- yl)-5-fluoro-4-methyl-2,7-naphthyridin-3-yl)methanesulfonamide

[0216] Tert-butyl 3-(3-amino-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate A solution of tert-butyl 3-(3-chloro-5-fluoro-6- (7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (90 mg, 0.114 mmol), diphenylmethanimine (30.9 mg, 0.171 mmol), Pd2(dba)3 (10.41 mg, 0.011 mmol) sodium 2- methylpropan-2-olate (32.8 mg, 0.341 mmol) and 2,2'-bis(diphenylphosphino)-1,1'- binaphthalene (14.16 mg, 0.023 mmol) in Toluene (1137 µL) was degassed with N2for 5 minutes. The reaction mixture was heated to 100 °C and stirred for 2 h. Saturated NH4Cl (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, andconcentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl (1R,5S)-3-(3-((diphenylmethylene)amino)-5- fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4- methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (75 mg, 0.080 mmol, 70.4 % yield) as a yellow oil. To a solution of tert-butyl 3-(3- ((diphenylmethylene)amino)-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (75 mg, 0.080 mmol) in THF (801 µL) was added hydrogen chloride in water 1N (160 µL, 0.160 mmol) and the resulting mixture was stirred at 0 °C for 3 h. Saturated NH4Cl (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl 3-(3- amino-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1- yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (35 mg, 0.045 mmol, 56.6 % yield) as a yellow oil. MS (ES+) C43H55F2N5O4Si requires: 771, found: 772 [M+H]+.1H NMR (600 MHz, CDCl3) δ 9.13 (s, 1H), 7.77 (dd, J = 9.1, 5.6 Hz, 1H), 7.48 (d, J = 2.6 Hz, 1H), 7.31 (d, J = 2.5 Hz, 1H), 7.29 – 7.28 (m, 1H), 5.32 – 5.27 (m, 2H), 4.62 (s, 2H), 4.45 – 4.27 (m, 2H), 3.84 (d, J = 11.8 Hz, 1H), 3.61 – 3.43 (m, 1H), 3.51 (s, 3H), 3.35 (d, J = 11.6 Hz, 1H), 3.15 – 3.08 (m, 1H), 2.38 (d, J = 2.7 Hz, 3H), 2.04 - 2.02 (m, 2H), 1.61 (br. s, 4H), 1.50 (br. s, 9H), 0.86 (dd, J = 25.9, 7.5 Hz, 18H), 0.47 (h, J = 7.5 Hz, 3H).

[0217] N-(1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-5-fluoro-4-methyl-2,7-naphthyridin-3-yl)methanesulfonamide To a solution of tert-butyl 3-(3-amino-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)- 8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (35 mg, 0.045 mmol) in THF (227 µL), pyridine(227 µL) and methanesulfonyl chloride (6.92 µL, 0.091 mmol) was added and the resulting mixture was stirred at 21 °C for 16 h. Saturated NH4Cl (5.00 mL) was then added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was passed through a silica gel plug using CH2Cl2 and concentrated under vacuum. The residue was then dissolved in CH2Cl2(412 µL) hydrogen chloride in dioxane 4N (103 µL, 0.412 mmol) was added and the resulting mixture was stirred at 21 °C for 2 h. Once deprotection was observed, the reaction was evaporated under vacuum. The crude was taken up in DMF (1 mL) and to this was added cesium fluoride (62.5 mg, 0.412 mmol) and stirred at 21 °C overnight. The following day, the reaction was heated to 60°C with additional CsF (62.5 mg, 0.412 mmol) for 5 h. The residue was purified by mass- triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 40%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give N- (1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-5- fluoro-4-methyl-2,7-naphthyridin-3-yl)methanesulfonamide bis(2,2,2-trifluoroacetate) (10 mg, 0.013 mmol, 28.9 % yield) as an orange solid. MS (ES+) C28H25F2N5O3S requires: 549, found: 550 [M+H]+. 1H NMR (600 MHz, MeOD) δ 9.19 (s, 1H), 7.88 (dd, J = 9.2, 5.7 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.24 (d, J = 2.6 Hz, 1H), 4.26 (s, 2H), 4.02 (dd, J = 18.7, 14.4 Hz, 2H), 3.68 – 3.61 (m, 2H), 3.48 (s, 3H), 3.27 (d, J = 1.0 Hz, 1H), 2.56 (d, J = 4.8 Hz, 3H), 2.52 – 2.43 (m, 2H), 2.27 – 2.20 (m, 2H). EXAMPLE 4N-(1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1- yl)-5-fluoro-4-methyl-2,7-naphthyridin-3-yl)acetamide

[0218] (3-(3-Acetamido-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate A solution of tert-butyl 3-(3-chloro-5-fluoro-6- (7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (30 mg, 0.038 mmol), acetamide (3.86 µL, 0.076 mmol), and cesium carbonate (37.1 mg, 0.114 mmol) in Dioxane (379 µL) was degassed with N2 for 2 minutes. Palladium(II) acetate (0.851 mg, 3.79 µmol) and (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane) (Xantphos) (4.39 mg, 7.58 µmol) were added and the mixture was degassed with N2 for an additional 5 minutes. The reaction mixture was heated to 100 °C and stirred for 6 h. Saturated NH4Cl (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2(3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl (3-(3-acetamido-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (12 mg, 0.015 mmol, 38.9 % yield) as a yellow oil. MS (ES+) C45H57F2N5O5Si requires: 813, found: 815 [M+2H]+.

[0219] N-(1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-5-fluoro-4-methyl-2,7-naphthyridin-3-yl)acetamide To a solution of tert-butyl 3-(3-acetamido-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (12 mg, 0.015 mmol) in CH2Cl2(147 µL) was added hydrogen chloride in dioxane (36.9 µL, 0.147 mmol) and the resulting mixture was stirred at 21 °C for 2 h. The volatiles were removed under reduced pressure. The crude was dissolved in 0.5 mL DMF and to this was added cesium fluoride (22.39 mg, 0.147 mmol) and the reaction was allowed to stir at 21 °C for 2 hr. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 50%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give N-(1-(3,8- diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-5-fluoro-4- methyl-2,7-naphthyridin-3-yl)acetamide bis(2,2,2-trifluoroacetate) (4 mg, 5.39 µmol, 36.6 % yield) as a yellow solid. MS (ES+) C29H25F2N5O2 requires: 513, found: 514 [M+H]+.1H NMR (600 MHz, MeOD) δ 9.22 (s, 1H), 7.88 (dd, J = 9.1, 5.7 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.25 (d, J = 2.5 Hz, 1H), 4.23 (s, 2H), 4.04 – 4.01 (m, 1H), 3.99 – 3.94 (m, 1H), 3.66 – 3.58 (m, 2H), 3.25 (s, 1H), 2.50 (d, J = 5.9 Hz, 3H), 2.48 – 2.43 (m, 2H), 2.22 (s, 3H), 2.21 – 2.20 (m, 2H). EXAMPLE 54-(6-(azetidin-3-yl)-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-2,7- naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0220] Tert-butyl 3-(3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-fluoro-6-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate A 50 °C suspension of zinc (92 mg, 1.4 mmol) in DMA (1.0 ml) was treated concurrently with 1,2- dibromoethane (20 µL, 0.23 mmol) and TMSCl (33 µL, 0.26 mmol) slowly over 5 min. The resulting mixture was allowed to stir for 30 min at 50 °C. To the grey suspension was added neat tert-butyl 3-iodoazetidine-1-carboxylate (0.12 ml, 0.71 mmol) dropwise and the resulting solution was stirred for 30 min at 50 °C. The resulting solution was cooled to room temperature then used immediately in the next step as a 0.2M solution of (1-(tert- butoxycarbonyl)azetidin-3-yl)zinc(II) iodide. Next, a mixture of tert-butyl 3-(3-chloro-5- fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4- methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, 0.063 mmol), PdCl2(dppf)-CH2Cl2 Adduct (5.2 mg, 6.3 μmol) and CuI (1 mg, 6.3 μmol) in DMA (620 µL) was degassed with N2 for 1 minute. The degassed reaction mixture was treated with the freshly prepared solution of (1-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide (316 µL, 0.063 mmol, 0.2M) The reaction mixture was then heated to 80 °C and stirred for 2 h. The reaction was quenched with sat NH4Cl (2 mL) and the layers were separated. The aqueous phase was extracted with EtOAc (5.00 mL), the combined organic layers were washed with brine (3 x 2 mL) dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50% EtOAc in hexanes) to give tert- butyl 3-(3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)- 8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (12.8 mg, 0.014 mmol, 22.21 % yield) as a brown oil. MS (ES+) C51H67F2N5O6Si requires: 911, found: 912 [M+H]+.

[0221] 4-(6-(Azetidin-3-yl)-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl- 2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol To a solution of tert-butyl 3-(3-(1-(tert-butoxycarbonyl)azetidin-3-yl)-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (12.8 mg, 0.014 mmol) in DCM (0.4 ml) was added TFA (0.022 ml, 0.281 mmol) and the resulting mixture was stirred at 21 °C for 3 h. The volatiles were removed under reduced pressure. The residue was taken up in DMF (0.4 mL) and treated with CsF (21.31 mg, 0.140 mmol). The resulting mixture was stirred at 60 °C for 1h then diluted with DMSO (0.6 mL) and purified by HPLC. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 20 - 60%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(6-(azetidin-3-yl)-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl- 2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (1.5 mg, 2.93 μmol, 20.90 % yield) as an orange oil. MS (ES+) C30H24F2N5O requires: 511, found: 512 [M+H]+.1H NMR (600 MHz, methanol-d4) δ 9.29 (s, 1H), 7.88 (dd, J = 9.2, 5.7 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.23 (d, J = 2.6 Hz, 1H), 4.65 – 4.56 (m, 1H), 4.56 – 4.51 (m, 1H), 4.42 (dd, J = 10.8, 9.0 Hz, 2H), 4.29 (s, 2H), 4.08 (dd, J = 24.6, 13.7 Hz, 2H), 3.71 (dd, J = 26.6, 13.7 Hz, 2H), 3.16 (s, 1H), 2.57 (d, J = 5.3 Hz, 3H), 2.52 – 2.42 (m, 2H), 2.27 (d, J = 6.6 Hz, 2H). EXAMPLE 61-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5- fluoro-8-methoxy-3-methyl-2,7-naphthyridine-4-carbonitrile

[0222] 2,6-Dichloro-5-fluoro-pyridine-3-carbonyl chloride To a solution of 2,6- dichloro-5-fluoro-pyridine-3-carboxylic acid (50 g, 238.11 mmol, 1 eq) in DCM (500 mL)was added DMF (870.16 mg, 11.91 mmol, 915.96 μL, 0.05 eq) and followed by oxalyl dichloride (36.27 g, 285.73 mmol, 25.01 mL, 1.2 eq) at 0 °C, the reaction mixture was stirred 30 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to give 2,6- dichloro-5-fluoro-pyridine-3-carbonyl chloride (54.4 g, crude) as yellow oil.

[0223] 2,6-Dichloro-5-fluoro-pyridine-3-carbohydroxamic acid To a mixture of NH2OH.HCl (24.82 g, 357.21 mmol, 1.5 eq) in EtOAc (300 mL) and H2O (150 mL) was added NaHCO3 (30.01 g, 357.21 mmol, 13.90 mL, 1.5 eq), to the mixture was added a solution of 2,6-dichloro-5-fluoro-pyridine-3-carbonyl chloride (54.4 g, 238.14 mmol, 1 eq) in EtOAc (150 mL) dropwise, the mixture was stirred at 20 °C for 1 h. LCMS showed 2,6-dichloro-5-fluoro-pyridine-3-carbonyl chloride was consumed and one main peak with desired mass. The reaction mixture was concentrated under reduced pressure to remove solvent. The crude product was triturated with DCM (100 mL) at 20 °C for 30 mins to afford 2,6-dichloro-5-fluoro-pyridine-3-carbohydroxamic acid (44 g, 195.55 mmol, 82.12% yield) as a white solid. MS (ES+) C6H3Cl2FN2O2 requires: 224, found 225 [M+H]+,1H NMR (400 MHz, DMSO-d6) δ = 11.54 - 10.86 (m, 1H), 9.56 (br s, 1H), 8.27 (d, J = 7.8 Hz, 1H).

[0224] [(2,6-Dichloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2-dimethylpropanoate To a mixture of 2,6-dichloro-5-fluoro-pyridine-3-carbohydroxamic acid (40 g, 177.77 mmol, 1 eq) and TEA (53.97 g, 533.32 mmol, 74.23 mL, 3 eq) in THF (1000 mL) was added 2,2-dimethylpropanoyl chloride (19.29 g, 160.00 mmol, 19.69 mL, 0.9 eq) at 20 °C, the mixture was stirred at 20 °C for 1 h. LCMS showed one main peak with desired mass. The reaction mixture was concentrated under reduced pressure to remove solvent, then diluted with EtOAc (400 mL), filtered and the filter cake was washed with EtOAc (50 mL x 3), the filtrate was concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (330 g SepaFlash® Silica Flash Column, Eluent of 0~20%Ethyl acetate / Petroleum ether gradient @ 200 mL / min) to afford [(2,6-dichloro-5- fluoro-pyridine-3-carbonyl)amino] 2,2-dimethylpropanoate (32 g, 103.52 mmol, 58.23%yield) as a white solid. MS (ES+) C11H11Cl2FN2O3requires: 308, found 309 [M+H]+,1H NMR (400 MHz, DMSO-d6) δ = 12.59 (br s, 1H), 8.32 (d, J = 7.6 Hz, 1H), 1.29 (s, 9H).

[0225] 6,8-Dichloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one To a mixture of [(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2-dimethylpropanoate (1 g, 3.23 mmol, 1 eq) in MeOH (10 mL) were added Cesium acetate (155.24 mg, 808.75 μmol, 0.25 eq) and dichlororhodium;1,2,3,4,5-pentamethylcyclopentane (95.08 mg, 161.75 μmol, 0.05 eq) and prop-1-yne (1 M in n-heptane, 6.46 mL, 2 eq), the mixture was stirred at 60 °C for 16 h. LCMS showed a major peak with desired mass. The reaction mixture was filtered and the filter cake was washed with MeOH(10 mL x 3), then dried over under reduced pressure to give 6,8-dichloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one (1.2 g, 4.86 mmol, 50.05% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 12.05 (s, 1H), 6.42 (s, 1H), 2.29 (s, 3H).

[0226] 6-Chloro-5-fluoro-8-methoxy-3-methyl-2H-2,7-naphthyridin-1-one To a solution of 6,8-dichloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one (0.3 g, 1.21 mmol, 1 eq) in DMA (10 mL) was added MeOH (194.53 mg, 6.07 mmol, 245.68 μL, 5 eq), the reaction mixture was stirred at 0 °C for 5 mins, LiHMDS (1 M in THF, 3.64 mL, 3 eq) was added at 0 °C, the mixture was stirred at 40 °C for 1.5 h. LCMS showed 6,8-dichloro-5- fluoro-3-methyl-2H-2,7-naphthyridin-1-one was consumed and 96% of peak with desired mass. The reaction mixture was poured into water (30 mL) and the pH was adjusted to 5 by addition HCl(1 N), filtered and the filter cake was washed with water (10 mL x 3), dried over under reduced pressure to afford 6-chloro-5-fluoro-8-methoxy-3-methyl-2H-2,7- naphthyridin-1-one (0.3 g, 989.14 μmol, 81.46% yield, 80% purity) as a white solid. MS (ES+) C10H8ClFN2O2requires: 242, found 243 [M+H]+,1H NMR (400 MHz, DMSO-d6) δ = 11.99 - 11.48 (m, 1H), 6.31 (s, 1H), 3.92 (s, 3H), 2.26 (s, 3H).

[0227] Tert-butyl 3-(6-chloro-5-fluoro-8-methoxy-3-methyl-2,7-naphthyridin-1-yl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of 6-chloro-5-fluoro-8- methoxy-3-methyl-2H-2,7-naphthyridin-1-one (0.39 g, 1.61 mmol, 1 eq) in DCM (5 mL) was added DIPEA (830.94 mg, 6.43 mmol, 1.12 mL, 4 eq) and Tf2O (997.70 mg, 3.54 mmol, 583.45 μL, 2.2 eq) at 0 °C under the protection of N2, the mixture was stirred at 20 °C for 1 h, to the mixture was added DIPEA (623.21 mg, 4.82 mmol, 839.90 μL, 3 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (682.45 mg, 3.21 mmol, 2 eq), the mixture was stirred at 20 °C for 0.5 h. LCMS showed 6-chloro-5-fluoro-8-methoxy-3-methyl-2H-2,7- naphthyridin-1-one was consumed and 92% of peak with desired mass. The reaction mixture was concentrated under reduced pressure to remove solvent and the residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 0~15% Ethyl acetate / Petroleum ether gradient @ 60 mL / min) to afford tert-butyl 3-(6-chloro-5- fluoro-8-methoxy-3-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (0.53 g, 1.21 mmol, 75.47% yield) as a yellow solid. MS (ES+) C21H26ClFN4O3 requires: 436, found 437 [M+H]+,1H NMR (400 MHz, DMSO-d6) δ = 6.96 (s, 1H), 4.20 - 4.10 (m, 2H), 4.01 (s, 3H), 3.88 (d, J = 12.1 Hz, 2H), 3.18 (d, J = 12.5 Hz, 2H), 2.44 (s, 3H), 1.80-1.62 (m, 4H), 1.43 (s, 9H).

[0228] Tert-butyl 3-(6-chloro-5-fluoro-4-iodo-8-methoxy-3-methyl-2,7-naphthyridin- 1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(6- chloro-5-fluoro-8-methoxy-3-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (0.47 g, 1.08 mmol, 1 eq) in DMF (5 mL) was added NIS (484.04 mg, 2.15 mmol, 2 eq), the mixture was stirred at 30 °C for 2 h. LCMS showed a main peak withdesired mass. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL x 3), the combined organic phase was washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 0~9% Ethyl acetate / Petroleum ether gradient @ 50 mL / min) to afford tert-butyl 3-(6-chloro- 5-fluoro-4-iodo-8-methoxy-3-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (0.59 g, 1.05 mmol, 97.45% yield) as a yellow solid. MS(ES+) C21H25ClFIN4O3 requires:562, found 563NMR (400 MHz, CDCl3) δ = 4.33 - 4.13 (m, 2H), 4.10 - 3.96 (m, 4H), 3.94 - 3.64 (m, 1H), 3.58 - 3.15 (m, 2H), 2.74 (s, 3H), 1.87-1.73 (m, 2H), 1.72 - 1.39 (m, 9H).

[0229] Tert-butyl 3-(6-chloro-4-cyano-5-fluoro-8-methoxy-3-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(6-chloro-5-fluoro-4-iodo-8-methoxy-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (0.2 g, 355.36 μmol, 1 eq) in DMF (1 mL) was added Zn(CN)2 (42 mg, 357.69 μmol, 22.70 μL, 1.01 eq) and Zn (42 mg, 642.30 μmol, 1.81 eq), Pd(dppf)Cl2(52.00 mg, 71.07 μmol, 0.2 eq) under the protection of N2, the mixture was stirred at 100 °C for 16 h. LCMS showed 24% of peak with desired mass. To the mixture was added water (10 mL) and extracted with EtOAc (10 mL x 3), the combined organic phase was washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-TLC (SiO2, Petroleum ether / Ethyl acetate = 3:1) to afford tert-butyl 3-(6-chloro-4-cyano-5-fluoro-8-methoxy-3- methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (59 mg, 127.73 μmol, 35.94% yield) as a yellow solid.

[0230] Tert-butyl 3-[4-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(6-chloro-4-cyano- 5-fluoro-8-methoxy-3-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (0.046 g, 99.59 μmol, 1 eq) and 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (76.56 mg, 149.38 μmol, 1.5 eq) in THF (2 mL) was added K3PO4 (1.5 M in H2O, 199.17 μL, 3 eq) and cataCXium® A Pd G3(8.43 mg, 11.58 μmol, 0.1 eq) under the protection of N2, the mixture was stirred at 60 °C for 16 h. LCMS showed tert-butyl 3-(6-chloro-4-cyano-5-fluoro-8- methoxy-3-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate was consumed and 33% of peak with desired mass. The reaction mixture was diluted with EtOAc (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 35 mL / min) to afford tert-butyl 3- [4-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-8-methoxy-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (60 mg, 73.89 μmol, 74.20% yield) as yellow oil. MS(ES+) C45H55F2N5O5Si requires:811, found 812 [M+H]+.

[0231] Tert-butyl 3-[4-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-5-fluoro-8-methoxy-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-[4-cyano-5-fluoro- 6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-3- methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (0.055 g, 67.73 μmol, 1 eq) in DMF (1 mL) was added CsF (25.72 mg, 169.33 μmol, 6.25 μL, 2.5 eq), the mixture was stirred at 30°C for 1 h. LCMS showed tert-butyl 3-[4-cyano-5-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-3-methyl- 2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate was consumed and 95% of peak with desired mass. To the mixture was added water (2 mL) and extracted with EtOAc (2 mL x 3), the combined organic phase was washed with brine (5 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 3-[4-cyano-6-[8- ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-8-methoxy-3-methyl-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (0.044 g, 67.10 μmol, 99.07% yield) as yellow oil. MS(ES+) C36H35F2N5O5 requires:655, found 656 [M+H]+.

[0232] 1-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1- naphthyl)-5-fluoro-8-methoxy-3-methyl-2,7-naphthyridine-4-carbonitrile To a solution of tert-butyl 3-[4-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5- fluoro-8-methoxy-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (0.044 g, 67.10 μmol, 1 eq) in DCM (0.9 mL) was added TFA (5.07 g, 44.43 mmol, 3.30 mL), the mixture was stirred at 20 °C for 0.5 h. LCMS showed tert-butyl 3-[4- cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-8-methoxy-3- methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate was consumed and 86% of peak with desired mass. The reaction mixture was poured into saturated NaHCO3(10 mL) and extracted with EtOAc (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna® C18250*50mm*15um; mobile phase: [water(FA)-ACN]; gradient:22%-42% B over 10 min), the eluent was concentrated and freeze dried to afford 1- (3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5-fluoro-8-methoxy-3-methyl-2,7-naphthyridine-4-carbonitrile (8.6 mg, 15.27 μmol, 22.76% yield, 99% purity, FA) as a white solid. MS(ES+) C29H23F2N5O2requires:511, found 512 [M+H]+,1H NMR (400 MHz, CD3OD) δ = 8.58 - 8.46 (m, 0.6H), 7.88-7.84 (m, 1H), 7.37 - 7.29 (m, 2H), 7.25 (d, J = 2.5 Hz, 1H), 4.48 - 4.17 (m, 2H), 4.05 (s, 3H), 3.94 - 3.81 (m, 2H), 3.70 - 3.56 (m, 2H), 2.70 (s, 3H), 1.97 - 1.75 (m, 4H).

[0233] The following Examples were synthesized with procedures that were similar to the examples disclosed herein and can generally be made by methods disclosed herein from the appropriate starting materials. Table 1. Example Compounds.EXAMPLE 344-(8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(oxetan-3-yloxy)-2,7- naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0234] Tert-butyl 3-(5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-3-(oxetan-3-yloxy)-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate A solution of tert- butyl 3-(3-chloro-5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (30 mg, 0.038 mmol), cesium carbonate (37.1 mg, 0.114 mmol), oxetan-3-ol (3.09 mg, 0.042 mmol), RuPhos Pd G4 (3.22 mg, 3.79 µmol) in Dioxane (379 µL) was degassed with N2 for 5 minutes. The reaction mixture was heated to 90°C and stirred for 2 h. Saturated NH4Cl (5.00 mL) solution was added and the layers were separated. The aqueous phase was extracted with CH2Cl2(3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (20 – 50 % EtOAc in hexanes) to give tert-butyl 3-(5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-3-(oxetan-3-yloxy)-2,7-naphthyridin-1- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10 mg, 0.012 mmol, 31.8 % yield) as a yellow oil. MS (ES+) C46H58F2N4O6Si requires: 828.4, found: 829.7 [M+H]+.

[0235] 4-(8-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(oxetan-3-yloxy)- 2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol To a solution of tert-butyl 3-(5-fluoro-6-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)- 4-methyl-3-(oxetan-3-yloxy)-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (10 mg, 0.012 mmol) in CH2Cl2 (241 µL) was added 2,2,2-trifluoroacetic acid (1.375 mg, 0.012 mmol) and the resulting mixture was stirred at rt for 1 h. The volatiles were removed under reduced pressure. The crude was redissolved in 0.3 mL DMSO and cesium fluoride (18.32 mg, 0.121 mmol) was added to the reaction and the reaction was stirred at rt overnight. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 50%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5- methyl-6-(oxetan-3-yloxy)-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (0.8 mg, 1.514 μmol, 12.55 % yield) as a yellow powder. MS (ES+) C30H26F2N4O3 requires: 528, found: 529 [M+H]+.1H NMR (600 MHz, CD3OD) δ 9.03 (s, 1H), 7.79 – 7.76 (m, 1H), 7.28 – 7.24 (m, 2H), 7.13 (d, J = 2.6 Hz, 1H), 5.65 – 5.60 (m, 1H), 5.00 (td, J = 6.8, 3.7 Hz, 2H), 4.16 (s, 3H), 3.89 – 3.81 (m, 2H), 3.52 – 3.48 (m, 2H), 3.15 (t, J = 1.5 Hz, 1H), 2.48 (d, J = 5.0 Hz, 3H), 2.33 – 2.29 (m, 2H), 2.22 (dd, J = 13.7, 5.7 Hz, 2H).

[0236] The following Examples were synthesized with procedures that were similar to the examples disclosed herein and can generally be made by methods disclosed herein from the appropriate starting materials. Table 2. Example CompoundsEXAMPLE 934-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8- fluoro-5-methoxy-1-methylpyrido[4,3-d]pyrimidin-2(1H)-one

[0237] 2,6-Dichloro-3-fluoro-pyridin-4-amine To a solution of 2, 6-dichloropyridin-4- amine (100 g, 613.48 mmol, 1 eq) in MeOH (1000 mL) and H2O (200 mL) was added Selectfluor™ (239.06 g, 674.82 mmol, 1.1 eq) at 25 °C. The mixture was stirred at 45 °C for 16 h. LCMS showed residual starting material and a peak (39%) with the mass of 2,6- dichloro-3-fluoro-pyridin-4-amine. The mixture was filtered and the filtrate was concentrated in vacuum. Then the residue was diluted with ethyl acetate (500 mL) and washed with water (300 mL x 3). Then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum. The residue was purified by prep-HPLC (column: Agela™ Innoval ODS-2250 mm*100 mm*10um;mobile phase: [water (FA) -ACN];B%: 20%-40%, 25 min). Then the mixture was concentrated in vacuum. Then the aqueous phase was extracted with ethyl acetate (4000 mL). The organic phase was concentrated in vacuum to afford 2,6-dichloro-3-fluoro-pyridin-4-amine (55 g, 288.68 mmol, 47.06% yield, 95% purity) as a white solid. MS (ES+) C5H3N2Cl2F requires:180, found:181 [M+H]+.1H NMR (400 MHz, DMSO-d6) δ ppm 6.99 (s, 2 H) 6.70 (d, J = 5.38 Hz, 1 H).

[0238] Tert-butyl N-tert-butoxycarbonyl-N-(2,6-dichloro-3-fluoro-4- pyridyl)carbamate To a solution of 2,6-dichloro-3-fluoro-pyridin-4-amine (55 g, 303.88 mmol, 1 eq) and DMAP (1.86 g, 15.19 mmol, 0.05 eq) in THF ( 500 mL) was added Boc2O (198.96 g, 911.63 mmol, 209.43 mL, 3 eq) at 25 °C. Then the mixture was stirred at 60 °C for 2.5 h. TLC (Petroleum ether : Ethyl acetate = 5:1) showed the starting material was consumed completely and one new spot was formed. The mixture was concentrated in vacuum. The crude product was triturated with MeOH (500 mL x 2) at 25 °C for 10 min. The mixture was filtered and the filtered cake was dried under vacuum to give tert-butyl N-tert- butoxycarbonyl-N-(2,6-dichloro-3-fluoro-4-pyridyl)carbamate (109 g, 277.34 mmol, 91.27% yield, 97% purity) as a white solid. MS (ES+) C15H19N2Cl2FO4 requires:380, found:381 [M+H]+.1H NMR (400 MHz, CDCl3) δ ppm 7.09 (d, J = 4.25 Hz, 1 H) 1.40 (s, 18H).

[0239] Tert-butyl 4-(tert-butoxycarbonylamino)-2,6-dichloro-5-fluoro-pyridine-3- carboxylate To a solution of DIPA (43.40 g, 428.88 mmol, 60.61 mL, 3 eq) in THF (270 mL) was added dropwise slowly n-BuLi (2.5 M, 171.55 mL, 3 eq) at -78 °C under N2. The mixture was stirred at -40 °C for 1 h under N2. Then tert-butyl N-tert-butoxycarbonyl-N-(2,6- dichloro-3-fluoro-4-pyridyl)carbamate (54.5 g, 142.96 mmol, 1 eq) in THF (500 mL) was added dropwise to the mixture at -78 °C under N2. The mixture was stirred at -78 °C for 0.5 h under N2. LCMS showed the mass of tert-butyl 4-(tert-butoxycarbonylamino)-2,6-dichloro-5- fluoro-pyridine-3-carboxylate. TLC (Petroleum ether : Ethyl acetate = 10:1) showed the starting material was consumed completely and one new spot was formed. The mixture was quenched slowly by water (2000 mL) at 0 °C. Then the mixture was extracted with ethyl acetate (500 mL x 3). The combined organic phase was washed with brine (1000 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was triturated with Petroleum ether : Ethyl acetate = 10:1 (200 mL) at 25 °C for 10 min, then the mixture was filtered and the filtrated cake was dried under vacuum to give the product. The filtrate was concentrated in vacuum and purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~5% Ethyl acetate / Petroleum ether gradient @ 100 mL / min). The products were combined and gave tert-butyl 4-(tert- butoxycarbonylamino)-2,6-dichloro-5-fluoro-pyridine-3-carboxylate (98.5 g, 255.79 mmol, 89.46% yield, 99% purity) as a white solid.

[0240] 4-Amino-2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid A mixture of tert- butyl 4-(tert-butoxycarbonylamino)-2,6-dichloro-5-fluoro-pyridine-3-carboxylate (98.5 g, 258.38 mmol, 1 eq) and HCl / dioxane (4 M, 400 mL, 6.19 eq) was stirred at 25 °C for 16 h. LCMS showed the tert-butyl 4-amino-2,6-dichloro-5-fluoronicotinate was still present, then HCl / dioxane (4 M, 400 mL, 6.19 eq) was added to the mixture at 25 °C. Then the mixture was stirred at 25 °C for another 5 h. LCMS showed the tert-butyl 4-amino-2, 6-dichloro-5- fluoronicotinate was still present and then the mixture was stirred at 25 °C for another 16 h.LCMS showed the tert-butyl 4-amino-2,6-dichloro-5-fluoronicotinate was still present and then HCl / dioxane (6 M, 200 mL, 4.64 eq) was added to the mixture at 25 °C. Then the mixture was stirred at 25 °C for another 2 h. LCMS showed the tert-butyl 4-amino-2,6- dichloro-5-fluoronicotinate was still present and a peak (92%) with the mass of 4-amino-2,6- dichloro-5-fluoro-pyridine-3-carboxylic acid. The mixture was filtered and the filtered cake was dried under vacuum to afford 4-amino-2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid (66 g, 217.10 mmol, 84.02% yield, 98% purity, 2HCl) as a white solid. MS (ES+) C6H3N2Cl2FO2·HCl requires: 223.9,ppm 8.20 - 11.13 (m, 2 H) 6.95 - 7.71 (m, 1 H).

[0241] 5,7-Dichloro-8-fluoro-2-sulfanyl-3H-pyrido[4,3-d]pyrimidin-4-one A mixture of 4-amino-2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid (3 g, 10.07 mmol, 1 eq, 2HCl) and SOCl2(21.31 g, 179.11 mmol, 12.99 mL, 17.79 eq) was stirred at 50 °C for 3 h. LCMS showed the starting material was still present and the mixture was stirred at 50 °C for another 0.5 h. LCMS showed the starting material was consumed completely and a peak (91%) with the mass of (4-amino-2,6-dichloro-5-fluoropyridin-3-yl) (piperidin-1-yl)methanone. Then the mixture was concentrated in vacuum. The residue was diluted with acetone (10 mL) which was added to the mixture of NH4SCN (2.30 g, 30.21 mmol, 2.30 mL, 3 eq) in acetone (20 mL) at 25 °C. Then the resulting mixture was stirred at 25 °C for 1 h. LCMS showed the 4- amino-2,6-dichloro-5-fluoronicotinoyl chloride was consumed completely and 5,7-dichloro- 8-fluoro-2-sulfanyl-3H-pyrido[4, 3-d]pyrimidin-4-one was formed. The mixture was diluted with water (60 mL) and stirred at 25 °C for 10 min. Then the mixture was filtered and washed with water (50 mLx2). Then the filtered cake was dried under vacuum to afford 5,7-dichloro- 8-fluoro-2-sulfanyl-3H-pyrido[4, 3-d]pyrimidin-4-one (1.7 g, 5.69 mmol, 56.47% yield, 89% purity) as a yellow solid. MS (ES+) C7H2N3Cl2FOS requires: 264.9, found: 265.9 [M+H]+.

[0242] 5,7-Dichloro-8-fluoro-2-methylsulfanyl-3H-pyrido[4,3-d]pyrimidin-4-one To a solution of 5,7-dichloro-8-fluoro-2-sulfanyl-3H-pyrido[4, 3-d]pyrimidin-4-one (49.9 g,187.54 mmol, 1 eq) in MeOH (500 mL) was added dropwise NaOH (1 M, 375.08 mL, 2 eq) and MeI (53.24 g, 375.08 mmol, 23.35 mL, 2 eq) at 25 °C. Then the mixture was stirred at 25 °C for 2 h. LCMS showed 5, 7-dichloro-8-fluoro-2-sulfanyl-3H-pyrido[4, 3-d]pyrimidin-4- one was consumed completely and a peak (78%) with the mass of 5,7-dichloro-8-fluoro-2- methylsulfanyl-3H-pyrido[4, 3-d]pyrimidin-4-one. The mixture was poured into water (1500 mL) and adjusted to pH 6 with HCl (1M). Then the mixture was filtered. The filtered cake was triturated with MeCN (500 mL x 2) at 25 °C for 10 min. Then the mixture was filtered and the filtered cake was dried under vacuum to afford 5,7-dichloro-8-fluoro-2- methylsulfanyl-3H-pyrido[4, 3-d]pyrimidin-4-one (51 g, 158.40 mmol, 84.47% yield, 87% purity) as a yellow solid. MS (ES+) C8H4N3Cl2FOS requires: 278.9, found:279.9 [M+H]+.

[0243] 5,7-Dichloro-8-fluoro-2-mercaptopyrido[4,3-d]pyrimidin-4(3H)-one To a solution of 5,7-dichloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (1 g, 3.57 mmol, 1 eq) in DMA (12 mL) was added sodium methoxide (5 M, 3.57 mL, 5 eq). The mixture was stirred at 50 °C for 1 h. LCMS showed a peak (54%) with mass of 7-chloro-8- fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one. The reaction mixture was diluted with water 20 mL and adjusted to pH=2 with 1M HCl. The mixture was filtered and the filter cake was triturated with MeOH ( 3 mL) at 20 °C for 2 hr. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 10~30% Ethyl acetate / Petroleum ether gradient @ 20 mL / min) to afford 7-chloro-8-fluoro-5- methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (700 mg, 2.54 mmol, 71.12% yield) as a white solid.

[0244] Tert-butyl 3-(7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3- d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of 7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (0.7 g, 2.54 mmol, 1 eq) in MeCN (10 mL) was added DIEA (984.46 mg, 7.62 mmol, 1.33 mL, 3 eq) and POCl3(778.64 mg, 5.08 mmol, 471.91 μL, 2 eq). The mixture was stirred at 80 °C for 1 h, then cooled to -10 °C. DIEA (984.46 mg, 7.62 mmol, 1.33 mL, 3 eq) and tert-butyl 3, 8- diazabicyclo[3.2.1]octane-8-carboxylate (539.02 mg, 2.54 mmol, 1 eq) were added. The mixture was stirred at 25 °C for 1 h. LCMS showed a peak (29%) with mass of tert-butyl 3- (7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate. The reaction mixture was diluted with water (100 mL) and the mixture was extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate / Petroleum ether gradient @ 60 mL / min) to afford tert-butyl 3-(7-chloro-8-fluoro-5- methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (700 mg, 1.49 mmol, 58.66% yield) as a yellow solid. MS (ES+) C20H25ClFN5O3S requires: 469, found: 470 [M+H]+.

[0245] Tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-2-(methylthio)pyrido[4,3- d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate A mixture of tert-butyl 3- (7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (450 mg, 957.53 μmol, 1 eq), 2-[2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (490.77 mg, 957.53 μmol, 1 eq), cataCXium® A Pd G3(69.73 mg, 95.75 μmol, 0.1 eq) and K3PO4 (1.5 M, 1.92 mL, 3 eq) in THF (10 mL) was degassed and purged with N2for 3 times, then stirred at 60 °C for 16 h under N2atmosphere. LCMS showed apeak (73%) with the desired mass. The reaction mixture was diluted with water (100 mL) and extracted with Ethyl acetate (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 20~50% Ethyl acetate / Petroleum ether gradient @ 20 mL / min) to afford tert-butyl 3-(8-fluoro-7-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-2- (methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (900 mg, 888.95 μmol, 92.84% yield, 81% purity) as a yellow solid. MS (ES+) C43H55F2N5O5SSi requires: 819, found 820 [M+H]+.

[0246] Tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-2-(methylsulfinyl)pyrido[4,3- d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)- 5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (710 mg, 865.78 μmol, 1 eq) in DCM (21 mL) was added m-CPBA (175.77 mg, 865.78 μmol, 85% purity, 1 eq). The mixture was stirred at 25 °C for 1 h, then further m- CPBA (17.58 mg, 86.58 μmol, 85% purity, 0.1 eq) was added. The mixture was stirred at 25 °C for 1 h. LCMS showed a peak (66%) with the desired mass. The reaction mixture was diluted with Na2SO3 solution (10 mL) and extracted with DCM (10 mL x 3). The combined organic layers were washed with NaHCO3 (10 mL x 3), brine (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give crude product tert-butyl 3- (8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5- methoxy-2-(methylsulfinyl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (800 mg, crude) as a yellow solid. MS (ES+) C43H55F2N5O6SSi requires:835, found:836 [M+H]+.

[0247] Tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-hydroxy-5-methoxypyrido[4,3- d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)- 5-methoxy-2-(methylsulfinyl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (800 mg, 956.86 μmol, 1 eq) in THF (15 mL) was added LiHMDS (1 M, 1.91 mL, 2 eq) under N2atmosphere. The mixture was stirred at 0 °C for 0.5 min, then H2O (86.19 mg, 4.78 mmol, 86.19 μL, 5 eq) was added at 0 °C. The mixture was stirred at 0 °C for 0.5 hr. LCMS showed a peak (56%) with desired mass. The reaction mixture was diluted with water 10 mL and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product tert-butyl 3-(8-fluoro-7-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-hydroxy-5- methoxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (800 mg, 567.10 μmol, 59.27% yield, 56% purity) as a yellow solid. MS (ES+) C42H53F2N5O6Si requires: 789, found: 790 [M+H]+.

[0248] Tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-1-methyl-2-oxo-1,2- dihydropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-hydroxy-5-methoxypyrido[4,3-d]pyrimidin-4- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (800 mg, 1.01 mmol, 1 eq) in DMF (15 mL) was added Cs2CO3 (989.86 mg, 3.04 mmol, 3 eq) and MeI (431.22 mg, 3.04 mmol, 189.13 μL, 3 eq). The mixture was stirred at 25 °C for 1 h. LCMS showed a peak (57%) with desired mass. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate / Petroleum ether gradient @ 40 mL / min) to afford tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-1-methyl-2-oxo-1,2- dihydropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (360 mg, 447.76 μmol, 44.21% yield) as a white solid. MS (ES+) C43H55F2N5O6Si requires: 803, found: 804 [M+H]+.

[0249] 4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-fluoro-3-hydroxy-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-1-methylpyrido[4,3-d]pyrimidin- 2(1H)-one To a solution of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-1-methyl-2-oxo-1,2- dihydropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (360 mg, 447.76 μmol, 1 eq) in DCM (4 mL) was added HCl / dioxane (4 M, 1 mL, 8.93 eq). The mixture was stirred at 25 °C for 1 h. LCMS showed a peak (94%) with desired mass. The reaction mixture was diluted with NaHCO3(20 mL) and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give 4-(3,8- diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-fluoro-3-hydroxy-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-1-methylpyrido[4,3-d]pyrimidin-2(1H)-one (280 mg, 411.62 μmol, 91.93% yield, 97% purity) as a yellow solid. MS (ES+) C36H43F2N5O3Si requires: 659, found: 660 [M+H]+.

[0250] 4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-5-methoxy-1-methylpyrido[4,3-d]pyrimidin-2(1H)- one To a solution of 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-fluoro-3- hydroxy-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methoxy-1-methylpyrido[4,3- d]pyrimidin-2(1H)-one (280 mg, 424.35 μmol, 1 eq) in DMF (5 mL) was added CsF (193.37 mg, 1.27 mmol, 46.94 μL, 3 eq). The mixture was stirred at 40 °C for 2 h. LCMS showed a peak (68%) with desired mass. The reaction mixture was filtered and the filtrate was purified by prep-HPLC (column: Phenomenex Luna® C18150*25 mm* 10um; mobile phase: [water (FA) -ACN]; B%: 28%-58%, 10min) to afford 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8- ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-5-methoxy-1-methylpyrido[4,3- d]pyrimidin-2(1H)-one (126.8 mg, 244.28 μmol, 57.57% yield, 97% purity) as a white solid. MS (ES+) C27H23F2N5O3requires: 503, found: 504 [M+H]+.1H NMR (400 MHz, CD3OD) δ = 8.47 (s, 1H), 7.89 - 7.83 (m, 1H), 7.37 - 7.29 (m, 2H), 7.25 (d, J = 2.3 Hz, 1H), 4.56 - 4.13 (m, 2H), 4.09 - 3.99 (m, 5H), 3.72 (d, J = 7.9 Hz, 3H), 3.69 - 3.53 (m, 3H), 2.17 - 1.90 (m, 4H).4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methylpyrido[4,3-d]pyrimidin-2(1H)-one bis(2,2,2- trifluoroacetate)

[0251] Tert-butyl (1R,5S)-3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate To a solution of 2,4,7-trichloro-8- fluoropyrido[4,3-d]pyrimidine (1 g, 3.96 mmol, 1 eq) in DCM (39.6 mL) was added tert- butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (0.841 g, 3.96 mmol, 1 eq) and N-ethyl-N- isopropylpropan-2-amine (3.37 mL, 19.81 mmol, 5 eq). The resulting mixture was stirred at 0 °C for 1 h. Saturated NH4Cl (10.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (2 x 10.00 mL) and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl (1R,5S)-3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane- 8-carboxylate (1.63 g, 3.81 mmol, 96 % yield) as a white solid. MS (ES+) C18H20Cl2FN5O2 requires: 427, found: 428 [M+H]+.

[0252] Tert-butyl (1R,5S)-3-(2-(benzyloxy)-7-chloro-8-fluoropyrido[4,3-d]pyrimidin- 4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl (1R,5S)-3- (2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (200mg, 0.467 mmol, 1 eq) in DMF (4670 µL) was added sodium hydride (18.68 mg, 0.467 mmol, 1 eq) and benzyl alcohol (36.4 µL, 0.350 mmol, 0.75 eq). The resultingmixture was stirred at 0°C for 10 min. The reaction was then allowed to reach RT and was stirred for 1.5 h. H2O (10.0 mL) was added and the layers were separated. The aqueous phase was extracted with EtOAc (3 x 10.0 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl (1R,5S)-3-(2- (benzyloxy)-7-chloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (200 mg, 0.400 mmol, 86 % yield) as a pale yellow liquid. MS (ES+) C25H27ClFN5O3 requires: 499, found: 500 [M+H]+.

[0253] Tert-butyl (1R,5S)-3-(2-(benzyloxy)-8-fluoro-7-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3- d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate A solution of tert-butyl (1R,5S)-3-(2-(benzyloxy)-7-chloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (200 mg, 0.400 mmol, 1 eq), ((2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (308 mg, 0.600 mmol, 1.5 eq), cataCXium® A Pd Gen.3 (29.1 mg, 0.040 mmol, 0.1 eq), and potassium phosphate (255 mg, 1.200 mmol, 3 eq) in THF (3000 µL) and water (1000 µL) was degassed with N2for 5 minutes. The reaction mixture was heated to 80 °C and stirred for 2 h. Saturated NH4Cl (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with EtOAc (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl (1R,5S)-3-(2-(benzyloxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (274 mg, 0.322 mmol, 81 % yield) as an off-white amorphous material. MS (ES+) C48H57F2N5O5Si requires: 850, found: 851 [M+H]+.

[0254] Tert-butyl (1R,5S)-3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-hydroxypyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate A reaction vessel was charged with tert-butyl (1R,5S)-3-(2-(benzyloxy)-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (274 mg, 0.322 mmol, 1 eq), Pd / C (68.6 mg, 0.064 mmol, 0.2 eq) and EtOH (3223 µL) under an atmosphere of N2. The suspension was degassed with N2for 5 minutes and purged with H2for 5 minutes. The reaction mixture was stirred under an atmosphere of H2 at 1atm for 1hr. The reaction mixture was purged with N2, filtered through Celite®, and concentrated under reduced pressure to give tert-butyl (1R,5S)-3-(8- fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2- hydroxypyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (239 mg, 0.314 mmol, 98 % yield) as a yellow solid. MS (ES+) C41H51F2N5O5Si requires: 759, found: 760 [M+H]+.

[0255] Tert-butyl (1R,5S)-3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2-dihydropyrido[4,3- d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl (1R,5S)-3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-hydroxypyrido[4,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (70 mg, 0.092 mmol, 1 eq) in DMSO (921 µL) wasadded cesium carbonate (90 mg, 0.276 mmol, 3 eq) and iodomethane (15.69 mg, 0.111 mmol, 1.2 eq). The resulting mixture was stirred at 100 °C for 1 h. Saturated NH4Cl (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x 5.00 mL), and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl (1R,5S)-3-(8-fluoro-7-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2- dihydropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (24 mg, 0.031 mmol, 33.7 % yield) as a yellow oil. MS (ES+) C42H53F2N5O5Si requires: 774, found: 775 [M+H]+.

[0256] 4-((1R,5S)-3,8-Diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methylpyrido[4,3-d]pyrimidin-2(1H)-one bis(2,2,2- trifluoroacetate) To a solution of tert-butyl (1R,5S)-3-(8-fluoro-7-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2- dihydropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (24 mg, 0.031 mmol, 1 eq) in DCM (155 µL) was added hydrogen chloride in dioxane (233 µL, 0.930 mmol, 30 eq). The resulting mixture was stirred at 0 °C for 2 h. The reaction was then evaporated under vacuum and redissolved in DMF, after which cesium fluoride (28.9 mg, 0.190 mmol, 6.13 eq) was added to the reaction and allowed to stir at RT for 1 h. Tetrabutylammonium fluoride (46.5 µL, 0.047 mmol, 1.5 eq) was added to the reaction, which led to the formation of a very yellow solution within 30 minutes. The volatiles were then removed under reduced pressure. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 40%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-((1R,5S)-3,8- diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-1- methylpyrido[4,3-d]pyrimidin-2(1H)-one bis(2,2,2-trifluoroacetate) (11 mg, 0.016 mmol, 50.6 % yield) as a pale yellow solid. MS (ES+) C26H21F2N5O2 requires: 473.5, found:474.3 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.77 (s, 1H), 7.88 (dd, J = 9.2, 5.7 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.35 (t, J = 8.9 Hz, 1H), 7.22 (d, J = 2.5 Hz, 1H), 4.70 (d, J = 14.1 Hz, 1H), 4.63 (d, J = 14.4 Hz, 1H), 4.22 (s, 2H), 3.82 (d, J = 14.2 Hz, 2H), 3.79 (d, J = 7.5 Hz, 3H), 3.64 (d, J = 1.0 Hz, 1H), 2.21 – 2.10 (m, 4H). EXAMPLE 954-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8- fluoro-1-methyl-1,6-naphthyridin-2(1H)-one

[0257] Ethyl 6-chloro-5-fluoro-4-(N-methylacetamido)nicotinate To a solution of ethyl 4,6-dichloro-5-fluoronicotinate (250 mg, 1.050 mmol) in MeCN (5251 µL) was added methanamine (2626 µL, 5.25 mmol) and the resulting mixture was stirred at rt for 1 h. Saturated NaHCO3 (10.0 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude material was then dissolved in neat acetyl chloride (824 mg, 10.50 mmol) and stirred at reflux with DMAP present overnight. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give ethyl 6-chloro-5-fluoro-4-(N-methylacetamido)nicotinate (100 mg, 0.364 mmol, 34.7 % yield) as a colorless oil. Compound does not ionize. Rotamers observed in1H NMR.1H NMR (600 MHz, CDCl3) δ 8.78 (dd, J = 57.5, 0.9 Hz, 1H), 4.39 (dq, J = 28.3, 7.1 Hz, 2H), 3.36 – 3.15 (m, 3H), 2.06 (d, J = 257.7 Hz, 3H), 1.39 (t, J = 7.2 Hz, 3H).

[0258] 7-Chloro-8-fluoro-4-hydroxy-1-methyl-1,6-naphthyridin-2(1H)-one To a solution of ethyl 6-chloro-5-fluoro-4-(N-methylacetamido)nicotinate (100 mg, 0.364 mmol) in THF (3641 µL) was added potassium bis(trimethylsilyl)amide (364 µL, 0.364 mmol) and the resulting mixture was stirred at -78 °C to 23 °C for 3 h. Reaction was quenched with NH4Cl and extracted with EtOAc. The aqueous layer was acidified with 1 N HCl (5 mL) (3x) until no more white precipitate formed and extracted with EtOAc (5 mL) each time. The organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The solid was washed with DCM and collected through filtration to give 7-chloro-8-fluoro-4-hydroxy-1- methyl-1,6-naphthyridin-2(1H)-one (67 mg, 0.293 mmol, 81 % yield) as a white solid. MS (ES+) C9H6ClFN2O2 requires: 228, found: 229 [M+H]+.

[0259] 7-Chloro-8-fluoro-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4-yl trifluoromethanesulfonate To a solution of 7-chloro-8-fluoro-4-hydroxy-1-methyl-1,6- naphthyridin-2(1H)-one (67 mg, 0.293 mmol) in DCM (2931 µL) was added trifluoromethanesulfonic anhydride (99 mg, 0.352 mmol) and N-ethyl-N-isopropylpropan-2- amine (114 mg, 0.879 mmol) and the resulting mixture was stirred at 0 °C for 1 h. H2O (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2(3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give 7-chloro-8-fluoro-1-methyl-2-oxo-1,2-dihydro-1,6- naphthyridin-4-yl trifluoromethanesulfonate (70 mg, 0.194 mmol, 66.2 % yield) as a yellow oil. MS (ES+) C10H5ClF4N2O4S requires: 360, found: 361 [M+H]+.

[0260] Tert-butyl 3-(7-chloro-8-fluoro-1-methyl-2-oxo-1,2-dihydro-1,6- naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of 7- chloro-8-fluoro-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4-yl trifluoromethanesulfonate (70 mg, 0.194 mmol) in Acetonitrile (1941 µL) was added tert-butyl 3,8- diazabicyclo[3.2.1]octane-8-carboxylate (49.4 mg, 0.233 mmol) and the resulting mixture was stirred at rt for 1 h. H2O (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 100 % EtOAc in hexanes) to give tert-butyl 3-(7- chloro-8-fluoro-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (40 mg, 0.095 mmol, 48.7 % yield) as a colorless foam-solid. MS (ES+) C20H24ClFN4O3 requires: 422.9, found: 446.2 [M+Na]+.

[0261] Tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2-dihydro-1,6- naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate A microwave vial was charged with tert-butyl 3-(7-chloro-8-fluoro-1-methyl-2-oxo-1,2-dihydro-1,6- naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (40 mg, 0.095 mmol), ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (9A) (63.0 mg, 0.123 mmol), potassium phosphate (60.2 mg, 0.284 mmol), cataCXium® A Pd G3 (6.89 mg, 9.46 µmol), and THF (709 µL). The reactionmixture was degassed with N2for 5 minutes. The vial was sealed and the reaction mixture was heated to 100 °C in the microwave reactor for 2.5 h. Saturated NH4Cl (5.00 mL) was added and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (45 mg, 0.058 mmol, 61.5 % yield) as a brown oil. MS (ES+) C43H54F2N4O5Si requires: 772, found: 773 [M+H]+.

[0262] 4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methyl-1,6-naphthyridin-2(1H)-one To a solution of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (45 mg, 0.058 mmol) in DCM (582 µL) was added hydrogen chloride (146 µL, 0.582 mmol) and the resulting mixture was stirred at 0 °C for 2 h and at 23 °C for 2 h. TFA (1 mL) was then added to the reaction and stirred for another 30 min. Saturated NaHCO3 (10.0 mL) was added and the layers were separated. The aqueous phase was extracted with EtOAc (3 x 5.00 mL), the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude was dissolved in DMF (1 mL) and to this was added cesium fluoride (44.2 mg, 0.291 mmol). The reaction was allowed to stir overnight at 23 °C., TBAF (1M in THF, 200 µL) was then added and the reaction was stirred for 3 hrs. The solvent was removed under reduced pressure. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 40%; 12 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methyl-1,6-naphthyridin-2(1H)-one bis(2,2,2-trifluoroacetate) (5 mg, 7.14 µmol, 12.26 % yield) as a yellow powder. MS (ES+) C27H22F2N4O2 requires: 472, found: 473 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.85 (s, 1H), 7.88 (dd, J = 9.1, 5.7 Hz, 1H), 7.38 – 7.31 (m, 2H), 7.24 (d, J = 2.6 Hz, 1H), 6.36 (s, 1H), 4.27 (s, 2H), 3.83 (d, J = 8.1 Hz, 3H), 3.66 (d, J = 13.5 Hz, 1H), 3.59 (d, J = 13.2 Hz, 1H), 3.53 (d, J = 1.0 Hz, 1H), 3.33 – 3.32 (m, 1H), 3.27 (s, 1H), 2.51 – 2.42 (m, 2H), 2.30 – 2.23 (m, 2H). EXAMPLE 964-(3,8-diazabicyclo[3.2.1]octan-3-yl)-3-bromo-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methyl-1,6-naphthyridin-2(1H)-one

[0263] Tert-butyl 3-(3-bromo-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2-dihydro-1,6- naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of tert-butyl 3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (130 mg, 0.168 mmol) in DCM (1682 µL) was added 1-bromopyrrolidine-2,5-dione (29.9 mg, 0.168 mmol) and the resulting mixture was stirred at 23 °C for 2 h. The reaction was directly loaded onto the column and was purified via silica gel chromatography (0 - 50 % EtOAc in hexanes) to give tert-butyl 3-(3-bromo-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1- yl)-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (140 mg, 0.164 mmol, 98 % yield) as a yellow oil. MS (ES+) C43H53BrF2N4O5Si requires: 852, found: 853 [M+H]+.

[0264] 4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-3-bromo-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methyl-1,6-naphthyridin-2(1H)-one To a solution of tert-butyl 3-(3-bromo-7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1- yl)-8-fluoro-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-4-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (32 mg, 0.046 mmol) in DCM (307 µL) was added hydrogen chloride in dioxane 4N (1.677 mg, 0.046 mmol) and the resulting mixture was stirred at 23 °C for 2 h. The volatiles were removed under reduced pressure. The residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 40%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-3-bromo-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methyl-1,6-naphthyridin-2(1H)-one bis(2,2,2- trifluoroacetate) (9 mg, 0.012 mmol, 25.10 % yield) as a yellow solid. MS (ES+) C27H21BrF2N4O2 requires: 551.4, found: 553.0 [M+H]+.1H NMR (600 MHz, MeOD) δ 9.14 (s, 1H), 7.88 (dd, J = 9.2, 5.7 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.34 (t, J = 8.9 Hz, 1H), 7.23 (d, J = 2.6 Hz, 1H), 4.23 (s, 2H), 4.21 – 4.16 (m, 2H), 3.94 (d, J = 7.8 Hz, 3H), 3.56 (s, 1H), 3.18 – 3.14 (m, 2H), 2.52 - 2.51 (3, 2H), 2.28 – 2.25 (m, 2H). EXAMPLE 9744-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)- 8-fluoro-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile

[0265] Methyl 4-bromo-3-fluoro-2-(methylamino)benzoate To a solution of methyl 4- bromo-2,3-difluorobenzoate (500 mg, 1.99 mmol) in acetonitrile (5 mL) was added methanamine (1.99 mL, 3.98 mmol) and the resulting mixture was stirred at 23 °C for 16 h. When no reaction was observed, the reaction was heated to 50 °C and stirred for 24 hours. After this time, reaction was observed. The reaction was cooled to room temperature and the volatiles removed under reduced pressure. The residue was purified via silica gel chromatography (0 - 30 % EtOAc in hexanes) to give methyl 4-bromo-3-fluoro-2- (methylamino)benzoate (269.9 mg, 1.03 mmol, 51.7 % yield) as a pale yellow solid. MS (ES+) C9H9BrFNO2 requires: 261 / 263, found: 262 / 264 [M+H]+.

[0266] Methyl 4-bromo-3-fluoro-5-iodo-2-(methylamino)benzoate To a solution of methyl 4-bromo-3-fluoro-2-(methylamino)benzoate (1.0 g, 3.82 mmol) in DMF (10 mL) was added N-iodosuccinimide (1.2 g, 5.72 mmol) and the resulting mixture was stirred at 70 °C for 16 h. The reaction mixture was poured into ice water and extracted with EtOAc (3 x 10.0 mL). The combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude was taken forward without further purification. MS (ES+) C9H8BrFINO2 requires: 358, found: 357, 359 [M-H]-. 1H NMR (600 MHz, DMSO) δ 7.99 (d, J = 1.8 Hz, 1H), 6.87 (s, 2H), 3.83 (s, 3H).

[0267] Methyl 4-bromo-5-cyano-3-fluoro-2-(methylamino)benzoate To a suspension of methyl 4-bromo-3-fluoro-5-iodo-2-(methylamino)benzoate (150 mg, 0.38 mmol) in DMF (4 mL) was added copper(I)cyanide (69.3 mg, 0.77 mmol), and the resulting mixture was stirred at 100 °C for 6 h. Once complete, the reaction mixture was filtered and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 30 % EtOAc in hexanes) to give methyl 4-bromo-5-cyano-3-fluoro-2- (methylamino)benzoate (65 mg, 0.22 mmol, 58.6 % yield) as a pale yellow solid. MS (ES+) C10H8BrFN2O2 requires: 286 / 288, found: 287 / 289 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.43 – 8.24 (m, 1H), 8.05 – 7.92 (m, 1H), 3.89 (s, 3H), 3.26 – 3.18 (m, 3H).

[0268] Methyl 5-cyano-3-fluoro-4-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(methylamino)benzoate A solution of methyl 4-bromo-5-cyano-3-fluoro-2-(methylamino)benzoate (65 mg, 0.22 mmol), ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (174 mg, 0.34 mmol), potassium phosphate (120 mg, 0.56 mmol) and cataCXium® A Pd G3 (16.51 mg, 0.023 mmol) in THF (2 mL) and Water (0.5 mL) was degassed with N2for 10 minutes. The reaction mixture was heated to 80 °C and stirred for 3 h. The reaction mixture was diluted with CH2Cl2 (2.00 mL) and washed with sat NH4Cl (2.00 mL). The layers were separated, and the aqueous phase was extracted with CH2Cl2 (2 x 2.00 mL). The combined organic layers were washed with sat NaCl, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0 - 50% EtOAc in hexanes) to give methyl 5-cyano-3-fluoro-4-(7- fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(methylamino)benzoate (55 mg, 0.093 mmol, 41.0 % yield) as a red solid. MS (ES+) C33H38F2N2O4Si requires: 592, found: 593 [M+H]+.

[0269] 8-Fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2,4-dioxo-1,2,3,4- tetrahydroquinazoline-6-carbonitrile To a solution of methyl 5-cyano-3-fluoro-4-(7- fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2- (methylamino)benzoate (55 mg, 0.093 mmol) in THF (1 mL) was added 2,2,2-trichloroacetyl isocyanate (0.022 mL, 0.186 mmol) and the resulting mixture was stirred at 23 °C for 30 min. To the reaction mixture was added ammonia (0.13 mL, 0.928 mmol), and the reaction mixture was stirred at rt for 18 h. The volatiles were removed under reduced pressure and the product was used without purification in the following step. MS (ES+) C33H35F2N3O4Si requires: 603, found: 604 [M+H]+.

[0270] Tert-butyl 3-(6-cyano-8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate To a solution of 8-fluoro-7-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2,4-dioxo- 1,2,3,4-tetrahydroquinazoline-6-carbonitrile (56 mg, 0.093 mmol) in acetonitrile (0.7 mL) and potassium carbonate (77 mg, 0.55 mmol) was added 2,4,6-trimethylbenzenesulfonyl chloride (60.9 mg, 0.27 mmol) and the resulting mixture was stirred at 23 °C for 18 h. A solution of tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (39.4 mg, 0.18 mmol) in acetonitrile (0.2 mL) was added, and the reaction mixture was stirred at rt for 15 min. The reaction mixture was diluted with EtOAc (1.00 mL) and washed with H2O (2.00mL). The layers were separated and the organic layer was washed with sat NaCl (2.00 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was taken forward without further purification. MS (ES+) C44H53F2N5O5Si requires: 797, found: 798 [M+H]+.

[0271] 4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methyl-2-oxo-1,2-dihydroquinazoline-6- carbonitrile To a solution of tert-butyl 3-(6-cyano-8-fluoro-7-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-1-methyl-2-oxo-1,2- dihydroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (26 mg, 0.033 mmol) in THF (0.3 mL) was added TBAF (0.036 mL, 0.033 mmol) and the resulting mixture was stirred at 25 °C for 1 h. The volatiles were removed under reduced pressure. To the residue in a solution of CH2Cl2 (0.3 mL) was added HCl (0.08 mL, 0.326 mmol) and the resulting mixture was stirred at 25 °C for 4 h. The volatiles were removed under reduced pressure and the residue was purified by mass-triggered preparative HPLC (Mobile phase: A = 0.1% TFA / H2O, B = 0.1% TFA / MeCN; Gradient: B = 10 - 40%; 20 min; Column: XBridge C18, 5 μm, 19 mm x 150 mm) to give 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3- hydroxynaphthalen-1-yl)-8-fluoro-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile 2,2,2-trifluoroacetate (2.4 mg, 3.92 µmol, 12.05 % yield) as a pale yellow solid. MS (ES+) C28H21F2N5O2requires: 497, found: 498 [M+H]+.1H NMR (600 MHz, MeOD) δ 8.05 (d, J = 7.8 Hz, 1H), 7.93 – 7.84 (m, 1H), 7.37 (dd, J = 17.8, 8.2 Hz, 2H), 7.15 (d, J = 15.2 Hz, 1H), 4.59 (dd, J = 33.1, 14.3 Hz, 2H), 4.21 (d, J = 15.4 Hz, 2H), 3.87 (d, J = 13.5 Hz, 1H), 3.81 – 3.73 (m, J = 6.1, 5.5 Hz, 4H), 3.62 (d, J = 7.9 Hz, 1H), 1.48 – 1.24 (m, 4H).

[0272] The following Examples were synthesized with procedures that were similar to the examples disclosed herein and can generally be made by methods disclosed herein from the appropriate starting materials.Table 3. Example Compounds.EXAMPLE 1244-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-hydroxytetralin-5-yl)-1-methyl- pyrido[4,3-d]pyrimidin-2-one Step 1 1-(8-bromotetralin-6-yl)ethanone

[0273] 1-tetralin-6-ylethanone (5 g, 28.70 mmol, 1 eq) was added into AlCl3 (9.57 g, 71.74 mmol, 3.92 mL, 2.5 eq) at 20 °C, and the mixture was stirred at 70 °C for 20 min. Then the reaction was cooled to 20°C and Br2 (5.50 g, 34.44 mmol, 1.77 mL, 1.2 eq) was added, and the mixture was stirred at 85 °C for 1 h. LCMS showed a peak (41%) of desired mass. The reaction mixture was quenched with water (300 mL) at 0 °C, then extracted with DCM (300 mL * 2). The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, eluent of 0~20% ethyl acetate / petroleum ether gradient @100 mL / min) and re-purified by prep-HPLC (column:Phenomenex luna C18150*40mm* 15um; mobile phase:[water(FA)-ACN]; gradient: 55%- 85% B over 10 min) and lyophilized to afford 1-(8-bromotetralin-6-yl)ethanone (1.7 g, 6.25 mmol, 21.76% yield, 93% purity) as a white solid.

[0274] MS (ES+) C12H13BrO requires: 252, found: 253, 255 [M+H]+

[0275] 1H NMR (400 MHz, DMSO-d6) δ ppm 7.90 (d, J = 3.5 Hz, 1H), 7.68 (d, J = 4.2 Hz, 1H), 2.81 (d, J = 4.3 Hz, 2H), 2.74 - 2.65 (m, 2H), 2.55 (s, 3H), 1.83 - 1.66 (m, 4H). Step 2 (8-bromotetralin-6-yl) acetate

[0276] To a solution of 1-(8-bromotetralin-6-yl)ethanone (1.68 g, 6.64 mmol, 1 eq) in DCM (30 mL) were added Na2SO4(1.18 g, 8.30 mmol, 841.69 μL, 1.25 eq), m-CPBA (2.69 g, 13.27 mmol, 85% purity, 2 eq) and trifluoromethanesulfonic acid (99.60 mg, 663.68 μmol, 58.73 μL, 0.1 eq) at 20 °C. The mixture was stirred at 20 °C for 16 hrs. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluent of 0~10% Ethyl acetate / Petroleum ether gradient @60 mL / min) to afford (8-bromotetralin-6-yl) acetate (1.1 g, 4.05 mmol, 60.97% yield, 99% purity) as a colorless oil.

[0277] 1H NMR (400 MHz, DMSO-d6) δ ppm 7.25 (d, J = 2.2 Hz, 1H), 6.89 (d, J = 1.8 Hz, 1H), 2.73 (t, J = 6.1 Hz, 2H), 2.62 (t, J = 6.3 Hz, 2H), 2.24 (s, 3H), 1.80 - 1.64 (m, 4H) Step 3 8-bromotetralin-6-ol

[0278] To a solution of (8-bromotetralin-6-yl) acetate (300 mg, 1.11 mmol, 1 eq) in MeOH (9 mL) was added MeONa (72.26 mg, 1.34 mmol, 1.11 mL, 1.2 eq). The mixture was stirred at 20 °C for 20 min. The reaction mixture was quenched with HCl (1M in water, 10 mL), then diluted with water (5 mL) and extracted with EtOAc (10 mL * 3). The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to give 8- bromotetralin-6-ol (250 mg, 1.05 mmol, 93.82% yield, 95% purity) as a colorless oil.

[0279] 1H NMR (400 MHz, DMSO-d6) δ ppm 9.44 (s, 1H), 6.82 (d, J = 2.4 Hz, 1H), 6.50 (d, J = 2.2 Hz, 1H), 2.63 (t, J = 6.1 Hz, 2H), 2.55 - 2.51 (m, 2H), 1.76 - 1.68 (m, 2H), 1.67 - 1.59 (m, 2H) Step 4 5-bromo-7-(methoxymethoxy)tetralin

[0280] To a solution of 8-bromotetralin-6-ol (250 mg, 1.10 mmol, 1 eq) and DIPEA (426.82 mg, 3.30 mmol, 575.23 μL, 3 eq) in DCM (6 mL) was added bromo(methoxy)methane (206.35 mg, 1.65 mmol, 134.78 μL, 1.5 eq) at 0 °C. The mixture was stirred at 25 °C for 0.5 h under N2 atmosphere. The reaction mixture was quenched with water (20 mL) at 0 °C, then extracted with DCM (20 mL * 3). The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, eluent of 0~10% Ethyl acetate / Petroleum ether gradient @60 mL / min) to afford 5-bromo-7- (methoxymethoxy)tetralin (200 mg, 700.72 μmol, 63.65% yield, 95% purity) as a colorless oil.

[0281] 1H NMR (400 MHz, DMSO-d6) δ ppm 7.09 (d, J = 2.2 Hz, 1H), 6.77 (s, 1H), 5.15 (s, 2H), 3.35 (s, 3H), 2.69 (t, J = 6.0 Hz, 2H), 2.59 - 2.55 (m, 2H), 1.84 - 1.76 (m, 2H), 1.68 - 1.63 (m, 2H) Step 5 2-[7-(methoxymethoxy)tetralin-5-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0282] To a solution of 5-bromo-7-(methoxymethoxy)tetralin (0.15 g, 553.20 μmol, 1.5 eq) in dioxane (2 mL) were added BPD (140.48 mg, 553.20 μmol, 1.5 eq), KOAc (108.58 mg, 1.11 mmol, 3 eq) and Pd(dppf)Cl2 (53.97 mg, 73.76 μmol, 0.2 eq) under the protection of N2, then the mixture was stirred at 90 °C for 16 hours. TLC (petroleum ether:EtOAc = 20:1) showed several spots were detected. The mixture was filtered with diatomite, the filtrate wasconcentrated under vacuum to give a residue. The residue was purified by flash column chromatography (4 g SepaFlash Silica Flash Column, eluent of 0~6% Ethyl acetate / Petroleum ether gradient @45 mL / min) to afford 2-[7-(methoxymethoxy)tetralin-5- yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (80 mg, 251.40 μmol, 53.33% yield) as a light yellow oil.

[0283] 1H NMR (400 MHz, CDCl3) δ ppm 7.27 - 7.24 (m, 1H), 6.84 (d, J = 2.4 Hz, 1H), 5.16 (s, 2H), 3.48 (s, 3H), 2.97 (t, J = 5.9 Hz, 2H), 2.76 (t, J = 5.7 Hz, 2H), 1.82 - 1.71 (m, 4H), 1.34 (s, 12H) Step 6 tert-butyl 3-[8-fluoro-7-[7-(methoxymethoxy)tetralin-5-yl]-1-methyl-2-oxo-pyrido[4,3- d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0284] To a mixture of 2-[7-(methoxymethoxy)tetralin-5-yl]-4,4,5,5-tetramethyl-1,3,2- dioxaborolane (60 mg, 188.55 μmol, 1 eq) and tert-butyl 3-(7-chloro-8-fluoro-1-methyl-2- oxo-pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (79.92 mg, 188.55 μmol, 1 eq) in THF (5 mL) were added K3PO4(1.5 M in water, 377.10 μL, 3 eq) and cataCXium® A Pd G3 (13.73 mg, 18.86 μmol, 0.1 eq). The mixture was degassed and placed under N23 times, then stirred at 60 °C for 2 hrs. LCMS showed the major peak (56%) with desired mass was detected. The mixture was added H2O (5 mL), extracted with EtOAc (5 mL * 3). The organic phase was collected and washed with brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated to give a crude product. The crude product was purified by prep-TLC (petroleum ether:EtOAc=1:3) to afford tert-butyl 3-[8-fluoro-7-[7- (methoxymethoxy)tetralin-5-yl]-1-methyl-2-oxo-pyrido[4,3-d]pyrimidin-4-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (90 mg, 153.71 μmol, 81.52% yield, 99% purity) as a yellow solid.

[0285] MS (ES+) C31H38N5O5F requires: 579, found: 580 [M+H]+Step 74-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-hydroxytetralin-5-yl)-1-methyl- pyrido[4,3-d]pyrimidin-2-one

[0286] To a solution of tert-butyl 3-[8-fluoro-7-[7-(methoxymethoxy)tetralin-5-yl]-1- methyl-2-oxo-pyrido[4,3-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (90 mg, 155.26 μmol, 1 eq) in DCM (3 mL) was added TFA (1.54 g, 13.46 mmol, 1 mL, 86.71 eq) and the mixture was stirred at 30 °C for 0.5 hr. LCMS showed a major peak (72%) with desired mass. The mixture was poured into ice cold saturated NaHCO3 (5 mL) while stirring, then the aqueous layers were separated and extracted with EtOAc (5 mL * 3). The organic phase was washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated to give a crude product. The crude product was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)- ACN];gradient:7%-37% B over 10 min) and lyophilized to afford 4-(3,8- diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-7-(7-hydroxytetralin-5-yl)-1-methyl-pyrido[4,3- d]pyrimidin-2-one (33.3 mg, 65.70 μmol, 42.31% yield, 95% purity, FA) as a white solid.

[0287] MS (ES+) C24H26FN5O2requires: 435, found: 436 [M+H]+

[0288] 1H NMR (400 MHz, CD3OD) δ ppm 8.75 (s, 1H), 8.48 (s, 0.5H), 6.66 (d, J = 2.4 Hz, 1H), 6.58 (d, J = 2.4 Hz, 1H), 4.62 (d, J = 13.4 Hz, 2H), 4.04 - 3.93 (m, 2H), 3.82 - 3.71 (m, 5H), 2.79 (t, J = 6.3 Hz, 2H), 2.46 (t, J = 6.2 Hz, 2H), 2.07 - 1.97 (m, 4H), 1.82 - 1.75 (m, 2H), 1.74 - 1.67 (m, 2H). EXAMPLE 1257-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-8-fluoro-1-methyl-4-(3-oxa-7,9- diazabicyclo[3.3.1]nonan-9-yl)-5-phenoxy-pyrido[4,3-d]pyrimidin-2-one Step 1 7-chloro-8-fluoro-2-methylsulfanyl-5-phenoxy-3H-pyrido[4,3-d]pyrimidin-4-one

[0289] To a solution of 5,7-dichloro-8-fluoro-2-methylsulfanyl-3H-pyrido[4,3- d]pyrimidin-4-one (400 mg, 1.43 mmol, 1 eq) in DMA (4 mL) were added Cs2CO3 (1.40 g, 4.28 mmol, 3 eq) and PhOH (161.27 mg, 1.71 mmol, 150.58 μL, 1.2 eq). The mixture was stirred at 80 °C for 16 hours under N2. LCMS showed starting material was consumed completely and 88% peak with desired mass. The reaction mixture was poured into water (30 mL), the pH was adjusted to 6 by addition HCl (1N) and filtered. The filter cake was washed with water (30 mL x 3), dried in vacuum to afford 7-chloro-8-fluoro-2-methylsulfanyl-5- phenoxy-3H-pyrido[4,3-d]pyrimidin-4-one (543 mg, 1.41 mmol, 99.07% yield, 88% purity) as a yellow solid.

[0290] MS (ES+) C14H9N3O2ClFS requires: 337, found: 338 [M+H]+

[0291] 1H NMR (400 MHz, DMSO-d6) δ = 13.45 - 12.95 (m, 1H), 7.44 (t, J = 7.9 Hz, 2H), 7.26 (t, J = 7.4 Hz, 1H), 7.16 (d, J = 7.7 Hz, 2H), 2.61 (s, 3H). Step 2 Tert-butyl 9-(7-chloro-8-fluoro-2-methylsulfanyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4- yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate

[0292] To a solution of 7-chloro-8-fluoro-2-methylsulfanyl-5-phenoxy-3H-pyrido[4,3- d]pyrimidin-4-one (200 mg, 521.09 μmol, 1 eq) in DCM (10 mL) were added DIPEA (538.77 mg, 4.17 mmol, 726.11 μL, 8 eq) and Tf2O (646.88 mg, 2.29 mmol, 378.29 μL, 4.4 eq) at 0 °C under the protection of N2. The mixture was stirred at 20 °C for 1 hour. To the mixture were added DIPEA (269.39 mg, 2.08 mmol, 363.06 μL, 4 eq) and tert-butyl 3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate (118.96 mg, 521.09 μmol, 1 eq). The mixture was stirred at 20 °C for 0.5 hour. LCMS showed a peak (54%) with desired mass. The reaction mixture was concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 9-(7-chloro-8- fluoro-2-methylsulfanyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate (433 mg, crude) as yellow oil.

[0293] MS (ES+) C25H27N5FClO4S requires: 547, found: 548 [M+H]+Step 3 Tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-2-methylsulfanyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate

[0294] To a solution of tert-butyl 9-(7-chloro-8-fluoro-2-methylsulfanyl-5-phenoxy- pyrido[4,3-d]pyrimidin-4-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (200 mg, 364.94 μmol, 1 eq) in THF (7.5 mL) were added cataCXium® A Pd G3 (26.58 mg, 36.49μmol, 0.1 eq), 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1-naphthyl]ethynyl-triisopropyl-silane (187.05 mg, 364.94 μmol, 1 eq) and K3PO4(1.5 M, 729.89 μL, 3 eq). The mixture was stirred at 60 °C for 16 hours under N2. LCMS showed a peak (68%) with desired mass. To the mixture was added water (15 mL) and extracted with ethyl acetate (15 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~25% Ethyl acetate / Petroleum ether gradient @ 60 mL / min) to afford tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-2-methylsulfanyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4- yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (156 mg, 163.27 μmol, 44.74% yield, 94% purity) as brown oil.

[0295] MS (ES+) C48H57N5F2O6SSi requires: 897, found: 898 [M+H]+Step 4 Tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-2-methylsulfonyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate

[0296] To a solution of tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-2-methylsulfanyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4- yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (136 mg, 151.42 μmol, 1 eq) in DCM (1 mL) was added m-CPBA (27.67 mg, 136.28 μmol, 85% purity, 0.9 eq) at 20 °C. The mixture was stirred at 20 °C for 1 hour. LCMS showed a peak (66%) with desired mass. The reaction mixture was quenched with Na2SO3(10 mL) and extracted with DCM (10 mL x 3). The combined organic phase was washed with Na2SO3 (10 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (4 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 40 mL / min) to afford tert-butyl 9-[8-fluoro- 7-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-2-methylsulfonyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate (54 mg, 46.44 μmol, 30.67% yield, 80% purity) as yellow oil.

[0297] MS (ES+) C48H57N5F2O8SSi requires: 929, found: 930 [M+H]+Step 5 Tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-2-oxo-5-phenoxy-1H-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate

[0298] To a solution of tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-2-methylsulfonyl-5-phenoxy-pyrido[4,3-d]pyrimidin-4- yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (27 mg, 29.03 μmol, 1 eq) in THF (1 mL) were added LiHMDS (1 M, 58.06 μL, 2 eq) and H2O (0.2 mL) under N2at 0 °C. The mixture was stirred at 0 °C for 1 hour under N2. A peak (61%) with desired mass was detected by LCMS. The reaction mixture was quenched with NH4Cl (15 mL) and extracted with ethyl acetate (15 mL x 3). The combined organic phase was washed with brine (15 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 9- [8-fluoro-7-[7-fluoro-3 -(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-2-oxo- 5-phenoxy-1H-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7- carboxylate (60 mg, crude) as yellow oil.

[0299] MS (ES+) C47H55N5F2O7Si requires: 867, found: 868 [M+H]+Step 6 Tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1-methyl-2-oxo-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate

[0300] To a solution of tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-2-oxo-5-phenoxy-1H-pyrido[4,3-d]pyrimidin-4-yl]-3- oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (60 mg, 44.93 μmol, 1 eq) in DMF (1 mL) were added MeI (38.26 mg, 269.57 μmol, 16.78 μL, 6 eq) and Cs2CO3(43.92 mg, 134.79 μmol, 3 eq) at 25 °C. The mixture was stirred at 25 °C for 1 hour. LCMS showed a peak (55%) with desired mass. To the mixture was added water (10 mL) and extracted with ethyl acetate (10 mL x 3), the combined organic phase was washed with brine (15 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-TLC (SiO2, Petroleum ether : Ethyl acetate= 1:1.5) to afford tert- butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1-methyl-2-oxo-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate (20 mg, 21.54 μmol, 47.94% yield, 95% purity) as yellow oil.

[0301] MS (ES+) C48H57N5F2O7Si requires: 881, found:882 [M+H]+Step 7 Tert-butyl 9-[7-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-8-fluoro-1-methyl- 2-oxo-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7- carboxylate

[0302] To a solution of tert-butyl 9-[8-fluoro-7-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1-methyl-2-oxo-5-phenoxy-pyrido[4,3-d]pyrimidin-4- yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (18 mg, 20.41 μmol, 1 eq) in DMF (1mL) was added CsF (20 mg, 61.2 μmol, 3 eq) at 30 °C. The mixture was stirred at 30 °C for 1 hour. LCMS showed a peak (98%) with desired mass. To the mixture was added water (3 mL) and extracted with ethyl acetate (3 mL x 3). The combined organic phase was washed with brine (3 mL x 3). Then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum to afford tert-butyl 9-[7-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-8-fluoro-1-methyl-2-oxo-5-phenoxy-pyrido[4,3-d]pyrimidin- 4-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (15 mg, crude) as yellow oil.

[0303] MS (ES+) C39H37N5F2O7requires: 725, found:726 [M+H]+Step 8 7-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-8-fluoro-1-methyl-4-(3-oxa-7,9- diazabicyclo[3.3.1]nonan-9-yl)-5-phenoxy-pyrido[4,3-d]pyrimidin-2-one

[0304] To a solution of tert-butyl 9-[7-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-8-fluoro-1-methyl-2-oxo-5-phenoxy-pyrido[4,3-d]pyrimidin-4-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate (15 mg, 20.67 μmol, 1 eq) in DCM (0.6 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL). The mixture was stirred at 25 °C for 20 min. LCMS showed a peak (73%) with desired mass. The mixture was adjusted pH to 7 by cold saturated aq. NaHCO3at 25 °C. Then the aqueous phase was extracted with ethyl acetate (20 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 20%-40% B over 9 min) and lyophilized to afford 7-(8-ethynyl-7-fluoro-3-hydroxy- 1-naphthyl)-8-fluoro-1-methyl-4-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl)-5-phenoxy- pyrido[4,3-d]pyrimidin-2-one (1 mg, 1.69 μmol, 8.15% yield, 98% purity, FA) as a yellow solid.

[0305] MS (ES+) C32H25N5F2O4·CH2O2 requires: 581, found:582 [M+H]+

[0306] 1H NMR (400 MHz, CD3OD) δ = 8.57 - 8.45 (m, 1H), 7.80 (dd, J = 5.8, 9.1 Hz, 1H), 7.40 - 7.33 (m, 2H), 7.33 - 7.28 (m, 1H), 7.28 - 7.24 (m, 1H), 7.23 - 7.14 (m, 3H), 7.07(d, J = 2.4 Hz, 1H), 4.64 - 4.57 (m, 2H), 4.29 - 4.15 (m, 2H), 4.14 - 4.02 (m, 2H), 3.79 (m, 4H), 3.67 - 3.43 (m, 4H) EXAMPLE 1264-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(pyridin-3- ylmethoxy)-2,7-naphthyridin-3-yl)-6-fluoro-5-((triisopropylsilyl)ethynyl)naphthalen-2- ol

[0307] MS (ES+) C33H27F2N5O2requires: 563, found: 564 [M+H]+.

[0308] 1H NMR (600 MHz, CD3OD) δ 9.12 (s, 1H), 8.82 (s, 1H), 8.64 (d, J = 5.1 Hz, 1H), 8.27 (d, J = 7.9 Hz, 1H), 7.87 (dd, J = 9.2, 5.7 Hz, 1H), 7.72 (dd, J = 7.9, 5.1 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.32 (d, J = 8.9 Hz, 1H), 7.23 (d, J = 2.6 Hz, 1H), 5.69 (s, 2H), 4.24 (s, 2H), 4.02 (dd, J = 25.5, 13.7 Hz, 2H), 3.66 (dd, J = 13.6, 6.9 Hz, 2H), 2.59 (d, J = 4.9 Hz, 3H), 2.39 – 2.31 (m, 2H), 2.23 – 2.16 (m, 2H). EXAMPLE 1274-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(pyridin-4- ylmethoxy)-2,7-naphthyridin-3-yl)-6-fluoro-5-((triisopropylsilyl)ethynyl)naphthalen-2- ol

[0309] MS (ES+) C33H27F2N5O2requires: 563, found: 564 [M+H]+.

[0310] 1H NMR (600 MHz, CD3OD) δ 9.10 (s, 1H), 8.66 (d, J = 5.5 Hz, 2H), 7.87 (dd, J = 9.1, 5.6 Hz, 1H), 7.75 (d, J = 5.4 Hz, 2H), 7.36 (d, J = 2.5 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.23 (d, J = 2.6 Hz, 1H), 5.73 (s, 2H), 4.20 (s, 2H), 3.98 (dd, J = 39.9, 13.7 Hz, 3H), 3.59 (dd, J = 13.8, 6.8 Hz, 2H), 2.65 (s, 3H), 2.32 – 2.26 (m, 2H), 2.17 – 2.13 (m, 2H). EXAMPLE 128(3R,4R)-1-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-5-fluoro-6-(7-fluoro-3-hydroxy- 8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-4-methyl-2,7-naphthyridin-3-yl)-4- fluoropyrrolidin-3-ol

[0311] MS (ES+) C31H28F3N5O2 requires: 559, found: 560 [M+H]+.

[0312] 1H NMR (600 MHz, CD3OD) δ 10.13 (s, 1H), 8.93 (s, 1H), 7.99 – 7.95 (m, 1H), 7.58 – 7.54 (m, 2H), 7.48 (dd, J = 16.4, 8.0 Hz, 2H), 7.38 (d, J = 2.6 Hz, 1H), 4.50 (d, J = 2.0 Hz, 1H), 4.22 (d, J = 2.0 Hz, 1H), 4.20 (s, 2H), 3.92 (s, 2H), 3.85 (s, 2H), 2.40 (d, J = 5.2 Hz, 4H), 2.03 (s, 3H), 1.59 (s, 2H), 1.34 – 1.28 (m, 2H), 1.17 – 1.08 (m, 3H), 0.87 (t, J = 7.5 Hz, 3H). EXAMPLE 1294-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(pyrimidin-5- ylmethoxy)-2,7-naphthyridin-3-yl)-6-fluoro-5-((triisopropylsilyl)ethynyl)naphthalen-2- ol

[0313] MS (ES+) C32H26F2N6O2requires: 564, found: 565 [M+H]+.

[0314] 1H NMR (600 MHz, CD3OD) δ 9.15 (s, 1H), 9.13 (d, J = 1.6 Hz, 1H), 8.96 (s, 2H), 7.87 (dd, J = 9.1, 5.6 Hz, 1H), 7.36 (t, J = 2.7 Hz, 1H), 7.33 (td, J = 8.9, 1.4 Hz, 1H), 7.24 (dd, J = 4.8, 2.6 Hz, 1H), 5.66 (s, 2H), 4.24 (s, 2H), 4.03 (q, J = 14.3, 11.3 Hz, 2H), 3.65 (t, J = 10.9 Hz, 2H), 2.58 (d, J = 4.8 Hz, 3H), 2.35 (s, 2H), 2.26 – 2.13 (m, 2H). EXAMPLE 1304-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(3-((1-methyl-1H- pyrazol-4-yl)oxy)azetidin-1-yl)-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2- ol

[0315] MS (ES+) C34H31F2N7O2 requires: 607, found: 608 [M+H]+.

[0316] 1H NMR (600 MHz, MeOD) δ 8.86 (s, 1H), 7.90 (dd, J = 9.2, 5.6 Hz, 1H), 7.41 (d, J = 2.5 Hz, 1H), 7.39 – 7.35 (m, 3H), 7.30 (d, J = 2.6 Hz, 1H), 7.21 (s, 1H), 4.73 – 4.66 (m, 3H), 4.44 (dd, J = 11.9, 6.7 Hz, 1H), 4.31 (d, J = 10.3 Hz, 2H), 4.20 (d, J = 14.4 Hz, 4H), 4.12 (d, J = 13.5 Hz, 2H), 2.44 (d, J = 4.3 Hz, 3H), 2.31 (dd, J = 22.8, 9.0 Hz, 2H), 2.17 (t, J = 7.9 Hz, 2H). EXAMPLE 1314-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(pyrrolidin-1-yl)- 2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0317] MS (ES+) C31H29F2N5O requires: 525, found: 526 [M+H]+. EXAMPLE 1324-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-((5-(pyrrolidin-1-yl) pyridin-2-yl)methoxy)-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0318] MS (ES+) C37H34F2N6O2 requires: 632, found: 633 [M+H]+. EXAMPLE 1334-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-((tetrahydrofuran- 3-yl)oxy)-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0319] MS (ES+) C31H28F2N4O3requires: 542, found: 543 [M+H]+. EXAMPLE 1344-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-((tetrahydro-2H- pyran-4-yl)oxy)-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0320] MS (ES+) C32H30F2N4O3 requires: 556, found: 557 [M+H]+. EXAMPLE 1354-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-(2-(tetrahydro-2H- pyran-4-yl)ethoxy)-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0321] MS (ES+) C34H34F2N4O3requires: 584, found: 585 [M+H]+.

[0322] 1H NMR (600 MHz, MeOD) δ 9.10 (s, 1H), 7.87 (dd, J = 9.2, 5.7 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.24 (d, J = 2.5 Hz, 1H), 4.58 – 4.53 (m, 2H), 4.25 (s, 2H), 4.04 (t, J = 14.1 Hz, 2H), 3.95 (dd, J = 11.4, 4.3 Hz, 2H), 3.92 (s, 2H), 3.68 (d, J = 13.2 Hz, 2H), 2.51 (d, J = 4.9 Hz, 3H), 2.42 (d, J = 8.5 Hz, 2H), 2.24 – 2.20 (m, 2H), 1.83 (t, J = 6.2 Hz, 2H), 1.73 (d, J = 13.3 Hz, 2H), 1.42 – 1.36 (m, 3H).EXAMPLE 1364-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(((S)-1,4-dimethylpiperazin-2- yl)methoxy)-4-fluoro-5-methyl-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2- ol

[0323] MS (ES+) C34H36F2N6O2requires: 598, found: 599 [M+H]+.

[0324] 1H NMR (600 MHz, MeOD) δ 9.14 (s, 1H), 7.87 (dd, J = 9.1, 5.7 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.33 (t, J = 8.9 Hz, 1H), 7.23 (s, 1H), 4.68 (s, 2H), 4.27 (s, 2H), 4.07 – 4.01 (m, 3H), 3.69 (dt, J = 15.3, 7.9 Hz, 3H), 3.60 (s, 2H), 3.09 (s, 3H), 2.86 (s, 3H), 2.82 (s, 2H), 2.56 (d, J = 5.0 Hz, 3H), 2.43 (d, J = 12.7 Hz, 2H), 2.26 – 2.22 (m, 2H). EXAMPLE 1374-(8-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-((5-methylpyridin- 2-yl)methoxy)-2,7-naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0325] MS (ES+) C34H29F2N5O2requires: 577, found: 578 [M+H]+. EXAMPLE 1408-[3-chloro-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5-fluoro-4-methyl-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octan-6-ol Step 1 8-(1-methyl-1-phenyl-ethyl)-3,8-diazabicyclo[3.2.1]oct-6-ene

[0326] To a solution of tert-butyl 8-(1-methyl-1-phenyl-ethyl) -3, 8- diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (2 g, 6.09 mmol, 1 eq) in MeOH (20 mL) was added HCl / MeOH (4 M, 6.00 mL, 3.94 eq) at 25 °C. Then the mixture was stirred at 35 °C for 1 h. LCMS showed a peak (90%) with the desired mass. The mixture was concentrated in vacuum. The residue was diluted with water (40 mL) and extracted with ethyl acetate (20 mL x 2). The combined aqueous phase was adjusted to pH = 12 by aq. NaOH (6M) at 0 °C. Then the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic phase was washed with brine (30 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford 8-(1-methyl-1-phenyl-ethyl) -3, 8-diazabicyclo[3.2.1]oct-6-ene (1.4 g, 6.01 mmol, 98.68% yield, 98% purity) as colorless oil.

[0327] MS (ES+) C15H20N2 requires:228, found: 229 [M+H]+

[0328] 1H NMR (400 MHz, CDCl3) δ = 7.61 (dd, J = 1.0, 8.2 Hz, 2H), 7.35 - 7.29 (m, 2H), 7.24 - 7.19 (m, 1H), 6.02 (s, 2H), 3.43 (s, 2H), 2.92 (dd, J = 1.7, 12.6 Hz, 2H), 2.33 (dd, J = 1.9, 12.5 Hz, 2H), 1.24 (s, 6H) Step 2 9H-fluoren-9-ylmethyl 8-(1-methyl-1-phenyl-ethyl)-3,8-diazabicyclo[3.2.1]oct-6-ene-3- carboxylate

[0329] To a solution of 8-(1-methyl-1-phenyl-ethyl) -3, 8-diazabicyclo[3.2.1]oct-6-ene (1.4 g, 6.13 mmol, 1 eq) in THF (15 mL) were added Na2CO3(1.95 g, 18.39 mmol, 3 eq) and 9H-fluoren-9-ylmethyl carbonochloridate (1.59 g, 6.13 mmol, 1 eq) at 0 °C. Then the mixture was stirred at 0 °C for 1 h. The mixture was filtered and the filtrate was diluted with ethyl acetate (30 mL), the mixture was washed with water (30 mL) and brine (20 mL x 2). The organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford 9H-fluoren-9-ylmethyl 8-(1-methyl-1-phenyl-ethyl) -3, 8-diazabicyclo[3.2.1]oct-6-ene-3- carboxylate (2.48 g, 5.39 mmol, 87.97% yield, 98% purity) as pink solid.

[0330] MS (ES+) C30H30N2O2requires: 450, found: 451 [M+H]+Step 3 9H-fluoren-9-ylmethyl 3,8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate

[0331] A mixture of 9H-fluoren-9-ylmethyl 8-(1-methyl-1-phenyl-ethyl) -3, 8- diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (2.48 g, 5.50 mmol, 1 eq) and TFA (76.13 g, 667.72 mmol, 49.60 mL, 121.31 eq) was stirred at 75 °C for 16 h. LCMS showed one main peak with desired mass. The mixture was concentrated in vacuum. The residue was diluted with water (30 mL) and adjusted to pH = 9 by sat. aq. Na2CO3. Then the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phase was washed with brine (30 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The crude product was triturated with (Petroleum ether : Ethyl acetate = 5:1, 20 mL) at 25 °C for 10 min to afford 9H-fluoren-9-ylmethyl 3, 8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (1.7 g, 5.01 mmol, 91.06% yield, 98% purity) as yellow solid.

[0332] MS (ES+) C21H20N2O2 requires:332, found: 333 [M+H]+Step 49H-fluoren-9-ylmethyl 8-(2,2,2-trifluoroacetyl)-3,8-diazabicyclo[3.2.1]oct-6-ene-3- carboxylate

[0333] To a solution of 9H-fluoren-9-ylmethyl 3, 8-diazabicyclo[3.2.1]oct-6-ene-3- carboxylate (1.25 g, 3.76 mmol, 1 eq) in DCM (25 mL) was added TFAA (947.81 mg, 4.51 mmol, 627.27 μL, 1.2 eq) at 25 °C. Then the mixture was stirred at 25 °C for 0.5 h. LCMS showed a peak (97%) with the desired mass. The mixture was concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford 9H-fluoren-9-ylmethyl 8-(2,2,2-trifluoroacetyl)-3,8-diazabicyclo[3.2.1]oct-6-ene-3- carboxylate (1.47 g, 3.43 mmol, 91.25% yield, 100% purity) as colorless oil.

[0334] MS (ES+) C23H19N2O3F3 requires: 428, found: 429 [M+H]+Step 5 1-(3,8-diazabicyclo[3.2.1]oct-6-en-8-yl)-2,2,2-trifluoro-ethanone

[0335] To a solution of 9H-fluoren-9-ylmethyl 8-(2, 2, 2-trifluoroacetyl) -3, 8- diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (1.47 g, 3.43 mmol, 1 eq) in EtOH (15 mL) was added Me2NH (2 M, 17.16 mL, 10 eq) at 25 °C. Then the mixture was stirred at 25 °C for 2 h. The mixture was concentrated in vacuum to afford 1-(3, 8-diazabicyclo[3.2.1]oct-6-en-8- yl) -2, 2, 2-trifluoro-ethanone (1.7 g, crude) as colorless oil. Step 6 tert-butyl 8-(2,2,2-trifluoroacetyl)-3,8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate

[0336] To a solution of 1-(3, 8-diazabicyclo[3.2.1]oct-6-en-8-yl) -2, 2, 2-trifluoro- ethanone (700 mg, 3.40 mmol, 1 eq) in DCM (20 mL) was added TEA (1.03 g, 10.19 mmol, 1.42 mL, 3 eq), Boc2O (1.11 g, 5.09 mmol, 1.17 mL, 1.5 eq) and DMAP (41.48 mg, 339.53 μmol, 0.1 eq) at 25 °C. The mixture was stirred at 25 °C for 16 h. The mixture was concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~9% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 8-(2, 2, 2-trifluoroacetyl) -3, 8-diazabicyclo[3.2.1]oct-6-ene- 3-carboxylate (640 mg, 2.09 mmol, 61.54% yield) as colorless oil.

[0337] 1H NMR (400 MHz, CDCl3) δ = 6.33 - 6.18 (m, 2H), 5.08 - 4.95 (m, 1H), 4.84 - 4.70 (m, 1H), 3.98 (dd, J = 1.0, 13.2 Hz, 1H), 3.82 (dd, J = 7.5, 12.0 Hz, 1H), 3.27 - 3.16 (m, 1H), 3.15 - 3.04 (m, 1H), 1.44 (s, 9H) Step 7 tert-butyl 3,8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate

[0338] To a solution of tert-butyl 8-(2, 2, 2-trifluoroacetyl) -3, 8-diazabicyclo[3.2.1]oct- 6-ene-3-carboxylate (640 mg, 2.09 mmol, 1 eq) in MeOH (10 mL) and H2O (2 mL) was added K2CO3(866.38 mg, 6.27 mmol, 3 eq) at 25 °C. Then the mixture was stirred at 25 °C for 2 h. The mixture was concentrated in vacuum. The residue was diluted with water (20 mL) and extracted with ethyl acetate (30 mLx2). Then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum to afford the product tert-butyl 3, 8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (412 mg, crude) as yellow oil. Step 8 tert-butyl 8-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]oct-6-ene-3-carboxylate

[0339] To a solution of 1, 3, 6-trichloro-5-fluoro-4-methyl-2, 7-naphthyridine (530 mg, 2.00 mmol, 1 eq) and DIEA (773.98 mg, 5.99 mmol, 1.04 mL, 3 eq) in NMP (10 mL) was added tert-butyl 3, 8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (412 mg, 1.96 mmol, 0.98 eq). Then the mixture was stirred at 130 °C for 16 h. LCMS showed a peak (72%) with the desired mass. The mixture was diluted with ethyl acetate (30 mL) and washed with brine (30 mL x 2), then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 0~9% Ethyl acetate / Petroleum ether gradient @ 200 mL / min) to afford tert-butyl 8-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1- yl) -3, 8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (500 mg, 1.09 mmol, 54.73% yield, 96% purity) as yellow solid.

[0340] MS (ES+) C20H21N4FCl2O2 requires: 438, found: 439 [M+H]+Step 9 tert-butyl 8-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-6-hydroxy-3,8- diazabicyclo[3.2.1]octane-3-carboxylate

[0341] To a solution of tert-butyl 8-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1- yl) -3, 8-diazabicyclo[3.2.1]oct-6-ene-3-carboxylate (400 mg, 910.52 μmol, 1 eq) in THF (5 mL) was added dropwise slowly BH3.THF (1 M, 1.37 mL, 1.5 eq) at 0 °C under the protection of N2. Then the mixture was stirred at 20 °C for 2 h. Then H2O (164.03 mg, 9.11 mmol, 164.03 μL, 10 eq) was added dropwise into the mixture at 0 °C under N2. Then NaOH (6 M, 758.77 μL, 5 eq) and H2O2(0.640 g, 5.64 mmol, 542.37 μL, 30% purity, 6.20 eq) were added to the mixture at 0 °C. Then the mixture was stirred at 40 °C for 2 h. LCMS showed a peak (50%) with the desired mass. The mixture was quenched by sat. Aq. Na2SO3(10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phase was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 0~33% Ethyl acetate / Petroleum ether gradient @ 150 mL / min) to affordtert-butyl 8-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl) -6-hydroxy-3, 8- diazabicyclo[3.2.1]octane-3-carboxylate (200 mg, 397.97 μmol, 43.71% yield, 91% purity) as yellow oil. MS (ES+) C20H23N4FCl2O3requires: 456, found: 457 [M+H]+Step 10 tert-butyl 8-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-6-hydroxy-3,8- diazabicyclo[3.2.1]octane-3-carboxylate Boc

[0342] To a solution of tert-butyl 8-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1- yl) -6-hydroxy-3, 8-diazabicyclo[3.2.1]octane-3-carboxylate (90 mg, 196.80 μmol, 1 eq), ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (100.87 mg, 196.80 μmol, 1 eq) and K3PO4 (1.5 M, 393.59 μL, 3 eq) in THF (4 mL) was added XPhos Pd G3 (16.93 mg, 19.68 μmol, 0.1 eq) under N2. Then the mixture was stirred at 60 °C for 3h under N2. LCMS showed a peak (31%) with the desired mass. The mixture was poured into water (5 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic phase was washed with brine (20 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep- TLC (Petroleum ether : Ethyl acetate = 1:1) to afford tert-butyl 8-[3-chloro-5-fluoro-6-[7- fluoro-3-(methoxymethoxy) -8-(2-triisopropylsilylethynyl) -1-naphthyl]-4-methyl-2, 7- naphthyridin-1-yl]-6-hydroxy-3, 8-diazabicyclo[3.2.1]octane-3-carboxylate (53 mg, 59.08 μmol, 30.02% yield, 90% purity) as yellow solid.

[0343] MS (ES+) C43H53N4F2ClO5Si requires: 806, found: 807 [M+H]+Step 11 tert-butyl 8-[3-chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro- 4-methyl-2,7-naphthyridin-1-yl]-6-hydroxy-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

[0344] To a solution of tert-butyl 8-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy) - 8-(2-triisopropylsilylethynyl) -1-naphthyl]-4-methyl-2, 7-naphthyridin-1-yl]-6-hydroxy-3, 8- diazabicyclo[3.2.1]octane-3-carboxylate (43 mg, 53.25 μmol, 1 eq) in DMF (1 mL) was added CsF (24.27 mg, 159.76 μmol, 5.90 μL, 3 eq) at 25 °C. Then the mixture was stirred at 25 °C for 40 min. LCMS showed a peak (84%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL). The organic phase was washed with brine (15 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 8-[3- chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-4-methyl-2, 7- naphthyridin-1-yl]-6-hydroxy-3, 8-diazabicyclo[3.2.1]octane-3-carboxylate (39 mg, 50.31 μmol, 94.48% yield, 84% purity) as yellow oil.

[0345] MS (ES+) C34H33N4F2ClO5requires: 650, found: 651 [M+H]+Step 12 8-[3-chloro-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5-fluoro-4-methyl-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octan-6-ol

[0346] To a solution of tert-butyl 8-[3-chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy) -1-naphthyl]-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl]-6-hydroxy-3, 8- diazabicyclo[3.2.1]octane-3-carboxylate (39 mg, 59.90 μmol, 1 eq) in DCM (0.9 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL) at 25 °C. Then the mixture was stirred at 25 °C for 20 min. LCMS showed a peak (82%) with the desired mass. The mixture was adjusted topH = 7 by sat. aq. NaHCO3at 0 °C. Then the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um;mobile phase: [water (FA) -ACN];gradient:15%-45% B over 10 min) and lyophilized to afford 8-[3-chloro-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl) -5- fluoro-4-methyl-2, 7-naphthyridin-1-yl]-3, 8-diazabicyclo[3.2.1]octan-6-ol (4 mg, 7.23 μmol, 12.08% yield, 100% purity, FA) as yellow solid.

[0347] MS (ES+) C27H21ClF2N4O2requires: 506, found: 507 [M+H]+

[0348] 1H NMR (400 MHz, CD3OD) δ = 9.27 - 9.18 (m, 1H), 8.50 - 8.42 (m, 1H), 7.91 - 7.84 (m, 1H), 7.38 - 7.29 (m, 3H), 7.20 (d, J = 2.4 Hz, 1H), 5.21 - 5.13 (m, 1H), 5.04 - 4.98 (m, 1H), 4.62 - 4.54 (m, 2H), 4.36 - 4.24 (m, 1H), 3.62 - 3.46 (m, 1H), 3.27 - 3.25 (m, 1H), 3.16 - 3.00 (m, 1H), 2.73 - 2.68 (m, 3H), 2.48 - 2.36 (m, 1H), 2.30 - 2.18 (m, 1H). EXAMPLE 1424-[6-chloro-4-fluoro-8-(6-fluoro-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-methyl-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 8-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-6-fluoro-3,8- diazabicyclo[3.2.1]octane-3-carboxylate

[0349] To a solution of tert-butyl 8-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1- yl)-6-hydroxy-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (90 mg, 196.80 μmol, 1 eq) in DCM (2 mL) was added DAST (63.44 mg, 393.59 μmol, 52.00 μL, 2 eq) at 25 °C. Then the mixture was stirred at 25 °C for 3 h. LCMS showed the starting material was consumed completely and one main peak with desired mass formed. The mixture was quenched by water (5 mL) and sat. aq. NaHCO3(5 mL). Then the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was washed with brine (10 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 0~7% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to give tert-butyl 8-(3,6-dichloro-5-fluoro- 4-methyl-2,7-naphthyridin-1-yl)-6-fluoro-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (53 mg, 110.77 μmol, 56.29% yield, 96% purity) as colorless oil.

[0350] MS (ES+) C20H22N4F2Cl2O2 requires: 458, found: 459 [M+H]+ Step 2 tert-butyl 8-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-6-fluoro-3,8- diazabicyclo[3.2.1]octane-3-carboxylate

[0351] To a solution of tert-butyl 8-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1- yl)-6-fluoro-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (42 mg, 91.44 μmol, 1 eq), 2-[2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (46.87 mg, 91.44 μmol, 1 eq) and K3PO4 (1.5 M, 182.88 μL, 3 eq) in THF (2 mL) was added XPhos Pd G3 (7.87 mg, 9.14 μmol, 0.1 eq) at 25 °C under N2. Then the mixture was stirred at 60 °C for 1.5 h under N2. LCMS showed the tert- butyl 8-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-6-fluoro-3,8- diazabicyclo[3.2.1]octane-3-carboxylate was consumed completely and a peak (20%) with the desired mass formed. The mixture was diluted with water (3mL) and extracted with ethylacetate (10 mL x 2). The combined organic phase was washed with brine (10 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep- TLC (Petroleum ether : Ethyl acetate = 2:1) to give tert-butyl 8-[3-chloro-5-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7- naphthyridin-1-yl]-6-fluoro-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (27 mg, 31.02 μmol, 33.93% yield, 93% purity) as colorless solid. MS (ES+) C43H52N4F3ClO4Si requires: 808, found: 809 [M+H]+Step 3 tert-butyl 8-[3-chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro- 4-methyl-2,7-naphthyridin-1-yl]-6-fluoro-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

[0352] To a solution of tert-butyl 8-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)- 8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-6-fluoro-3,8- diazabicyclo[3.2.1]octane-3-carboxylate (27 mg, 33.36 μmol, 1 eq) in DMF (1 mL) was added CsF (15.20 mg, 100.07 μmol, 3.69 μL, 3 eq) at 25 °C. Then the mixture was stirred at 25 °C for 40 min. LCMS showed a peak (91%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL). The organic phase was washed with brine (15 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give tert-butyl 8-[3- chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-4-methyl-2,7- naphthyridin-1-yl]-6-fluoro-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (31 mg, crude) as yellow oil. MS (ES+) C34H32N4F3ClO4 requires: 652, found: 653 [M+H]+Step 4 4-[6-chloro-4-fluoro-8-(6-fluoro-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-methyl-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0353] To a solution of tert-butyl 8-[3-chloro-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-4-methyl-2,7-naphthyridin-1-yl]-6-fluoro-3,8- diazabicyclo[3.2.1]octane-3-carboxylate (31 mg, 47.47 μmol, 1 eq) in DCM (0.6 mL) was added TFA (307.00 mg, 2.69 mmol, 0.2 mL) at 25 °C. Then the mixture was stirred at 25 °C for 20 min. LCMS showed a peak (86%) with the desired mass. The mixture was adjusted to pH = 7 by sat. aq. NaHCO3 at 0 °C. Then the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 24%-44% B over 10 min) and lyophilized to give 4-[6-chloro-4-fluoro-8-(6-fluoro-3,8-diazabicyclo[3.2.1]octan-8- yl)-5-methyl-2,7-naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (0.7 mg, 1.24 μmol, 2.60% yield, 98% purity, FA) as yellow solid.

[0354] MS (ES+) C27H20ClF3N4O requires: 508, found: 509 [M+H]+

[0355] 1H NMR (400 MHz, CD3OD) δ = 9.26 - 9.15 (m, 1H), 7.87 (dd, J = 5.9, 8.9 Hz, 1H), 7.43 - 7.27 (m, 3H), 5.52 - 5.33 (m, 1H), 3.50 - 3.38 (m, 1H), 3.26 (s, 1H), 3.24 - 3.11 (m, 4H), 2.93 - 2.82 (m, 2H), 2.74 - 2.65 (m, 3H), 2.52 - 2.35 (m, 2H).2-amino-4-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-[[(2S)-1- methylpyrrolidin-2-yl]methoxy]-2,7-naphthyridin-3-yl]-7-fluoro-benzothiophene-3- carbonitrile Step 1 tert-butyl 3-[6-chloro-5-fluoro-4-methyl-3-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0356] To a solution of tert-butyl 3-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (500 mg, 1.13 mmol, 1 eq) and [(2S)-1- methylpyrrolidin-2-yl]methanol (164.90 mg, 1.43 mmol, 170 μL, 1.26 eq) in dioxane (32 mL) were added Xantphos (65.6 mg, 113.37 μmol, 0.1 eq), Cs2CO3 (740 mg, 2.27 mmol, 2 eq) and Pd2(dba)3(104.00 mg, 113.57 μmol, 0.1 eq), the mixture was stirred at 100 °C for 5 h under N2. LCMS showed a peak (24%) with the desired mass. The reaction mixture was filtered. The filtrate was concentrated under vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 25~75% Ethyl acetate / Petroleum ether gradient @45 mL / min) and re-purified by prep-TLC (SiO2, Petroleum ether / Ethyl acetate = 1:1) to afford tert-butyl 3-[6-chloro-5-fluoro-4-methyl-3- [[(2S)-1-methylpyrrolidin-2-yl]methoxy]-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (200 mg, 384.59 μmol, 33.95% yield) as yellow oil. MS (ES+) C26H35N5O3ClF requires: 519, found: 520 [M+H]+Step 2 tert-butyl 3-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5- fluoro-4-methyl-3-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0357] To a solution of tert-butyl 3-[6-chloro-5-fluoro-4-methyl-3-[[(2S)-1- methylpyrrolidin-2-yl]methoxy]-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (120 mg, 230.75 μmol, 1 eq), tert-butyl N-[3-cyano-7-fluoro-4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiophen-2-yl]carbamate (145 mg, 346.65 μmol, 1.5 eq) and K3PO4 (1.5 M, 0.46 mL, 2.99 eq) in dioxane (4.6 mL) was added cataCXium® A Pd G3(20 mg, 27.46 μmol, 0.119 eq), the mixture was stirred at 80 °C for 16 h under N2. LCMS showed a peak (19%) with the desired mass. The mixture was cooled and poured into water (6 mL). The aqueous phase was extracted with ethyl acetate (10 mL × 2). The combined organic phase was washed with brine (3 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep-TLC (SiO2, Ethyl acetate : Methanol = 3:2) to afford tert-butyl 3-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7- fluoro-benzothiophen-4-yl]-5-fluoro-4-methyl-3-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]- 2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, 64.44 μmol, 27.93% yield) as yellow oil. MS (ES+) C40H47N7O5F2S requires: 775, found: 776 [M+H]+Step 3 2-amino-4-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-[[(2S)-1- methylpyrrolidin-2-yl]methoxy]-2,7-naphthyridin-3-yl]-7-fluoro-benzothiophene-3- carbonitrile

[0358] To a solution of tert-butyl 3-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro- benzothiophen-4-yl]-5-fluoro-4-methyl-3-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, 64.44 μmol, 1 eq) in DCM (1.1 mL) was added TFA (552.60 mg, 4.85 mmol, 360 μL, 75.21 eq), the mixture was stirred at 20 °C for 0.5 h. The mixture was concentrated under reduced pressure (<30 °C). The residue was purified by prep-HPLC (column: Phenomenex Luna C18150*25 mm* 10um;mobile phase: [water (FA) -ACN];gradient:11%-31% B over 10 min) and lyophilized to afford 2-amino-4-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-methyl-6-[[(2S)-1- methylpyrrolidin-2-yl]methoxy]-2,7-naphthyridin-3-yl]-7-fluoro-benzothiophene-3- carbonitrile (5.5 mg, 8.85 μmol, 13.73% yield, 100% purity, FA) as yellow solid. MS (ES+) C30H31F2N7OS requires: 575, found: 576 [M+H]+

[0359] 1H NMR (400 MHz, CD3OD) δ ppm 9.07 (s, 1H), 8.53 (s, 1H), 7.20 (dd, J = 5.2, 8.3 Hz, 1H), 7.00 (dd, J = 8.4, 9.4 Hz, 1H), 4.76 - 4.70 (m, 1H), 4.62 - 4.54 (m, 1H), 4.10 - 4.00(m, 2H), 3.88 (d, J = 13.3 Hz, 1H), 3.77 (d, J = 13.0 Hz, 1H), 3.57 -3.48(m, 2H), 3.24 - 3.15 (m, 1H), 2.72 (s, 3H), 2.70 - 2.51 (m, 2H), 2.44 (d, J = 6.1 Hz, 3H), 2.41 (d, J = 7.9 Hz, 2H), 2.29 - 2.20 (m, 1H), 2.17 - 2.07 (m, 2H), 2.00 - 1.92 (m, 2H), 1.91 - 1.80 (m, 1H). EXAMPLE 1454-(8-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)-6-chloro-4-fluoro-5-methyl-2,7- naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol Step 1 tert-butyl 9-(2,2,2-trifluoroacetyl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate

[0360] To a solution of tert-butyl 3-oxa-7, 9-diazabicyclo[3.3.1]nonane-7-carboxylate (300 mg, 1.31 mmol, 1 eq) in DCM (15 mL) was added TFAA (414.01 mg, 1.97 mmol,274.00 μL, 1.5 eq) and DIEA (509.53 mg, 3.94 mmol, 686.69 μL, 3 eq) at 0 °C. The mixture was stirred at 20 °C for 16 hr. The residue was diluted with water (30 mL) and extracted with Dichloromethane (30 mL x 3). The combined organic layers were washed with water (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to give tert-butyl 9-(2, 2, 2-trifluoroacetyl) -3-oxa-7, 9- diazabicyclo[3.3.1]nonane-7-carboxylate (420 mg, 1.30 mmol, 98.55% yield) as a yellow oil.1H NMR (400 MHz, CDCl3) δ = 4.58 - 4.47 (m, 1H), 4.44 - 4.28 (m, 2H), 4.14 - 4.03 (m, 2H), 3.90 - 3.78 (m, 3H), 3.36 - 3.24 (m, 1H), 3.23 - 3.10 (m, 1H), 1.49 (s, 9H). Step 2 2,2,2-trifluoro-1-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl)ethanone

[0361] To a solution of tert-butyl 9-(2, 2, 2-trifluoroacetyl) -3-oxa-7, 9- diazabicyclo[3.3.1]nonane-7-carboxylate (420 mg, 1.30 mmol, 1 eq) in DCM (2 mL) was added HCl / dioxane (4 M, 2 mL) at 25 °C for 1 h. The mixture was concentrated in vacuum to give the product 2, 2, 2-trifluoro-1-(3-oxa-7, 9-diazabicyclo[3.3.1]nonan-9-yl) ethanone (290 mg, 1.29 mmol, 99.88% yield) as yellow oil.1H NMR (400 MHz, DMSO-d6) δ = 8.50 - 8.29 (m, 1H), 4.52 (s, 1H), 4.24 (s, 1H), 4.15 - 4.06 (m, 2H), 3.78-3.86 (m, 2H), 3.61 (s, 2H), 3.37 - 3.25 (m, 2H) Step 3 1-[7-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-3-oxa-7,9- diazabicyclo[3.3.1]nonan-9-yl]-2,2,2-trifluoro-ethanone

[0362] To a solution of 1, 3, 6-trichloro-5-fluoro-4-methyl-2, 7-naphthyridine (343 mg, 1.29 mmol, 1 eq) and DIEA (500.91 mg, 3.88 mmol, 675.08 μL, 3 eq) in dioxane (10 mL) was added 2, 2, 2-trifluoro-1-(3-oxa-7, 9-diazabicyclo[3.3.1]nonan-9-yl) ethanone (289.62 mg, 1.29 mmol, 1 eq) at 25 °C. Then the mixture was stirred at 100 °C for 16 h. LCMS showed a peak (63%) with the desired mass. The mixture was concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to give 1- [7-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl) -3-oxa-7, 9- diazabicyclo[3.3.1]nonan-9-yl]-2, 2, 2-trifluoro-ethanone (450 mg, 943.26 μmol, 73.01% yield, 95% purity) as yellow solid. MS (ES+) C17H14N4F4Cl2O2 requires: 452, found: 453 [M+H]+Step 4 7-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-3-oxa-7,9- diazabicyclo[3.3.1]nonane

[0363] To a solution of 1-[7-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl) -3- oxa-7, 9-diazabicyclo[3.3.1]nonan-9-yl]-2, 2, 2-trifluoro-ethanone (430 mg, 948.77 μmol, 1 eq) in MeOH (10 mL), H2O (2 mL) and DCM (3 mL) was added K2CO3(393.38 mg, 2.85 mmol, 3 eq) at 25 °C. Then the mixture was stirred at 45 °C for 48 h. LCMS showed a peak (83%) with the desired mass. The mixture was concentrated in vacuum. The residue was diluted with (ethyl acetate : Methanol = 10:1, 30 mL), washed with water (20 mL x 2), then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum to give 7-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl) -3-oxa-7, 9- diazabicyclo[3.3.1]nonane (310 mg, 755.02 μmol, 79.58% yield, 87% purity) as yellow solid. MS (ES+) C15H15N4FCl2O requires: 356, found: 357 [M+H]+Step 5 tert-butyl 7-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-3-oxa-7,9- diazabicyclo[3.3.1]nonane-9-carboxylate

[0364] To a solution of 7-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl) -3- oxa-7, 9-diazabicyclo[3.3.1]nonane (310 mg, 867.84 μmol, 1 eq) in DCM (10 mL) was added TEA (175.63 mg, 1.74 mmol, 241.58 μL, 2 eq) and Boc2O (227.28 mg, 1.04 mmol, 239.25 μL, 1.2 eq) at 25 °C. Then the mixture was stirred at 25 °C for 1 h. LCMS showed a peak (80%) with the desired mass. The mixture was concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 5~16% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to give tert-butyl 7-(3, 6- dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl) -3-oxa-7, 9-diazabicyclo[3.3.1]nonane-9- carboxylate (307 mg, 590.74 μmol, 68.07% yield, 88% purity) as yellow solid. MS (ES+) C20H23N4FCl2O3requires: 456, found: 457 [M+H]+Step 6 tert-butyl 7-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-9-carboxylate Boc

[0365] To a solution of tert-butyl 7-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1- yl) -3-oxa-7, 9-diazabicyclo[3.3.1]nonane-9-carboxylate (297 mg, 649.43 μmol, 1 eq), ((2- fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1- yl)ethynyl)triisopropylsilane (332.85 mg, 649.43 μmol, 1 eq) and K3PO4 (1.5 M, 1.30 mL, 3 eq) in THF (13 mL) was added XPhos Pd G4 (55.88 mg, 64.94 μmol, 0.1 eq) at 25 °C under the protection of N2. Then the mixture was stirred at 60 °C for 3 h under N2. LCMS showed apeak (27%) with the desired mass. The mixture was extracted with ethyl acetate (5 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 5~25% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to give tert-butyl 7-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy) -8-(2- triisopropylsilylethynyl) -1-naphthyl]-4-methyl-2, 7-naphthyridin-1-yl]-3-oxa-7, 9- diazabicyclo[3.3.1]nonane-9-carboxylate (146 mg, 159.12 μmol, 24.50% yield, 88% purity) as yellow oil. MS (ES+) C43H53N4F2ClO5Si requires: 806, found: 807 [M+H]+

[0366] 1H NMR (400 MHz, CDCl3) δ = 9.41 - 9.33 (m, 1H), 7.85 - 7.77 (m, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.35 - 7.29 (m, 2H), 5.36 - 5.27 (m, 2H), 4.42 - 4.18 (m, 3H), 4.06 - 3.78 (m, 7H), 3.52 (s, 3H), 2.72 (d, J = 4.8 Hz, 3H), 1.25 (s, 9H), 0.85 (dd, J = 7.5, 13.3 Hz, 21H). Step 7 tert-butyl 7-[3-chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro- 4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate

[0367] To a solution of tert-butyl 7-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy) - 8-(2-triisopropylsilylethynyl) -1-naphthyl]-4-methyl-2, 7-naphthyridin-1-yl]-3-oxa-7, 9- diazabicyclo[3.3.1]nonane-9-carboxylate (56 mg, 69.36 μmol, 1 eq) in DMF (1 mL) was added CsF (31.61 mg, 208.07 μmol, 7.68 μL, 3 eq) at 25 °C. Then the mixture was stirred at 25 °C for 40 min. LCMS showed a peak (86%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL). The organic phase was washed with brine (15 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give tert-butyl 7-[3- chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy) -1-naphthyl]-5-fluoro-4-methyl-2, 7- naphthyridin-1-yl]-3-oxa-7, 9-diazabicyclo[3.3.1]nonane-9-carboxylate (60 mg, crude) as yellow oil. MS (ES+) C34H33N4F2ClO5 requires: 650, found: 651 [M+H]+Step 8 4-(8-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)-6-chloro-4-fluoro-5-methyl-2,7- naphthyridin-3-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0368] To a solution of tert-butyl 7-[3-chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy) -1-naphthyl]-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl]-3-oxa-7, 9- diazabicyclo[3.3.1]nonane-9-carboxylate (60 mg, 92.15 μmol, 1 eq) in DCM (0.9 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL) at 25 °C. Then the mixture was stirred at 25 °C for 0.5 h. LCMS showed a peak (72%) with the desired mass. The mixture was adjusted to pH = 7 by sat. aq. NaHCO3at 0 °C. Then the mixture was extracted with ethyl acetate (10 mLx3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um;mobile phase: [water (FA) -ACN];gradient:20%-50% B over 10 min) and lyophilized to give 4-[6-chloro-4-fluoro-5-methyl-8-(3-oxa-7, 9- diazabicyclo[3.3.1]nonan-7-yl) -2, 7-naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (9.3 mg, 18.16 μmol, 19.71% yield, 99% purity) as pink solid.

[0369] MS (ES+) C27H21N4F2ClO2requires: 506, found: 507 [M+H]+

[0370] 1H NMR (400 MHz, MeOD) δ = 9.24 (s, 1H), 7.87 (dd, J = 5.7, 9.1 Hz, 1H), 7.38 - 7.30 (m, 2H), 7.25 (d, J = 2.3 Hz, 1H), 4.44 - 4.31 (m, 2H), 4.27 - 4.14 (m, 2H), 4.12 - 4.04 (m, 2H), 3.78-3.88 (m, 2H), 3.28 (s, 3H), 2.71 (d, J = 5.4 Hz, 3H). EXAMPLE 1466-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5-fluoro-4-methyl-1-(3-oxa-7,9- diazabicyclo[3.3.1]nonan-7-yl)-2,7-naphthyridine-3-carbonitrile Step 1 tert-butyl 7-[3-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-9-carboxylate

[0371] To a solution of tert-butyl 7-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy) - 8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-9-carboxylate (90 mg, 111.46 μmol, 1 eq), Zn(CN)2 (0.03 g, 255.48 μmol, 16.22 μL, 2.29 eq) and Zn (0.22 g, 3.36 mmol, 30.18 eq) in DMF (2 mL) was added Pd(dppf)Cl2(24.47 mg, 33.44 μmol, 0.3 eq) at 25 °C under the protection of N2. Then the mixture was stirred at 100 °C under N2 for 16 h. LCMS showed a peak (75%) with the desired mass. The mixture was filtered and diluted with ethyl acetate (10 mL) and washed with brine (10 mL x 2), then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography (4 g SepaFlash® Silica Flash Column, Eluent of 5~16% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 7-[3-cyano-5-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate (47 mg, 54.19 μmol, 48.61% yield, 92% purity) as yellow oil. MS (ES+) C44H53N5F2O5Si requires: 797, found: 798 [M+H]+Step 2 tert-butyl 7-[3-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-4- methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-9-carboxylate Boc

[0372] To a solution of tert-butyl 7-[3-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy) - 8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-9-carboxylate (47 mg, 58.90 μmol, 1 eq) in DMF (1 mL) was added CsF (26.84 mg, 176.69 μmol, 6.52 μL, 3 eq) at 25 °C. Then the mixture was stirred at 25 °C for 40 min. LCMS showed a peak (90%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL). The organic phase was washed with brine (15 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 7-[3- cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy) -1-naphthyl]-5-fluoro-4-methyl-2, 7- naphthyridin-1-yl]-3-oxa-7, 9-diazabicyclo[3.3.1]nonane-9-carboxylate (51 mg, crude) as yellow oil. MS (ES+) C35H33N5F2O5requires: 641, found: 642 [M+H]+Step 3 6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5-fluoro-4-methyl-1-(3-oxa-7,9- diazabicyclo[3.3.1]nonan-7-yl)-2,7-naphthyridine-3-carbonitrile

[0373] To a solution of tert-butyl 7-[3-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy) -1-naphthyl]-5-fluoro-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane- 9-carboxylate (51 mg, 79.48 μmol, 1 eq) in DCM (0.6 mL) was added TFA (307.00 mg, 2.69 mmol, 0.2 mL) at 25 °C. Then the mixture was stirred at 25 °C for 0.5 h. LCMS showed a peak (80%) with the desired mass. The mixture was adjusted to pH = 7 by sat. aq. NaHCO3 at 0 °C. Then the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um;mobile phase: [water (FA) -ACN]; gradient:18%-48% B over 10 min) and lyophilized to afford 6-(8- ethynyl-7-fluoro-3-hydroxy-1-naphthyl) -5-fluoro-4-methyl-1-(3-oxa-7,9- diazabicyclo[3.3.1]nonan-7-yl)-2,7-naphthyridine-3-carbonitrile (10.3 mg, 18.76 μmol, 23.60% yield, 99% purity, FA) as yellow solid. MS (ES+) C28H21F2N5O2requires: 497, found: 498 [M+H]+

[0374] 1H NMR (400 MHz, CD3OD) δ = 9.34 (s, 1H), 8.29 (s, 1H), 7.89 (dd, J = 5.8, 9.1 Hz, 1H), 7.38 (d, J = 2.5 Hz, 1H), 7.34 (t, J = 9.0 Hz, 1H), 7.27 (d, J = 2.5 Hz, 1H), 4.36-4.48 (m, 2H), 4.16-4.27 (m, 2H), 4.13 - 4.04 (m, 2H), 3.86 (d, J = 13.4 Hz, 2H), 3.39 - 3.34 (m, 2H), 3.29-3.30 (m, 1H), 2.84 (d, J = 5.9 Hz, 3H).4-[5,6-dicyclopropyl-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-1-methoxy-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 3-chloropropyl 4-methylbenzenesulfonate

[0375] To a solution of 3-chloropropan-1-ol (10 g, 105.78 mmol, 8.84 mL, 1 eq) in DCM (60 mL) were added TosCl (30.25 g, 158.66 mmol, 1.5 eq) and Et3N (32.11 g, 317.33 mmol, 44.17 mL, 3 eq). The mixture was stirred at 0 °C for 4 h. To the mixture was added water (60 mL) and extracted with ethyl acetate (60 mL × 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 150 mL / min) to afford 3-chloropropyl 4- methylbenzenesulfonate (23.4 g, 94.08 mmol, 88.94% yield) as colorless oil.1H NMR (400 MHz, CDCl3) δ = 7.79 - 7.75 (m, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.16 (t, J = 5.9 Hz, 2H), 3.54 (t, J = 6.2 Hz, 2H), 2.43 (s, 3H), 2.11 - 2.03 (m, 2H). Step 2 1,8-dichlorooct-4-yne

[0376] To a solution of 5-chloropent-1-yne (4.5 g, 43.88 mmol, 1 eq) in THF (100 mL) was added n-BuLi (2.5 M, 18.08 mL, 1.03 eq) at -70 °C under nitrogen. Then the mixture was warmed to 20 °C. To the mixture was added a solution of 3-chloropropyl 4- methylbenzenesulfonate (10.91 g, 43.88 mmol, 1 eq) in THF (20 mL) followed by TBAI (1.62 g, 4.39 mmol, 0.1 eq). The mixture was stirred at 70 °C for 2 h under nitrogen. The mixture was quenched with 200 mL of saturated NH4Cl solution and extracted with ethyl acetate (200 mL × 2). The combined organic layers were washed with 200 mL of brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to afford a residue which was purified by flash silica gel chromatography (80 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford 1,8-dichlorooct-4-yne (3.8 g, 19.10 mmol, 43.52% yield, 90% purity) as colorless oil.1H NMR (400 MHz, CDCl3) δ = 3.65 (t, J = 6.4 Hz, 4H), 2.40 - 2.31 (m, 4H), 2.00 - 1.88 (m, 4H).Step 3 2-cyclopropylethynylcyclopropane

[0377] To a solution of diisopropylamine (6.02 g, 59.52 mmol, 8.41 mL, 4.1 eq) in THF (30 mL) was added n-BuLi (2.5 M, 23.81 mL, 4.1 eq) at -70 °C over a period of 30 min under nitrogen. Then the mixture was added to a solution of 1,8-dichlorooct-4-yne (2.6 g, 14.52 mmol, 1 eq) in THF (30 mL) at -70 °C under nitrogen via an injection syringe. The mixture was warmed to 0 °C and stirred at this temperature for 1 h. The mixture was quenched with 60 mL of water, the organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under vacuum at 30 °C. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford 2- cyclopropylethynylcyclopropane (2 g, crude) as yellow oil.1H NMR (400 MHz, CDCl3) δ = 1.20 - 1.14 (m, 2H), 0.72 - 0.65 (m, 4H), 0.64 - 0.56 (m, 4H). Step 4 6,8-dichloro-3,4-dicyclopropyl-5-fluoro-2H-2,7-naphthyridin-1-one

[0378] To a solution of [(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2- dimethylpropanoate (460 mg, 1.49 mmol, 1 eq) and 2-cyclopropylethynylcyclopropane (236.97 mg, 2.23 mmol, 1.5 eq) in MeOH (6 mL) were added cesium acetate (71.41 mg, 0.372 mmol, 0.25 eq) and pentamethylcyclopentadienyl rhodium(III) chloride dimer (43.74 mg, 0.074 mmol, 0.05 eq). The mixture was stirred at 60 °C for 16 h under nitrogen. The mixture was filtered and the filter cake was dried to afford 6,8-dichloro-3,4-dicyclopropyl-5- fluoro-2H-2,7-naphthyridin-1-one (200 mg, 0.575 mmol, 38.63% yield, 90% purity) as a white solid.

[0379] MS (ES+) C14H11N2FCl2O requires:312 and 314, found:313 and 315 [M+H]+.

[0380] 1H NMR (400 MHz, DMSO-d6) δ = 11.02 (s, 1H), 2.43 - 2.32 (m, 1H), 2.02 - 1.85 (m, 1H), 1.10 - 1.03 (m, 4H), 1.01 - 0.94 (m, 2H), 0.53 (d, J = 5.0 Hz, 2H).Step 5 6-chloro-3,4-dicyclopropyl-5-fluoro-8-methoxy-2H-2,7-naphthyridin-1-one

[0381] To a solution of 6,8-dichloro-3,4-dicyclopropyl-5-fluoro-2H-2,7-naphthyridin-1- one (180 mg, 0.575 mmol, 1 eq) in DMA (2 mL) were added MeOH (92.09 mg, 2.87 mmol, 0.116 mL, 5 eq) followed by LiHMDS (1 M, 2.87 mL, 5 eq) at 0 °C. Then the mixture was warmed to 40 °C and stirred at 40 °C for 16 h. LCMS showed the reaction was completed and 81% of desired mass formed. The mixture was diluted with 10 mL of water and extracted with ethyl acetate (10 mL × 2). The combined organic layers were concentrated. The residue was triturated with 5 mL of methanol and the mixture was filtered. The filter cake was dried to afford 6-chloro-3,4-dicyclopropyl-5-fluoro-8-methoxy-2H-2,7-naphthyridin-1-one (146 mg, 0.426 mmol, 74.04% yield, 90% purity) as a white solid.

[0382] MS (ES+) C15H14N2FClO2 requires:308 and 310, found:309 and 311 [M+H]+.

[0383] 1H NMR (400 MHz, DMSO-d6) δ = 10.73 (s, 1H), 3.90 (s, 3H), 2.42 - 2.27 (m, 1H), 2.02 - 1.82 (m, 1H), 1.14 - 0.89 (m, 6H), 0.90 - 0.10 (m, 2H). Step 6 tert-butyl 3-(6-chloro-3,4-dicyclopropyl-5-fluoro-8-methoxy-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0384] To a solution of 6-chloro-3,4-dicyclopropyl-5-fluoro-8-methoxy-2H-2,7- naphthyridin-1-one (146 mg, 0.473 mmol, 1 eq) in DCM (6 mL) were added DIEA (244.47 mg, 1.89 mmol, 0.329 mL, 4 eq) and Tf2O (293.53 mg, 1.04 mmol, 0.172 mL, 2.2 eq). The mixture was stirred at 25 °C for 1 h. Then to the mixture were added DIEA (122.24 mg,0.946 mmol, 0.165 mL, 2 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (200.78 mg, 0.946 mmol, 2 eq). The mixture was stirred at 25 °C for 16 h. LCMS showed the reaction was completed and 88% of desired mass formed. The mixture was diluted with 10 mL of water and extracted with 10 mL of dichloromethane. The organic layer was dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated to afford a residue which was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 90%-100% B over 10 min). The eluent was freeze-dried to afford tert-butyl 3-(6-chloro-3,4-dicyclopropyl-5-fluoro-8-methoxy-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (112 mg, 0.212 mmol, 44.73% yield, 95% purity) as a brown solid. MS (ES+) C26H32ClFN4O3requires:502, found:503 [M+H]+. Step 7 tert-butyl 3-[3,4-dicyclopropyl-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0385] To a solution of tert-butyl 3-(6-chloro-3,4-dicyclopropyl-5-fluoro-8-methoxy-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (112 mg, 0.223 mmol, 1 eq) and 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (136.95 mg, 0.267 mmol, 1.2 eq) in dioxane (4.5 mL) and H2O (1.5 mL) were added K3PO4(141.79 mg, 0.668 mmol, 3 eq) CataCXium® A Pd G3 (16.22 mg, 0.022 mmol, 0.1 eq). The mixture was stirred at 100 °C for 16 h under nitrogen. LCMS showed 15% of desired mass formed. The mixture was concentrated to remove dioxane, then diluted with 5 mL of water and extracted with 5 mL of ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The mixture was filtered and the filtrate was concentrated to afford a residue. The residue was purified by prep-TLC (Petroleum ether : Ethyl acetate=10:1) to afford tert-butyl 3-[3,4-dicyclopropyl-5-fluoro-6-[7- fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (36 mg, 0.038 mmol, 17.06% yield, 90% purity) as yellow oil. MS (ES+) C49H62F2N4O5Si requires:852, found:853 [M+H]+. Step 8 tert-butyl 3-[3,4-dicyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]- 5-fluoro-8-methoxy-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0386] To a solution of tert-butyl 3-[3,4-dicyclopropyl-5-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (36 mg, 0.042 mmol, 1 eq) in DMF (1 mL) was added CsF (19.23 mg, 0.127 mmol, 3 eq). The mixture was stirred at 40 °C for 30 min. LCMS showed the reaction was completed and 88% of desired mass was detected. The mixture was diluted with 3 mL of water and extracted with 3 mL of ethyl acetate. The organic layer was washed with 3 mL of brine and dried over anhydrous sodium sulfate. The filtrate was concentrated to afford tert-butyl 3-[3,4-dicyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-8-methoxy-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (29 mg, crude) as yellow oil.

[0387] MS (ES+) C40H42N4F2O5 requires:696, found:697 [M+H]+. Step 9 4-[5,6-dicyclopropyl-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-1-methoxy-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0388] To a solution of tert-butyl 3-[3,4-dicyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-8-methoxy-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (29 mg, 0.042 mmol, 1 eq) in DCM (0.6 mL) was added TFA (307.00 mg, 2.69 mmol, 0.2 mL, 64.69 eq). The mixture was stirred at 30 °C for 30 min.54% of desired mass was detected by LCMS. The mixture was quenched with 5 mL of saturated NaHCO3aqueous solution, extracted with 5 mL of dichloromethane. The organic layer was concentrated to afford a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 25%- 55% B over 10 min). The eluent was freeze-dried to afford 4-[5,6-dicyclopropyl-8-(3,8- diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-1-methoxy-2,7-naphthyridin-3-yl]-5-ethynyl-6- fluoro-naphthalen-2-ol (1.5 mg, 0.002 mmol, 5.72% yield, 95% purity, FA) as a yellow solid.

[0389] MS (ES+) C33H30N4F2O2 requires:552, found:553 [M+H]+.

[0390] 1H NMR (400 MHz, CD3OD) δ = 8.55 (s, 1H), 7.84 (dd, J = 5.6, 8.8 Hz, 1H), 7.33 - 7.28 (m, 2H), 7.23 (d, J = 2.3 Hz, 1H), 4.02 (s, 3H), 3.97 - 3.82 (m, 4H), 3.18 (s, 1H), 2.73 - 2.62 (m, 1H), 2.30 - 2.10 (m, 3H), 2.08 - 1.93 (m, 3H), 1.20 - 1.08 (m, 3H), 1.07 - 0.99 (m, 4H), 0.61 (d, J = 5.6 Hz, 2H). EXAMPLE 148tert-butyl 3-[3-chloro-4-cyclopropyl-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5- fluoro-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate Step 1 tert-butyl 3-(3,6-dichloro-4-cyclopropyl-5-fluoro-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0391] To a solution of tert-butyl 3-(3,6-dichloro-5-fluoro-4-iodo-2,7-naphthyridin-1-yl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (500 mg, 903.84 μmol, 1 eq) in toluene (15 mL) were added cyclopropylboronic acid (155.27 mg, 1.81 mmol, 2 eq), Pd(OAc)2(40.58 mg, 180.77 μmol, 0.2 eq), tricyclohexylphosphane (50.69 mg, 180.77 μmol, 58.60 μL, 0.2 eq) and K3PO4(1.5 M, 2.41 mL, 4 eq). The mixture was stirred at 100 °C for 16 h under nitrogen. LCMS showed the reaction was completed, several peaks were showed on LCMS and 79% of desired mass was detected. The mixture was concentrated to remove toluene, then diluted with 20 mL of water and extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed with 20 mL of brine, dried over anhydrous sodium sulfate and filtrated. The filtrate was concentrated to afford crude residue. The crude residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 3-(3,6-dichloro-4- cyclopropyl-5-fluoro-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (370 mg, 696.67 μmol, 77.08% yield, 88% purity) as a brown solid.

[0392] MS (ES+) C22H25N4Cl2FO2 requires:466 and 468, found:467 and 469[M+H]+. Step 2 tert-butyl 3-[3-chloro-4-cyclopropyl-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0393] To a solution of tert-butyl 3-(3,6-dichloro-4-cyclopropyl-5-fluoro-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (270 mg, 577.71 μmol, 1 eq) and 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (355.32 mg, 693.25 μmol, 1.2 eq) in THF (6 mL) were added XPhos Pd G4 (49.71 mg, 57.77 μmol, 0.1 eq) and K3PO4 (1.5 M, 1.16 mL, 3 eq). The mixture was stirred at 60 °C for 16 h under nitrogen. LCMS showed 12% of desired mass. The mixture was concentrated to remove THF, then diluted with 20 mL of water and extracted with 20 mL of ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to afford crude residue. The residue was purified by prep- TLC (Petroleum ether : Ethyl acetate=5:1) to afford tert-butyl 3-[3-chloro-4-cyclopropyl-5- fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (87 mg, 92.59 μmol, 16.03% yield, 87% purity) as yellow oil. MS (ES+) C45H55ClF2N4O4Si requires:816, found:817[M+H]+. Step 3 tert-butyl 3-[3-chloro-4-cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-5-fluoro-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0394] To a solution of tert-butyl 3-[3-chloro-4-cyclopropyl-5-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (77 mg, 94.19 μmol, 1 eq) in DMF (2 mL) was added CsF (42.92 mg, 282.58 μmol, 10.43 μL, 3 eq). The mixture was stirred at 40 °C for 30 min. LCMS showed the reaction was completed and 84% of desired mass was present. The mixture was diluted with 5 mL of water and extracted with 5 mL of ethyl acetate. The organic layer was washed with 5 mL of brine and dried over anhydrous sodium sulfate. The filtratewas concentrated to afford tert-butyl 3-[3-chloro-4-cyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (62 mg, crude) as yellow oil.

[0395] MS (ES+) C36H35N4ClF2O4requires:660, found:661 [M+H]+. Step 4 tert-butyl 3-[3-chloro-4-cyclopropyl-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5- fluoro-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0396] To a solution of tert-butyl 3-[3-chloro-4-cyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (62 mg, 93.78 μmol, 1 eq) in DCM (0.6 mL) was added TFA (307.00 mg, 2.69 mmol, 0.2 mL, 28.71 eq). The mixture was stirred at 30 °C for 20 min. LCMS showed the reaction was complete and 78% of desired mass was detected. The mixture was quenched with 5 mL of saturated aqueous NaHCO3solution, then diluted with 5 mL of dichloromethane. The organic layer was concentrated to afford a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 20%-50% B over 10 min). The eluent was concentrated and freeze-dried to afford tert-butyl 3-[3-chloro-4-cyclopropyl-6-(8-ethynyl-7- fluoro-3-hydroxy-1-naphthyl)-5-fluoro-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane- 8-carboxylate (7.9 mg, 11.68 μmol, 12.45% yield, 98% purity, FA) as a white solid.

[0397] MS (ES+) C29H23N4ClF2O requires:516, found:517 [M+H]+.

[0398] 1H NMR (400 MHz, METHANOL-d4) δ = 9.20 (s, 1H), 8.52 (s, 1H), 7.88 (dd, J = 5.9, 9.2 Hz, 1H), 7.40 - 7.30 (m, 2H), 7.24 (d, J = 2.2 Hz, 1H), 4.13 - 3.97 (m, 4H), 3.60 (t, J = 13.2 Hz, 2H), 3.29 (s, 1H), 2.38 - 2.23 (m, 2H), 2.21 - 2.02 (m, 3H), 1.20 - 1.08 (m, 2H), 0.82 - 0.64 (m, 2H).EXAMPLE 1495-ethynyl-4-[6-ethynyl-4-fluoro-5-methyl-8-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl)- 2,7-naphthyridin-3-yl]-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 9-(3,6-dichloro-5-fluoro-4-methyl-2,7-naphthyridin-1-yl)-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate

[0399] To a solution of 1, 3, 6-trichloro-5-fluoro-4-methyl-2, 7-naphthyridine (500 mg, 1.88 mmol, 1 eq) and tert-butyl 3-oxa-7, 9-diazabicyclo[3.3.1]nonane-7-carboxylate (515.91 mg, 2.26 mmol, 1.2 eq) in NMP (10 mL) was added DIEA (730.19 mg, 5.65 mmol, 984.08 μL, 3 eq). Then the mixture was stirred at 130 °C for 16 h. LCMS showed a peak (90%) with the desired mass. The mixture was diluted with ethyl acetate (20 mL) and washed with brine (25 mL x 3), then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 0~16% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 9-(3, 6-dichloro-5- fluoro-4-methyl-2,7-naphthyridin-1-yl)-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (640 mg, 1.34 mmol, 71.34% yield, 96% purity) as orange solid. MS (ES+) C20H23N4Cl2FO3requires: 456, found: 457 [M+H]+Step 2 tert-butyl 9-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate

[0400] To a solution of tert-butyl 9-(3, 6-dichloro-5-fluoro-4-methyl-2, 7-naphthyridin-1- yl) -3-oxa-7, 9-diazabicyclo[3.3.1]nonane-7-carboxylate (630 mg, 1.38 mmol, 1 eq), ((2- fluoro-6-(methoxymethoxy) -8-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) naphthalen- 1-yl) ethynyl) triisopropylsilane (706.06 mg, 1.38 mmol, 1 eq) in THF (27 mL) were added K3PO4 (1.5 M, 2.76 mL, 3 eq) and XPhos Pd G4 (118.54 mg, 137.76 μmol, 0.1 eq) at 25 °C under N2. Then the mixture was stirred at 60 °C for 5 h under N2. LCMS showed a peak (25%) with the desired mass. The mixture was diluted with 10 mL of water and extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 5~23% Ethyl acetate / Petroleum ether gradient @ 150 mL / min) to afford tert-butyl 9-[3-chloro-5-fluoro-6- [7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-4-methyl-2,7- naphthyridin-1-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (350 mg, 403.13 μmol, 29.26% yield, 93% purity) as yellow oil. MS (ES+) C43H53N4F2ClO5Si requires: 806, found: 807 [M+H]+

[0401] 1H NMR (400 MHz, CDCl3) δ = 9.11 (s, 1H), 7.81 (dd, J = 5.7, 9.0 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.35 - 7.28 (m, 2H), 5.35 - 5.27 (m, 2H), 4.52 - 4.24 (m, 3H), 4.10 - 3.90 (m, 5H), 3.83 - 3.75 (m, 1H), 3.52 (s, 3H), 3.43 - 3.23 (m, 1H), 2.73 (d, J = 5.3 Hz, 3H), 1.25 (s, 9H), 0.86 (dd, J = 7.5, 16.0 Hz, 18H), 0.48 - 0.40 (m, 3H). Step 3tert-butyl 9-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-4-methyl-3-(2-trimethylsilylethynyl)-2,7-naphthyridin-1-yl]-3-oxa-7,9- diazabicyclo[3.3.1]nonane-7-carboxylate

[0402] To a solution of tert-butyl 9-[3-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy) - 8-(2-triisopropylsilylethynyl) -1-naphthyl]-4-methyl-2, 7-naphthyridin-1-yl]-3-oxa-7, 9- diazabicyclo[3.3.1]nonane-7-carboxylate (120 mg, 148.62 μmol, 1 eq), ethynyl (trimethyl) silane (145.97 mg, 1.49 mmol, 205.88 μL, 10 eq), CuI (2.83 mg, 14.86 μmol, 0.1 eq) and TEA (45.12 mg, 445.85 μmol, 62.06 μL, 3 eq) in DMF (1 mL) was added Pd(PPh3)2Cl2(10.43 mg, 14.86 μmol, 0.1 eq) at 25 °C under the protection of N2. Then the mixture was stirred at 80 °C for 14 h under N2. LCMS showed a peak (32%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL) and filtered. Then the filtrate was washed with brine (15 mL x 2), then the organic phase was dried with anhydrous Na2SO4, filtered and the filtrate was concentrated in vacuum. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 5~23% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) and prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um;mobile phase: [water (FA) -ACN];gradient:95%-100% B over 10 min) and lyophilized to afford tert-butyl 9-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy) -8-(2- triisopropylsilylethynyl) -1-naphthyl]-4-methyl-3-(2-trimethylsilylethynyl) -2, 7- naphthyridin-1-yl]-3-oxa-7, 9-diazabicyclo[3.3.1]nonane-7-carboxylate (23 mg, 25.67 μmol, 17.27% yield, 97% purity) as yellow oil. MS (ES+) C48H62N4F2O5Si2requires: 868, found: 869 [M+H]+Step 4 tert-butyl 9-[3-ethynyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro- 4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate

[0403] To as solution of tert-butyl 9-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy) -8-(2- triisopropylsilylethynyl) -1-naphthyl]-4-methyl-3-(2-trimethylsilylethynyl) -2, 7- naphthyridin-1-yl]-3-oxa-7, 9-diazabicyclo[3.3.1]nonane-7-carboxylate (23 mg, 26.46 μmol, 1 eq) in DMF (1 mL) was added CsF (12.06 mg, 79.38 μmol, 2.93 μL, 3 eq) at 25 °C. Then the mixture was stirred at 25 °C for 40 min. LCMS showed a peak (98%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL). The organic phase was washed with brine (15 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 9-[3-ethynyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy) -1-naphthyl]-5- fluoro-4-methyl-2,7-naphthyridin-1-yl]-3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate (22 mg, crude) as colorless oil. MS (ES+) C36H34N4F2O5 requires: 640, found: 641 [M+H]+Step 5 5-ethynyl-4-[6-ethynyl-4-fluoro-5-methyl-8-(3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl)- 2,7-naphthyridin-3-yl]-6-fluoro-naphthalen-2-ol

[0404] To a solution of tert-butyl 9-[3-ethynyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy) -1-naphthyl]-5-fluoro-4-methyl-2, 7-naphthyridin-1-yl]-3-oxa-7, 9- diazabicyclo[3.3.1]nonane-7-carboxylate (22 mg, 34.34 μmol, 1 eq) in DCM (0.6 mL) was added TFA (307.00 mg, 2.69 mmol, 0.2 mL, 78.41 eq) at 25 °C. Then the mixture was stirred at 25 °C for 20 min. LCMS showed a peak (86%) with the desired mass. The mixture wasadjusted to pH = 7 by sat. aq. NaHCO3at 0 °C. Then the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um; mobile phase: [water (FA) -ACN]; gradient: 18%-48% B over 10 min) and lyophilized to afford 5-ethynyl-4-[6-ethynyl-4-fluoro-5-methyl-8-(3-oxa-7, 9- diazabicyclo[3.3.1]nonan-9-yl) -2, 7-naphthyridin-3-yl]-6-fluoro-naphthalen-2-ol (3.7 mg, 6.75 μmol, 19.66% yield, 99% purity, FA) as gray solid. MS (ES+) C29H22F2N4O2requires: 496, found: 497 [M+H]+.

[0405] 1H NMR (400 MHz, CD3OD) δ = 9.08 (s, 1H), 8.54 (s, 1H), 7.88 (dd, J = 5.7, 9.3 Hz, 1H), 7.37 - 7.31 (m, 2H), 7.24 (d, J = 2.6 Hz, 1H), 4.38 - 4.33 (m, 2H), 4.22 - 4.17 (m, 2H), 4.16 - 4.12 (s, 2H), 4.02 (s, 1H), 3.71 - 3.62 (m, 2H), 3.46 - 3.40 (m, 2H), 3.27 (s, 1H), 2.83 (d, J = 6.0 Hz, 3H). EXAMPLE 1504-[5-cyclopropyl-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 6-chloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one

[0406] Two batches. To a solution of [(6-chloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2-dimethylpropanoate (1 g, 3.64 mmol, 1 eq), cesium acetate (174.71 mg, 910.16 μmol, 0.25 eq) and pentamethylcyclopentadienyl rhodium(III) chloride dimer (114.35 mg, 182.03 μmol, 0.05 eq) in MeOH (5 mL) was added prop-1-yne (1 M in heptane, 7.28 mL, 2 eq) at 20°C under N2, then the mixture was stirred at 60 °C for 16 h. LCMS showed a peak (98 %) with the desired mass. The reaction mixture was filtered and the filter cake was washed with MeOH (10 mL x 2), dried under reduced pressure to give 6-chloro-5-fluoro-3-methyl-2H-2,7- naphthyridin-1-one (1.9 g, 8.94 mmol, 81.82% yield, 100% purity) as yellow solid1H NMR (400 MHz, DMSO-d6) δ = 11.96 (s, 1H), 8.86 (s, 1H), 6.44 (s, 1H),2.27 (s, 3H) Step 2 tert-butyl 3-(6-chloro-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0407] To a solution of 6-chloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one (1.9 g, 8.94 mmol, 1 eq) in DCM (20 mL) was added DIPEA (4.62 g, 35.75 mmol, 6.23 mL, 4 eq) and Tf2O (5.55 g, 19.66 mmol, 3.24 mL, 2.2 eq) at 0 °C under N2, then the mixture was stirred at 20 °C for 1 h. To the mixture were added DIPEA (3.46 g, 26.81 mmol, 4.67 mL, 3 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3.79 g, 17.87 mmol, 2 eq) at 20 °C , then the mixture was stirred at 20 °C for 0.5 h. LCMS showed a peak (74 %) with the desired mass. The mixture was added H2O (20 mL), then extracted with ethyl acetate (20 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (80 g, SepaFlash® Silica Flash Column, Eluent of 0~8% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 3-(6-chloro-5-fluoro-3-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3.3 g, 4.95 mmol, 55.36% yield, 61% purity) as yellow solid MS (ES+) C20H24N4FClO2requires: 406, found: 407[M+H]+Step 3 tert-butyl 3-(6-chloro-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0408] To a solution of tert-butyl 3-(6-chloro-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (300 mg, 737.32 μmol, 1 eq) in DMF (5 mL) was added NIS (248.83 mg, 1.11 mmol, 1.5 eq) at 20 °C , then the mixture was stirred at 20 °C for 2 h. LCMS showed a peak (95 %) with the desired mass. The mixture was filtered, the filter cake was washed with ethyl acetate (10 mL x 3), the filter cake was dried under reduced pressure to afford desired product. The filtrate was concentrated under reduced pressure to afford crude product. The mixture was added diluted with brine (10 mL) and extracted with ethyl acetate (10 mL x 3), the combined organic phase was washed with saturated Na2SO3 (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to afford tert- butyl 3-(6-chloro-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (150 mg, 273.10 μmol, 37.04% yield, 97% purity) as yellow solid.

[0409] MS (ES+) C20H23N4FClIO2requires: 532, found: 533 [M+H]+1H NMR (400 MHz, CDCl3) δ = 8.95 (s, 1H), 4.52 - 4.19 (m, 2H), 3.95 - 3.80 (m, 2H), 3.54 - 3.43 (m, 2H), 2.83 (s, 3H), 2.03 - 1.90 (m, 4H), 1.51 (s, 9H) Step 4 tert-butyl 3-(6-chloro-4-cyclopropyl-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0410] To a solution of tert-butyl 3-(6-chloro-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin- 1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (130 mg, 244.00 μmol, 1 eq), cyclopropylboronic acid (52.40 mg, 610.01 μmol, 2.5 eq) in Tol. (4 mL) were added K3PO4(1.5 M, 650.68 μL, 4 eq), PCy3 (17.11 mg, 61.00 μmol, 19.78 μL, 0.25 eq) and Pd(OAc)2(10.96 mg, 48.80 μmol, 0.2 eq) at 20 °C, then the mixture was stirred at 100 °C for 16 h. LCMS showed a peak (53 %) with the desired mass. The mixture was diluted with H2O (5 mL), then extracted with ethyl acetate (5 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep- TLC (SiO2, Petroleum ether : Ethyl acetate= 3:1) to afford tert-butyl 3-(6-chloro-4- cyclopropyl-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (100 mg, 138.72 μmol, 56.85% yield, 62% purity) as yellow solid

[0411] MS (ES+) C23H28N4FClO2requires: 446 found: 447 [M+H]+Step 5 tert-butyl 3-(6-chloro-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0412] To a solution of tert-butyl 3-(6-chloro-4-cyclopropyl-5-fluoro-3-methyl-2,7- naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (90 mg, 201.37 μmol, 1 eq), 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]ethynyl-triisopropyl-silane (154.81 mg, 302.05 μmol, 1.5 eq) in THF (2 mL) were added K3PO4(1.5 M, 402.73 μL, 3 eq) and cataCXium® A Pd G3(29.33 mg, 40.27 μmol, 0.2 eq) at 20 °C under N2. The mixture was stirred at 60 °C for 16 h. LCMS showed a peak (35 %)with the desired mass. The mixture was added H2O (5 mL) and extracted with EtOAc (10mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO2, Petroleum ether : Ethyl acetate= 2.5:1) to afford tert-butyl 3-(6-chloro-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 67.75 μmol, 33.64% yield, 54% purity) as yellow solid.

[0413] MS (ES+) C46H58N4F2O4Si requires:796, found: 797 [M+H]+Step 6tert-butyl 3-[4-cyclopropyl-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5- fluoro-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0414] To a solution of tert-butyl 3-[4-cyclopropyl-5-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 125.46 μmol, 1 eq) in DMF (2 mL) was added CsF (2.06 g, 13.54 mmol, 0.5 mL, 107.96 eq) at 20 °C , then the mixture was stirred at 20 °C for 1 h. LCMS showed a peak (42 %) with the desired mass. The reaction mixture was diluted with ice-water (5 mL), then extracted with ethyl acetate (5mL x 3), washed with brine (5 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 3-[4-cyclopropyl-6-[8- ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-3-methyl-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, 78.04 μmol, 62.20% yield) as yellow solid. MS (ES+) C37H38N4F2O4 requires:640, found: 641 [M+H]+Step 7 4-[5-cyclopropyl-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0415] To a solution of tert-butyl 3-[4-cyclopropyl-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, 78.04 μmol, 1 eq) in DCM (1.5 mL) was added TFA (614.00 mg, 5.38 mmol, 0.4 mL) at 20 °C, then the mixture was stirred at 20 °Cfor 40 min. LCMS showed a peak (46 %) with the desired mass. The mixture was quenched with NaHCO3(15 mL) at 0 °C, extracted with ethyl acetate (10 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient:18%-48% B over 2 min) to afford 4-[5- cyclopropyl-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7-naphthyridin-3-yl]- 5-ethynyl-6-fluoro-naphthalen-2-ol (8.5 mg, 15.04 μmol, 19.27% yield, 96% purity, FA) as yellow solid.

[0416] MS (ES+) C30H26F2N4O requires:496, found: 497 [M+H]+

[0417] 1H NMR (400 MHz, CD3OD) δ = 9.18 (s, 1H), 8.54 (s, 1H), 7.88 (dd, J = 5.6, 9.0 Hz, 1H), 7.38 - 7.30 (m, 2H), 7.22 (d, J = 2.6 Hz, 1H), 4.25 - 4.05 (m, 2H), 3.98 - 3.83 (m, 2H), 3.61 - 3.44 (m, 2H), 3.19 (s, 1H), 2.69 (s, 3H), 2.43 - 2.30 (m, 2H), 2.19 - 2.11 (m, 3H), 1.15 - 1.05 (m, 2H), 0.67 - 0.46 (m, 2H) EXAMPLE 1514-[5-bromo-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7-naphthyridin-3- yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 3-[4-bromo-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0418] To a solution of tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (40 mg, 52.84 μmol, 1 eq) in DMF (0.5 mL) was added NBS (14.11 mg, 79.26 μmol, 1.5 eq). The mixture was stirred at 25 °C for 2 hrs. LCMS showed a peak (70%) with desired mass. The mixture was diluted with H2O (5 mL) and extracted with EtOAc (5 mL x 2), the combined organic phase was washed with saturated Na2SO3(10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-TLC (petroleum ether: ethyl acetate= 3:1) to afford tert-butyl 3-[4-bromo-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (32 mg, 38.28 μmol, 72.45% yield) as light yellow oil.

[0419] MS (ES+) C43H53N4F2BrO4Si requires: 834, found: 835 [M+H]+Step 2 tert-butyl 3-[4-bromo-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro- 3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0420] To a solution of tert-butyl 3-[4-bromo-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)- 8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (32 mg, 38.28 μmol, 1 eq) in DMF (0.5 mL) wasadded CsF (17.45 mg, 114.85 μmol, 4.24 μL, 3 eq). The reaction mixture was stirred at 25 °C for 0.5 hr. LCMS showed a peak (59%) with desired mass. The mixture was diluted with H2O (5 mL) and extracted with EtOAc (5 mL x 2), the combined organic phase was washed with brine (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl 3-[4-bromo-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5- fluoro-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (15 mg, crude) as yellow oil. MS (ES+) C34H33N4F2BrO4requires: 678, found: 679 [M+H]+Step 3 4-[5-bromo-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7-naphthyridin-3- yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0421] To a solution of tert-butyl 3-[4-bromo-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (15 mg, 22.07 μmol, 1 eq) in DCM (0.9 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL). The mixture was stirred at 25 °C for 0.5 hr. LCMS showed a peak (43%) with desired mass. The mixture was added into cold saturated NaHCO3(5 mL) and extracted with EtOAc (5 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-HPLC (column: Phenomenex Luna C18150*25mm*10um; mobile phase: [water(FA)-ACN]; gradient: 27%-57% B over 9 min). The sample was lyophilized to afford 4-[5-bromo-8-(3,8- diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7-naphthyridin-3-yl]-5-ethynyl-6-fluoro- naphthalen-2-ol (2.0 mg, 3.44 μmol, 15.58% yield, 100% purity, FA) as a pink solid.

[0422] MS (ES+) C27H21BrF2N4O requires: 534, found: 535 [M+H]+

[0423] 1H NMR (400 MHz, CD3OD) δ = 9.22 (s, 1H), 7.94 - 7.83 (m, 1H), 7.40 - 7.29 (m, 2H), 7.24 (s, 1H), 4.12 - 3.92 (m, 4H), 3.66 - 3.52 (m, 2H), 3.27 (s, 1H), 2.75 (s, 3H), 2.36 - 2.24 (m, 2H), 2.15-2.07 (m, 2H).EXAMPLE 1521-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5- fluoro-3-methyl-2,7-naphthyridine-4-carbonitrile Step 1 tert-butyl 3-(6-chloro-4-cyano-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0424] To a solution of tert-butyl 3-(6-chloro-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin- 1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (600 mg, 1.13 mmol, 1 eq), DMF (6 mL) was added Zn powder (10 mg, 152.93 μmol, 0.14 eq), Zn(CN)2 (100 mg, 851.64 μmol, 0.75 eq) and Pd(dppf)Cl2 (82.40 mg, 112.62 μmol, 0.1 eq) at 20 °C under the protection of N2. The mixture was stirred at 60 °C for 2 h. LCMS showed a peak (66 %) with the desired mass. The mixture was filtered, diluted with ethyl acetate (10 mL), washed with brine (10 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 10~50% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 3- (6-chloro-4-cyano-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (160 mg, 237.10 μmol, 21.05% yield, 64% purity) as yellow solid. MS (ES+) C21H23N5FClO2requires: 431, found: 432[M+H]+Step 2tert-butyl 3-[4-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0425] To a solution of 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (156.65 mg, 305.63 μmol, 1.1 eq), tert-butyl 3-(6-chloro-4-cyano-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (120 mg, 277.85 μmol, 1 eq) in THF (7 mL) were added K3PO4 (1.5 M, 555.70 μL, 3 eq) and cataCXium® A Pd G3 (20.23 mg, 27.78 μmol, 0.1 eq) at 20 °C under N2. The mixture was stirred at 60 °C for 16 h. LCMS showed a peak (83 %) with the desired mass. The mixture was diluted with H2O (5 mL) and extracted with ethyl acetate (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO2, Petroleum ether : Ethyl acetate= 3:1) to afford tert-butyl 3-[4-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (150 mg, 187.98 μmol, 67.66% yield, 98% purity) as yellow solid. MS (ES+) C44H53N5F2O4Si requires: 781, found: 782 [M+H]+Step 3 tert-butyl 3-[4-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-3- methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0426] To a solution of tert-butyl 3-[4-cyano-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)- 8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (140 mg, 179.03 μmol, 1 eq) in DMF (2 mL) was added CsF (81.58 mg, 537.08 μmol, 19.83 μL, 3 eq) at 20 °C. The mixture was stirred at 20 °C for 40 min. LCMS showed a peak (98 %) with the desired mass. The reaction mixture was diluted with ice-water (5 mL), then extracted with ethyl acetate (5 mL x 3), washed with brine (5 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 3-[4-cyano-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 159.83 μmol, 89.28% yield) as yellow solid. MS (ES+) C35H33N5F2O4 requires: 625 found: 626 [M+H]+Step 4 1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5- fluoro-3-methyl-2,7-naphthyridine-4-carbonitrile

[0427] To a solution of tert-butyl 3-[4-cyano-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)- 1-naphthyl]-5-fluoro-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (100 mg, 159.83 μmol, 1 eq) in DCM (2.5 mL) was added TFA (1.23 g, 10.77 mmol, 0.8 mL, 67.38 eq) at 20 °C, then the mixture was stirred at 20 °C for 40 min. LCMS showed a peak (73 %) with the desired mass. The mixture was added NaHCO3 (15mL) at 0°C, then extracted with ethyl acetate (10 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep- HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water(FA)- ACN];gradient:15%-45% B over 2 min) to afford 1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-6- (8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-5-fluoro-3-methyl-2,7-naphthyridine-4- carbonitrile (47.1 mg, 89.29 μmol, 55.86% yield, n / a purity, FA) as yellow solid

[0428] MS (ES+) C28H21F2N5O requires:481, found: 482 [M+H]+

[0429] 1H NMR (400 MHz, CD3OD) δ = 9.15 (s, 1H), 8.44 (s, 1H), 7.89 (dd, J = 5.8, 9.1 Hz, 1H), 7.38 (d, J = 2.6 Hz, 1H), 7.37 - 7.32 (m, 1H), 7.25 (d, J = 2.6 Hz, 1H), 4.70 - 4.60 (m, 2H), 4.18 - 4.04 (m, 2H), 3.95 - 3.80 (m, 2H), 3.30 - 3.28 (m, 1H), 2.78 (s, 3H), 2.16 - 2.03 (m, 4H) EXAMPLE 1534-[5-chloro-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7-naphthyridin-3- yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 6-chloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one

[0430] A mixture of [(6-chloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2- dimethylpropanoate (1 g, 3.64 mmol, 1 eq), cesium acetate (174.71 mg, 910.16 μmol, 0.25 eq) and pentamethylcyclopentadienyl rhodium dichloride dimer (107.01 mg, 182.03 μmol, 0.05 eq) in MeOH (5 mL) was degassed and purged with N2for 3 times and then to the mixture was added prop-1-yne (1 M, 7.28 mL, 2 eq). The mixture was stirred at 60 °C for 16 hrs under N2 atmosphere. LCMS showed a peak (97%) with desired mass. The reactionmixture was filtered and the filter cake was washed with MeOH (10 mL x 2), dried over under reduced pressure to afford 6-chloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one (1.63 g, crude) as a white solid. MS (ES+) C9H6ClFN2O requires: 212, found: 213 [M+H]+1H NMR (400 MHz, DMSO-d6) δ = 12.00 (s, 1H), 8.88 (s, 1H), 6.49 - 6.42 (m, 1H), 2.30 (s, 3H). Step 2 tert-butyl 3-(6-chloro-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0431] To a solution of 6-chloro-5-fluoro-3-methyl-2H-2,7-naphthyridin-1-one (2.1 g, 9.88 mmol, 1 eq) in DCM (30 mL) were added DIPEA (5.11 g, 39.51 mmol, 6.88 mL, 4 eq) and Tf2O (6.13 g, 21.73 mmol, 3.59 mL, 2.2 eq) at 0 °C under the protection of N2. The mixture was stirred at 25 °C for 1 hr. Then to the mixture was added DIPEA (3.83 g, 29.63 mmol, 5.16 mL, 3 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (4.19 g, 19.75 mmol, 2 eq). The reaction was stirred at 25 °C for 0.5 hr. LCMS showed a peak (67%) with desired mass. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was diluted with H2O (50 mL) and extracted with EtOAc (5 mL x 2). The combined organic layers was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (80 g SepaFlash ® Silica Flash Column, Eluent of 0~6% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 3-(6-chloro-5-fluoro-3- methyl-2,7-naphthyridin-1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.4 g, 2.96 mmol, 29.96% yield, 86% purity) as a yellow solid. MS (ES+) C20H24N4FClO2 requires: 406, found: 407 [M+H]+1H NMR (400 MHz, CDCl3) δ = 8.95 (s, 1H), 7.12 (s, 1H), 4.55 - 4.22 (m, 2H), 3.96 (d, J = 12.1 Hz, 2H), 3.59 - 3.23 (m, 2H), 2.64 - 2.49 (m, 3H), 2.03 - 1.93 (m, 4H), 1.51 (s, 9H). Step 3tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0432] To a solution of tert-butyl 3-(6-chloro-5-fluoro-3-methyl-2,7-naphthyridin-1-yl)- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (300 mg, 737.32 μmol, 1 eq) in THF (15 mL) were added 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1-naphthyl]ethynyl-triisopropyl-silane (377.90 mg, 737.32 μmol, 1 eq), K3PO4 (1.5 M, 1.5 mL, 3.05 eq) and cataCXium® A Pd G3(53.70 mg, 73.73 μmol, 0.1 eq) at 25 °C under the protection of N2. The mixture was stirred at 60 °C for 16 hrs under N2. LCMS showed a peak (26%) with desired mass. To the mixture was added additional 2-[2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (377.90 mg, 737.32 μmol, 1 eq) and cataCXium® A Pd G3(53.70 mg, 73.73 μmol, 0.1 eq). The reaction was stirred at 60 °C for 2 hrs under N2. The mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL x 2). The combined organic layers was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (275 mg, 261.56 μmol, 35.47% yield, 72% purity) as yellow oil. MS (ES+) C43H54N4F2O4Si requires: 756, found: 757 [M+H]+Step 4 tert-butyl 3-[4-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0433] To a solution of tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 132.10 μmol, 1 eq) in DMF (1 mL) was added NCS (14.11 mg, 105.68 μmol, 0.8 eq). The mixture was stirred at 60 °C for 1 hr. LCMS showed a peak (74%) with desired mass. The mixture was diluted with H2O (5 mL) and extracted with EtOAc (5 mL x 2), the combined organic phase was washed with saturated Na2SO3(10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford tert-butyl 3-[4-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (72 mg, 72.78 μmol, 55.09% yield, 80% purity) as yellow oil. MS (ES+) C43H53N4F2ClO4Si requires: 790, found: 791 [M+H]+Step 5 tert-butyl 3-[4-chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro- 3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0434] To a solution of tert-butyl 3-[4-chloro-5-fluoro-6-[7-fluoro-3-(methoxymethoxy)- 8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (72 mg, 90.97 μmol, 1 eq) in DMF (1 mL) was added CsF (41.46 mg, 272.92 μmol, 10.07 μL, 3 eq). The mixture was stirred at 25 °C for 0.5 hr. LCMS showed a peak (74%) with desired mass. The mixture was diluted with H2O (5 mL) and extracted with EtOAc (5 mL x 2), the combined organic phase was washed with brine (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 3-[4-chloro-6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro- 3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, crude) as yellow oil. MS (ES+) C34H33N4F2ClO4 requires: 634, found: 635 [M+H]+Step 6 4-[5-chloro-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-2,7-naphthyridin-3- yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0435] To a solution of tert-butyl 3-[4-chloro-6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 157.46 μmol, 1 eq) in DCM (1.2 mL) was added TFA (614.00 mg, 5.38 mmol, 0.4 mL). The mixture was stirred at 25 °C for 0.5 hr. LCMS showed a peak (38%) with desired mass. The mixture was added into cold saturated NaHCO3(10 mL) and extracted with EtOAc (10 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 20%-50% B over 2 min). The eluent lyophilized to afford 4-[5-chloro-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl- 2,7-naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (5.3 mg, 9.57 μmol, 6.08% yield, 97% purity, FA) as a pink solid.

[0436] MS (ES+) C27H21ClF2N4O requires: 490, found: 491 [M+H]+

[0437] 1H NMR (400 MHz, CD3OD) δ = 9.21 (s, 1H), 8.53 (s, 1H), 7.90-7.85 (m, 1H), 7.39 - 7.30 (m, 2H), 7.24 (d, J = 2.4 Hz, 1H), 4.10 - 3.89 (m, 4H), 3.65-3.53 (m, 2H), 3.27 (s, 1H), 2.69 (s, 3H), 2.38 - 2.24 (m, 2H), 2.18 - 2.05 (m, 2H). EXAMPLE 1544-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-iodo-6-methyl-2,7-naphthyridin-3-yl]- 5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-4-iodo-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate

[0438] To a solution of tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-iodo-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate;tert-butyl 3-[5-fluoro-6-[7-fluoro-3- (methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-3-methyl-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (27 mg, 16.46 μmol, 1 eq) in DMF (0.5 mL) was added NIS (3.70 mg, 16.46 μmol, 1 eq). The reaction mixture was stirred at 60 °C for 16 hrs. LCMS showed a peak (82%) with desired mass. The mixture was diluted with H2O (5 mL) and extracted with EtOAc (5 mL x 2), the combined organic phase was washed withsaturated Na2SO3(10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-TLC (Petroleum ether: Ethyl acetate= 2.5: 1) to afford tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-iodo-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (16 mg, 15.59 μmol, 94.66% yield, 86% purity) as yellow oil. MS (ES+) C43H53N4F2IO4Si requires: 882, found: 883 [M+H]+Step 2 tert-butyl 3-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-4-iodo-3- methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0439] To a solution of tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-4-iodo-3-methyl-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (26 mg, 29.45 μmol, 1 eq) in DMF (0.5 mL) was added CsF (13.42 mg, 88.35 μmol, 3.26 μL, 3 eq). The mixture was stirred at 25 °C for 0.5 hr. LCMS showed a peak (78%) with desired mass. The mixture was diluted with H2O (10 mL) and extracted with EtOAc (5 mL x 2), the combined organic phase was washed with brine (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 3-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-4-iodo-3- methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, crude) as yellow oil. MS (ES+) C34H33N4F2IO4requires: 726, found: 727 [M+H]+Step 3 4-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-iodo-6-methyl-2,7-naphthyridin-3-yl]- 5-ethynyl-6-fluoro-naphthalen-2-ol

[0440] To a solution of tert-butyl 3-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (50 mg, 68.82 μmol, 1 eq) in DCM (0.9 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL). The mixture was stirred at 25 °C for 0.5 hr. LCMS showed a peak (62%) with desired mass. The mixture was added into cold saturated NaHCO3 (10 mL) and extracted with EtOAc (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 20%-50% B over 2 min). The eluent was concentrated under reduced pressure and freeze-dried to afford 4-[8- (3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5-iodo-6-methyl-2,7-naphthyridin-3-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol (2.5 mg, 3.94 μmol, 5.72% yield, 99% purity, FA) as a pink solid.

[0441] MS (ES+) C27H21F2IN4O requires: 582, found: 583 [M+H]+

[0442] 1H NMR (400 MHz, CD3OD) δ = 9.23 (s, 1H), 7.93-7.85 (m, 1H), 7.40 - 7.30 (m, 2H), 7.23 (d, J = 2.6 Hz, 1H), 4.14 - 3.93 (m, 4H), 3.59 (t, J = 14.1 Hz, 2H), 3.25 (s, 1H), 2.87 (s, 3H), 2.38 - 2.22 (m, 2H), 2.16 - 2.06 (m, 2H). EXAMPLE 1554-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5,6-bis(hydroxymethyl)-1-methoxy-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-olStep 1 2-(4-tetrahydropyran-2-yloxybut-2-ynoxy)tetrahydropyran

[0443] To a solution of but-2-yne-1,4-diol (800 mg, 9.29 mmol, 1 eq) in DCM (10 mL) were added DHP (1.72 g, 20.44 mmol, 1.87 mL, 2.2 eq) and TsOH (96.01 mg, 557.56 μmol, 0.06 eq), then the mixture was stirred at 20 °C for 16 h. The mixture was washed with H2O (10 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~5% Ethyl acetate / Petroleum ether gradient @ 200 mL / min) to afford 2-(4- tetrahydropyran-2-yloxybut-2-ynoxy)tetrahydropyran (1.2 g, crude) as a colorless solid. 1H NMR (400 MHz, CD3Cl) δ = 4.78 (t, J = 3.2 Hz, 2H), 4.41 - 4.16 (m, 4H), 3.89 - 3.75 (m, 2H), 3.58 - 3.44 (m, 2H), 1.87 - 1.45 (m, 12H) Step 2 6,8-dichloro-5-fluoro-3,4-bis(tetrahydropyran-2-yloxymethyl)-2H-2,7-naphthyridin-1- one

[0444] To a solution of [(2,6-dichloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2- dimethylpropanoate (450 mg, 1.46 mmol, 1 eq) in MeOH (6 mL) were added 2-(4- tetrahydropyran-2-yloxybut-2-ynoxy)tetrahydropyran (740.45 mg, 2.91 mmol, 2 eq), cesium acetate (83.83 mg, 436.72 μmol, 0.3 eq) and pentamethylcyclopentadienyl rhodium dichloride dimer (64.01 mg, 101.90 μmol, 0.07 eq), the mixture was stirred at 60 °C for 16 h. LCMS showed a peak (34%) with desired mass. The mixture was concentrated in vacuum, diluted with ethyl acetate (20 mL) and washed with H2O (20 mL). The organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 20~25% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford 6,8-dichloro-5-fluoro-3,4- bis(tetrahydropyran-2-yloxymethyl)-2H-2,7-naphthyridin-1-one (500 mg, 758.71 μmol, 52.12% yield, 70% purity) as a yellow solid. MS (ES+) C20H23N2Cl2O5F requires: 460, found: 461 [M+H]+Step 3 6-chloro-5-fluoro-8-methoxy-3,4-bis(tetrahydropyran-2-yloxymethyl)-2H-2,7- naphthyridin-1-one

[0445] To a solution of 6,8-dichloro-5-fluoro-3,4-bis(tetrahydropyran-2-yloxymethyl)- 2H-2,7-naphthyridin-1-one (450 mg, 975.48 μmol, 1 eq) in DMA (5 mL) was added MeOH (156.28 mg, 4.88 mmol, 197.37 μL, 5eq) followed by LiHMDS (1 M, 4.88 mL, 5 eq) at 0 °C under N2. Then the mixture was stirred at 40 °C for 16 h under N2. LCMS showed a peak (47%) with desired mass. The mixture was quenched by NH4Cl (10 mL), added HCl (1 M) to adjust pH = 7, extracted with ethyl acetate (20 mL x 3), washed with brine (60 mL x 2), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 25~40% Ethyl acetate / Petroleum ether gradient @ 40 mL / min) to afford 6-chloro-5-fluoro-8-methoxy- 3,4-bis(tetrahydropyran-2-yloxymethyl)-2H-2,7-naphthyridin-1-one (225 mg, 339.80 μmol, 34.83% yield, 69% purity) as a white solid. MS (ES+) C21H26N2ClO6F requires: 456, found: 457 [M+H]+Step 4 tert-butyl 3-[6-chloro-5-fluoro-8-methoxy-3,4-bis(tetrahydropyran-2-yloxymethyl)-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0446] To a solution of 6-chloro-5-fluoro-8-methoxy-3,4-bis(tetrahydropyran-2- yloxymethyl)-2H-2,7-naphthyridin-1-one (200 mg, 437.74 μmol, 1 eq) in DCM (3 mL) were added DIEA (452.60 mg, 3.50 mmol, 609.97 μL, 8 eq) and Tf2O (494.01 mg, 1.75 mmol, 288.90 μL, 4 eq) at 0 °C, and the mixture was stirred at 20 °C for 1 h. Then DIEA (226.30mg, 1.75 mmol, 304.99 μL, 4 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (185.85 mg, 875.48 μmol, 2 eq) were added, the mixture was stirred at 20 °C for 1 h. LCMS showed a peak (75%) with desired mass. The mixture was quenched by H2O (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 10~12% Ethyl acetate / Petroleum ether gradient @ 60 mL / min) to afford tert-butyl 3-[6-chloro-5-fluoro-8- methoxy-3,4-bis(tetrahydropyran-2-yloxymethyl)-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (280 mg, 387.00 μmol, 88.41% yield, 90% purity) as a brown oil. MS (ES+) C32H44N4O7ClF requires: 650, found: 651 [M+H]+Step 5 tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-8-methoxy-3,4-bis(tetrahydropyran-2-yloxymethyl)-2,7-naphthyridin-1-yl]- 3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0447] To a solution of tert-butyl 3-[6-chloro-5-fluoro-8-methoxy-3,4- bis(tetrahydropyran-2-yloxymethyl)-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (250 mg, 383.93 μmol, 1 eq) in dioxane (5 mL) were added 2-[2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (236.13 mg, 460.71 μmol, 1.2 eq), K3PO4(1.5 M, 767.86 μL, 3 eq) and XPhos Pd G4(33.04 mg, 38.39 μmol, 0.1 eq), and the mixture was stirred at 100 °C for 16 h under N2. LCMS showed a peak (62%) with desired mass. The mixture was quenched with sat. aq. NH4Cl (10 mL) and extracted with ethyl acetate (10 mL x 3), then dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, eluent of 9~20% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-3,4- bis(tetrahydropyran-2-yloxymethyl)-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (250 mg, 224.71 μmol, 58.53% yield, 90% purity) as brown oil. MS (ES+) C55H74F2N4O9Si requires: 1001, found: 1002 [M+H]+Step 6 tert-butyl 3-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-8- methoxy-3,4-bis(tetrahydropyran-2-yloxymethyl)-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0448] To a solution of tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-8-methoxy-3,4-bis(tetrahydropyran-2-yloxymethyl)- 2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10 mg, 9.99 μmol, 1 eq) in DMF (0.5 mL) was added CsF (6.07 mg, 39.95 μmol, 1.47 μL, 4 eq), and the mixture was stirred at 30 °C for 1 h. LCMS showed a peak (95%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL), washed with brine (10 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 3-[6-[8-ethynyl-7-fluoro-3- (methoxymethoxy)-1-naphthyl]-5-fluoro-8-methoxy-3,4-bis(tetrahydropyran-2- yloxymethyl)-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (15 mg, crude) as a yellow solid. MS (ES+) C46H54N4F2O9requires: 844, found:845 [M+H]+Step 7 4-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-5,6-bis(hydroxymethyl)-1-methoxy-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0449] To a solution of tert-butyl 3-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-5-fluoro-8-methoxy-3,4-bis(tetrahydropyran-2-yloxymethyl)-2,7-naphthyridin-1- yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (15 mg, 17.75 μmol, 1 eq) in DCM (0.6 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL), the mixture was stirred at 20 °C for 1 h. LCMS showed a peak (57%) with the desired mass. The mixture was quenched by sat. aq. NaHCO3 (10 mL), extracted with ethyl acetate (10 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient: 16%- 36% B over 2 min) and lyophilized to afford 4-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4- fluoro-5,6-bis(hydroxymethyl)-1-methoxy-2,7-naphthyridin-3-yl]-5-ethynyl-6-fluoro- naphthalen-2-ol (1.3 mg, 2.25 μmol, 12.66% yield, 100% purity, FA) as a yellow solid.

[0450] MS (ES+) C29H26N4F2O4 requires: 532, found: 533 [M+H]+

[0451] 1H NMR (400 MHz, CD3OD) δ = 8.60 - 8.47 (m, 1H), 7.70 - 7.60 (m, 1H), 7.37 - 7.25 (m, 3H), 5.10 - 5.00 (m, 2H), 4.95 - 4.90 (m, 2H), 4.33 - 4.22 (m, 1H), 4.15 - 4.07 (m, 2H), 4.06 (s, 3H), 3.70 - 3.60 (m, 1H), 3.52 - 3.43 (m, 1H), 3.25 - 3.20 (m, 1H), 3.18 (s, 1H), 2.35 -2.25 (m, 1H), 2.25 -2.10 (m, 1H), 2.10 -1.95 (m, 2H).4-[5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-9-fluoro-1,3-dihydrofuro[3,4- c][2,7]naphthyridin-8-yl]-5-ethynyl-6-fluoro-naphthalen-2-olStep 1 3,4-bis[[tert-butyl(dimethyl)silyl]oxymethyl]-6-chloro-5-fluoro-2H-2,7-naphthyridin-1- one

[0452] To a solution of [(6-chloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2- dimethylpropanoate (1 g, 3.64 mmol, 1eq) in MeOH (10 mL) was added tert-butyl-[4-[tert- butyl(dimethyl)silyl]oxybut-2-ynoxy]-dimethyl-silane (2.29 g, 7.28 mmol, 2 eq), cesium acetate (209.65 mg, 1.09 mmol, 0.3 eq) and pentamethylcyclopentadienyl rhodium dichloride dimer (160.08 mg, 254.85 μmol, 0.07eq), the mixture was stirred at 70 °C for 3 h. LCMS showed a peak (32%) with desired mass. The mixture was concentrated in vacuum. The residue was diluted with ethyl acetate (10 mL) and filtered, the filtrate was concentrated in vacuum and purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 0~4% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford 3,4-bis[[tert-butyl(dimethyl)silyl]oxymethyl]-6-chloro-5-fluoro-2H-2,7-naphthyridin-1-one (1 g, 1.85 mmol, 50.75% yield, 90% purity) as a yellow solid. MS (ES+) C22H36ClFN2O3Si2requires: 486, found: 487 [M+H]+Step 2 tert-butyl 3-[3,4-bis[[tert-butyl(dimethyl)silyl]oxymethyl]-6-chloro-5-fluoro-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0453] To a solution of 3,4-bis[[tert-butyl(dimethyl)silyl]oxymethyl]-6-chloro-5-fluoro- 2H-2,7-naphthyridin-1-one (900 mg, 1.85 mmol, 1 eq) in DCM (10 mL) were added DIEA (1.91 g, 14.78 mmol, 2.57 mL, 8 eq) and Tf2O (2.08 g, 7.39 mmol, 1.22 mL, 4 eq) at 0 °C, then the mixture was stirred at 20 °C for 1 h. Then to the mixture were added DIEA (477.54mg, 3.69 mmol, 643.59 μL, 2 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (784.39 mg, 3.69 mmol, 2 eq), it was stirred at 20 °C for 1.5 h. LCMS showed a peak (86%) with desired mass. The organic phase was washed with brine (20 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 3~4% Ethyl acetate / Petroleum ether gradient @100 mL / min) to afford tert-butyl 3-[3,4-bis[[tert- butyl(dimethyl)silyl]oxymethyl]-6-chloro-5-fluoro-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (1 g, 1.39 mmol, 75.46% yield, 95% purity) as a yellow solid. MS (ES+) C33H54N4ClO4FSi2requires: 680, found: 681 [M+H]+

[0454] 1H NMR (400 MHz, CDCl3) δ = 8.97 (s, 1H), 5.13 (s, 2H), 4.88 (s, 2H), 4.46 - 4.25 (m, 2H), 3.86 (d, J = 12.0 Hz, 2H), 3.62 - 3.36 (m, 2H), 2.05 - 1.94 (m, 4H), 1.51 (s, 9H), 0.92 (d, J = 0.6 Hz, 18H), 0.12 (d, J = 18.2 Hz, 12H) Step 3 tert-butyl 3-[6-chloro-5-fluoro-3,4-bis(hydroxymethyl)-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0455] To a solution of tert-butyl 3-[3,4-bis[[tert-butyl(dimethyl)silyl]oxymethyl]-6- chloro-5-fluoro-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (720 mg, 1.06 mmol, 1 eq) in DMF (10 mL) was added CsF (963.01 mg, 6.34 mmol, 234.03 μL, 6 eq) and the mixture was stirred at 30 °C for 6 h. LCMS showed a peak(45%) with desired mass. The mixture was diluted with ethyl acetate (50 mL).The combined organic phase was washed with brine (50 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 40~50% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford tert-butyl 3-[6-chloro-5-fluoro-3,4-bis(hydroxymethyl)-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (150 mg, 208.65 μmol, 19.75% yield, 63% purity) as a brown oil.

[0456] MS (ES+) C21H26N4ClO4F requires: 452, found: 453 [M+H]+Step 4 tert-butyl 3-(8-chloro-9-fluoro-1,3-dihydrofuro[3,4-c][2,7]naphthyridin-5-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0457] To a solution of tert-butyl 3-[6-chloro-5-fluoro-3,4-bis(hydroxymethyl)-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (135 mg, 298.08 μmol, 1 eq) in THF (2 mL) was added NaHMDS (1 M, 894.23 μL, 3 eq) at 0 °C, and the mixture was stirred at 0 °C for 0.2 h under N2. Then TosCl (68.19 mg, 357.69 μmol, 1.2 eq) was added at 0 °C, it was stirred at 0 °C for 1 h under N2. To the mixture was added TosCl (28.41 mg, 149.04 μmol, 0.5 eq) and stirred at 0 °C for 0.5 h under N2. LCMS showed a peak (7%) with desired mass. The mixture was quenched by sat. aq. NH4Cl (20 mL), extracted with ethyl acetate (20 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-TLC (SiO2, Petroleum ether : Ethyl acetate = 2:1) to afford tert- butyl 3-(8-chloro-9-fluoro-1,3-dihydrofuro[3,4-c][2,7]naphthyridin-5-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (10 mg, 17.48 μmol, 5.86% yield, 76% purity) as a white solid. MS (ES+) C21H24N4O3ClF requires: 434, found: 435 [M+H]+Step 5 tert-butyl 3-[9-fluoro-8-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1,3-dihydrofuro[3,4-c][2,7]naphthyridin-5-yl]-3,8-diazabicyclo[3.2.1]octane- 8-carboxylate

[0458] To a solution of tert-butyl 3-(8-chloro-9-fluoro-1,3-dihydrofuro[3,4- c][2,7]naphthyridin-5-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10 mg, 22.99 μmol, 1 eq) in THF (0.4 mL) were added 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl-triisopropyl-silane (17.68 mg, 34.49 μmol, 1.5 eq), K3PO4(1.5 M, 45.99 μL, 3 eq) and cataCXium® A Pd G3(1.67 mg, 2.30 μmol, 0.1 eq), the mixture was stirred at 60 °C for 16 h under N2. LCMS showed a peak (36%) with desired mass. The mixture was quenched with sat. aq. NH4Cl (10 mL) and extracted with ethyl acetate (10 mL x 3), then dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-TLC (SiO2, Petroleum ether : Ethyl acetate = 3:1) to afford tert-butyl 3-[9-fluoro-8-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-1,3-dihydrofuro[3,4-c][2,7]naphthyridin-5-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (10 mg, 12.23 μmol, 53.18% yield, 96% purity) as a pink solid. MS (ES+) C44H54F2N4O5Si requires: 784, found: 785 [M+H]+Step 6 tert-butyl 3-[8-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-9-fluoro-1,3- dihydrofuro[3,4-c][2,7]naphthyridin-5-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0459] To a solution of tert-butyl 3-[9-fluoro-8-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-1,3-dihydrofuro[3,4-c][2,7]naphthyridin-5-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (10 mg, 12.74 μmol, 1 eq) in DMF (0.5 mL) wasadded CsF (7.74 mg, 50.96 μmol, 1.88 μL, 4 eq), and the mixture was stirred at 30 °C for 1 h. LCMS showed a peak (93%) with the desired mass. The mixture was diluted with ethyl acetate (10 mL), washed with brine (10 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum to afford tert-butyl 3-[8-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-9-fluoro-1,3-dihydrofuro[3,4-c][2,7]naphthyridin-5-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (15 mg, crude) as a yellow solid. MS (ES+) C35H34N4F2O5 requires: 628, found: 629 [M+H]+Step 7 4-[5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-9-fluoro-1,3-dihydrofuro[3,4- c][2,7]naphthyridin-8-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol

[0460] To a solution of tert-butyl 3-[8-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-9-fluoro-1,3-dihydrofuro[3,4-c][2,7]naphthyridin-5-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (15 mg, 23.86 μmol, 1 eq) in DCM (0.6 mL) was added TFA (307.00 mg, 2.69 mmol, 0.2 mL), the mixture was stirred at 30 °C for 1 h. LCMS showed a peak (78%) with the desired mass. The mixture was quenched by sat. aq. NaHCO3 (10 mL), extracted with ethyl acetate (10 mL x 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um; mobile phase: [water(FA)-ACN]; gradient:14%-44% B over 2 min) and lyophilized to afford 4-[5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-9-fluoro-1,3- dihydrofuro[3,4-c][2,7]naphthyridin-8-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (1 mg, 1.88 μmol, 7.90% yield, 100% purity, FA) as a yellow solid.

[0461] MS (ES+) C28H22N4F2O2requires: 484, found: 485 [M+H]+

[0462] 1H NMR (400 MHz, CD3OD) δ = 9.30 (s, 1H), 8.52 (s, 1H), 7.98 - 7.81 (m, 1H), 7.43 - 7.30 (m, 2H), 7.28 - 7.23 (m, 1H), 5.47 (s, 2H), 5.09 (s, 2H), 4.17 - 3.98 (m, 4H), 3.75 - 3.60 (m, 2H), 3.27(s, 1H), 2.48 - 3.32 (m, 2H), 2.25 - 2.10 (m, 2H). EXAMPLE 1575-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-9- fluoro-2-methyl-1H-pyrrolo[3,4-c][2,7]naphthyridin-3-one Step 1 methyl 4-[tert-butoxycarbonyl(methyl)amino]but-2-ynoate

[0463] To a solution of tert-butyl N-methyl-N-prop-2-ynyl-carbamate (11 g, 65.00 mmol, 1.1 eq) in THF (110 mL) was added dropwise n-BuLi (2.5 M, 26.00 mL, 1.1 eq) at -78 °C over 0.5 h. After addition, the mixture was stirred at 20 °C for 0.5 h, and then methyl carbonochloridate (6.830 g, 72.28 mmol, 5.58 mL, 1.22 eq) in THF (60 mL) was added dropwise at -78 °C. The resulting mixture was stirred at -78 °C for 0.5 h, then it was allowed to slowly warm up to 20 °C. The reaction mixture was quenched with ice water (400 mL) at 0 °C and extracted with ethyl acetate (400 mL x 3). The combined organic layers were washed with brine (300 mL x 3), dried over (Na2SO4), filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford methyl 4-[tert-butoxycarbonyl(methyl)amino]but-2-ynoate (4.8 g, 21.12 mmol, 35.74% yield) as a yellow oil.

[0464] 1H NMR (400 MHz, CDCl3) δ = 4.27 - 4.12 (m, 2H), 3.78 (s, 3H), 2.93 (s, 3H), 1.47 (s, 9H). Step 2 methyl 4-[[tert-butoxycarbonyl(methyl)amino]methyl]-6-chloro-5-fluoro-1-oxo-2H-2,7- naphthyridine-3-carboxylate

[0465] To a solution of [(6-chloro-5-fluoro-pyridine-3-carbonyl)amino] 2,2- dimethylpropanoate (1 g, 3.64 mmol, 1 eq) in MeOH (10 mL) were added cesium acetate (174.71 mg, 910.16 μmol, 0.25 eq), methyl 4-[tert-butoxycarbonyl(methyl)amino]but-2- ynoate (1.65 g, 7.28 mmol, 2 eq) and pentamethylcyclopentadienyl rhodium dichloride dimer (107.01 mg, 182.03 μmol, 0.05 eq). The mixture was stirred at 60 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was triturated with (MeOH 5 mL) at 0 °C for 30 min to afford methyl 4-[[tert- butoxycarbonyl(methyl)amino]methyl]-6-chloro-5-fluoro-1-oxo-2H-2,7-naphthyridine-3- carboxylate (1.2 g, 3.00 mmol, 82.44% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) δ = 12.39 (s, 1H), 9.05 (s, 1H), 4.55 (s, 2H), 3.89 (s, 3H), 2.59 (s, 3H), 1.41 (s, 9H) Step 3 methyl 1-(8-tert-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-[[tert- butoxycarbonyl(methyl)amino]methyl]-6-chloro-5-fluoro-2,7-naphthyridine-3- carboxylate

[0466] To a solution of methyl 4-[[tert-butoxycarbonyl(methyl)amino]methyl]-6-chloro- 5-fluoro-1-oxo-2H-2,7-naphthyridine-3-carboxylate (800 mg, 2.00 mmol, 1 eq) in DCM (15 mL) were added DIEA (1.29 g, 10.00 mmol, 1.74 mL, 5 eq) and Tf2O (1.13 g, 4.00 mmol, 660.30 μL, 2 eq) at 0 °C. The mixture was stirred at 25 °C for 1 h. DIEA (517.22 mg, 4.00 mmol, 697.06 μL, 2 eq) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (509.75mg, 2.40 mmol, 1.2 eq) were added. The mixture was stirred at 25 °C for 0.5 h. LCMS showed a peak with desired mass. The reaction mixture was quenched by addition water (30 mL) at 0 °C, and then extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (20 mL x 5), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 20 mL / min) to afford methyl 1-(8-tert-butoxycarbonyl- 3,8-diazabicyclo[3.2.1]octan-3-yl)-4-[[tert-butoxycarbonyl(methyl)amino]methyl]-6-chloro- 5-fluoro-2,7-naphthyridine-3-carboxylate (1 g, 1.62 mmol, 80.76% yield, 96% purity) as a yellow oil.

[0467] MS (ES+) C28H37ClFN5O6 requires: 593, found: 594 [M+H]+. Step 4 tert-butyl 3-(8-chloro-9-fluoro-2-methyl-3-oxo-1H-pyrrolo[3,4-c][2,7]naphthyridin-5- yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0468] To a solution of methyl 1-(8-tert-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octan-3- yl)-4-[[tert-butoxycarbonyl(methyl)amino]methyl]-6-chloro-5-fluoro-2,7-naphthyridine-3- carboxylate (400.00 mg, 673.32 μmol, 1 eq) in DCM (2 mL) was added TFA (921.00 mg, 8.08 mmol, 0.6 mL, 12.00 eq). The mixture was stirred at 20 °C for 0.5 h. The reaction mixture was concentrated under reduced pressure to a yellow oil. The oil was diluted with MeCN (5 mL) and TEA (266.31 mg, 2.63 mmol, 366.32 μL, 5 eq). The mixture was stirred at 60 °C for 16 hr. Then Boc2O (344.63 mg, 1.58 mmol, 362.77 μL, 3 eq) was added at 20 °C. The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was triturated with solvent (Petroleum ether : Ethyl acetate= 1 : 1) (5 mL) at 20 °C for 1 h to afford tert-butyl 3-(8-chloro-9-fluoro-2- methyl-3-oxo-1H-pyrrolo[3,4-c][2,7]naphthyridin-5-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate (250 mg, 487.10 μmol, 92.54% yield, 90% purity) as a yellow solid.

[0469] MS (ES+) C22H25ClFN5O3requires: 461, found: 462 [M+H]+. Step 5 tert-butyl 3-[8-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-9-fluoro-2-methyl- 3-oxo-1H-pyrrolo[3,4-c][2,7]naphthyridin-5-yl]-3,8-diazabicyclo[3.2.1]octane-8- carboxylate

[0470] A mixture of tert-butyl 3-(8-chloro-9-fluoro-2-methyl-3-oxo-1H-pyrrolo[3,4- c][2,7]naphthyridin-5-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (200.00 mg, 432.98 μmol, 1 eq), 2-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (185.07 mg, 519.57 μmol, 1.2 eq), CataCXium A Pd G3(63.07 mg, 86.60 μmol, 0.2 eq), and K3PO4 (1.5 M, 865.96 μL, 3 eq) in THF (4 mL) was degassed and purged with N2for 3 times, and then the mixture was stirred at 60 °C for 16 h under N2atmosphere. The reaction mixture was diluted with water (10 mL) and extracted with Ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (20 mL x 5), dried over (Na2SO4), filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO2, Petroleum ether : Ethyl acetate = 0:1) and repurified by prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um; mobile phase: [water (FA) -ACN];gradient:54%-84% B over 10 min) to afford tert-butyl 3-[8-[8-ethynyl-7-fluoro- 3-(methoxymethoxy)-1-naphthyl]-9-fluoro-2-methyl-3-oxo-1H-pyrrolo[3,4- c][2,7]naphthyridin-5-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (110 mg, 167.76 μmol, 38.75% yield, crude) as a yellow oil. MS (ES+) C36H35F2N5O5requires: 655, found: 656 [M+H]+. Step 6 5-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-9- fluoro-2-methyl-1H-pyrrolo[3,4-c][2,7]naphthyridin-3-one

[0471] To a solution of tert-butyl 3-[8-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-9-fluoro-2-methyl-3-oxo-1H-pyrrolo[3,4-c][2,7]naphthyridin-5-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate (30.00 mg, 45.75 μmol, 1 eq) in DCM (1 mL) was added TFA (460.50 mg, 4.04 mmol, 0.3 mL, 88.27 eq). The mixture was stirred at 25 °C for 0.5 h. LCMS showed a peak (58%) with desired mass. The reaction mixture was diluted with NaHCO3 solution (10 mL) and extracted with Ethyl acetate : THF = 1:1 (10 mL x 5) dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25 mm* 10um; mobile phase: [water (FA) -ACN]; gradient:14%-44% B over 10 min) and lyophilized to afford 5- (3,8-diazabicyclo[3.2.1]octan-3-yl)-8-(8-ethynyl-7-fluoro-3-hydroxy-1-naphthyl)-9-fluoro-2- methyl-1H-pyrrolo[3,4-c][2,7]naphthyridin-3-one (3.1 mg, 5.45 μmol, 11.91% yield, 98% purity, FA) as a red solid.

[0472] MS (ES+) C29H23F2N5O2requires: 511, found: 512 [M+H]+.

[0473] 1H NMR (400 MHz, CD3OD) δ = 9.41 (s, 1H), 8.38 (s, 1H), 7.95 - 7.86 (m, 1H), 7.45 - 7.26 (m, 3H), 4.97 - 4.93 (m, 2H), 4.32 - 4.18 (m, 4H), 3.85 - 3.71 (m, 2H), 3.30 - 3.28 (m, 4H), 2.50 - 2.38 (m, 2H), 2.30 - 2.12 (m, 2H).4-[8-(3-azabicyclo[3.1.0]hexan-6-yl)-4-fluoro-5,6-dimethyl-2,7-naphthyridin-3-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 6-(6-chloro-5-fluoro-3,4-dimethyl-2,7-naphthyridin-1-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate

[0474] A mixture of 1-bromo-6-chloro-5-fluoro-3,4-dimethyl-2,7-naphthyridine (300 mg, 1.04 mmol, 1 eq) , tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (160.19 mg, 518.08 μmol, 0.5 eq), CataCXium A Pd G3 (75.46 mg, 103.62 μmol, 0.1 eq), and K3PO4 (1.5 M, 2.07 mL, 3 eq) in THF (8 mL) was degassed and purged with N2for 3 times, and then the mixture was stirred at 60 °C for 1 h under N2 atmosphere. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL) dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 30 mL / min) to afford tert-butyl 6-(6-chloro-5-fluoro-3,4-dimethyl-2,7-naphthyridin-1-yl)-3- azabicyclo[3.1.0]hexane-3-carboxylate (210 mg, 455.51 μmol, 43.96% yield, 85% purity) as a yellow oil. MS (ES+) C20H23ClFN3O2 requires: 391, found: 392 [M+H]+. Step 2 tert-butyl 6-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-3,4-dimethyl-2,7-naphthyridin-1-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0475] A mixture of tert-butyl 6-(6-chloro-5-fluoro-3,4-dimethyl-2,7-naphthyridin-1-yl)- 3-azabicyclo[3.1.0]hexane-3-carboxylate (170 mg, 433.82 μmol, 1 eq), 2-[2-fluoro-6- (methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]ethynyl- triisopropyl-silane (333.52 mg, 650.73 μmol, 1.5 eq), CataCXium A Pd G3 (63.19 mg, 86.76 μmol, 0.2 eq) and K3PO4(1.5 M, 867.64 μL, 3 eq) in THF (3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 60 °C for 16 h under N2 atmosphere. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (10 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate / Petroleum ether gradient @ 20 mL / min). to afford tert-butyl 6-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-3,4-dimethyl-2,7-naphthyridin-1-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (140 mg, 188.68 μmol, 43.49% yield) as a yellow oil. MS (ES+) C43H53F2N3O4Si requires: 741, found: 742 [M+H]+. Step 3 tert-butyl 6-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-3,4- dimethyl-2,7-naphthyridin-1-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate

[0476] To a solution of tert-butyl 6-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2- triisopropylsilylethynyl)-1-naphthyl]-3,4-dimethyl-2,7-naphthyridin-1-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (120 mg, 161.73 μmol, 1 eq) in DMF (0.5 mL) was added CsF (122.83 mg, 808.65 μmol, 29.85 μL, 5 eq). The mixture was stirred at 25 °C for 1 h. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (10mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl 6-[6-[8-ethynyl- 7-fluoro-3-(methoxymethoxy)-1-naphthyl]-5-fluoro-3,4-dimethyl-2,7-naphthyridin-1-yl]-3- azabicyclo[3.1.0]hexane-3-carboxylate (90 mg, 153.68 μmol, 95.02% yield) as a brown solid. MS (ES+) C34H33F2N3O4 requires: 585, found: 586 [M+H]+. Step 4 4-[8-(3-azabicyclo[3.1.0]hexan-6-yl)-4-fluoro-5,6-dimethyl-2,7-naphthyridin-3-yl]-5- ethynyl-6-fluoro-naphthalen-2-ol

[0477] To a solution of tert-butyl 6-[6-[8-ethynyl-7-fluoro-3-(methoxymethoxy)-1- naphthyl]-5-fluoro-3,4-dimethyl-2,7-naphthyridin-1-yl]-3-azabicyclo[3.1.0]hexane-3- carboxylate (90 mg, 153.68 μmol, 1 eq) in DCM (2 mL) was added TFA (921.00 mg, 8.08 mmol, 0.6 mL, 52.56 eq). The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was diluted with NaHCO3 (10 mL) and extracted with a solution of ethyl acetate : THF = 1:1 (20 mL x 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18150*25mm* 10um;mobile phase: [water (FA) -ACN]; gradient: 18%- 48% B over 10 min) and lyophilized to afford 4-[8-(3-azabicyclo[3.1.0]hexan-6-yl)-4-fluoro- 5,6-dimethyl-2,7-naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol (7.8 mg, 15.68 μmol, 10.20% yield, 98% purity, FA) as a white solid.

[0478] MS (ES+) C27H21F2N3O requires: 441, found: 442 [M+H]+.

[0479] 1H NMR (400 MHz, CD3OD) δ = 9.51 (s, 1H), 8.53 (s, 1H), 7.92 - 7.85 (m, 1H), 7.40 - 7.30 (m, 2H), 7.27 - 7.21 (m, 1H), 3.71 - 3.64 (m, 2H), 3.61 - 3.54 (m, 2H), 3.13 (s, 1H), 3.06 - 3.00 (m, 1H), 2.72 - 2.58 (m, 8H). EXAMPLE 1594-[8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-fluoro-6-methyl-5-(trifluoromethyl)-2,7- naphthyridin-3-yl]-5-ethynyl-6-fluoro-naphthalen-2-ol Step 1 tert-butyl 3-[6-chloro-5-fluoro-3-methyl-4-(trifluoromethyl)-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate Boc

[0480] To a solution of tert-butyl 3-(6-chloro-5-fluoro-4-iodo-3-methyl-2,7-naphthyridin- 1-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (100 mg, 187.70 μmol, 1 eq) in DMF (2 mL) were added CuI (71.49 mg, 375.39 μmol, 2 eq) and methyl 2,2-difluoro-2- fluorosulfonyl-acetate (108.18 mg, 563.09 μmol, 71.64 μL, 3 eq) at 20 °C under N2. The mixture was stirred at 100 °C for 5 h. LCMS showed a peak (60 %) with the desired mass. The mixture was diluted with water (5 mL), then extracted with ethyl acetate (10 mL x 3), washed with brine (5 mL x 3), the combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-TLC (SiO2, Petroleum ether : Ethyl acetate = 2:1) to afford tert-butyl 3-[6-chloro-5-fluoro-3-methyl-4-(trifluoromethyl)-2,7-naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (60 mg, 122.56 μmol, 65.30% yield, 97% purity) as yellow solid. MS (ES+) C21H23N4F4ClO2 requires: 474, found: 475[M+H]+Step 2 tert-butyl 3-[5-fluoro-6-[7-fluoro-3-(methoxymethoxy)-8-(2-triisopropylsilylethynyl)-1- naphthyl]-3-methyl-4-(trifluoromethyl)-2,7-naphthyridin-1-yl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylate

[0481] To a solution of tert-butyl 3-[6-chloro-5-fluoro-3-methyl-4-(trifluoromethyl)-2,7- naphthyridin-1-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (60 mg, 126.35 μmol, 1 eq) in THF (1 mL) were added 2-[2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl...

Claims

CLAIMS What is claimed is:

1. A compound of Formula III,or a salt thereof, wherein J1is chosen from N and CCl; Z is chosen from benzothiophene, tetrahydrobenzothiophene, pyridinyl, benzoindazolyl, quinolinyl, and isoquinolinyl, any of which may be optionally substituted by one or more groups chosen from alkyl, alkynyl, amino, hydroxyl, cyano, haloalkyl, and halo; ORR1is chosen from OH and NH2; R2is chosen from H and halo; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl;A is chosen from -OCH2-, -OCH2CH2-, -OC(CH3)CH-, heterocycloalkyl, and a bond; X is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8;R4is chosen from H, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, heteroaryloxy, alkoxy, amino, alkylamino, dialkylamino, -C(O)OR10, alkylthio, and halo, wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkoxy, heterocycloalkyl, heterocycloalkoxy, amido, aryl, heteroaryl, heteroaryloxy, alkoxy, amino, and alkylthio may be optionally substituted with one or more R5; OR A, R4, and R7combine to form a 5- membered heterocycloalkyl optionally substituted with one or more R5; each R5is independently chosen from alkyl, cycloalkyl, aryl, haloalkoxy, haloalkenyl, amino, alkylamino, dialkylamino, hydroxyalkylamino, alkyl sulfonyl, - C(O)OR10, heterocycloalkyl, hydroxyl, alkoxy, oxo, cyano, and halo, or two R5may combine to form a cycloalkyl or heterocycloalkyl; R6is chosen from H, alkyl, acyl, and heterocycloalkylalkyl; R7is chosen from alkyl, cycloalkyl, alkynyl, halo, amino, and cyano, wherein alkyl, cycloalkyl, and alkynyl may be optionally substituted with one or more R9; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; each R9is independently chosen from deuterium, alkyl, amino, alkyl sulfonyl, hydroxyl, alkoxy, cyano, and halo; R10is chosen from H and C1-6alkyl; R11is halo; OR R7and R11may combine to form a 6-membered heterocycloalkyl; each R12is independently chosen from halo and alkynyl; n is chosen from 0, 1, and 2; and m is chosen from 1 and 2.

2. The compound of claim 1, or a salt thereof, wherein Z is chosen from benzothiophene, tetrahydrobenzothiophene, pyridinyl, benzoindazolyl, and isoquinolinyl, any of which may be optionally substituted by one, two, or three groups chosen from alkyl, alkynyl, amino, hydroxyl, cyano, haloalkyl, and halo.

3. The compound of claim 2, or a salt thereof, wherein Z is chosen from benzothiophene and tetrahydrobenzothiophene, either of which may be optionally substituted by two or three groups chosen from fluoro, cyano, and amino.

4. The compound of claim 3, or a salt thereof, wherein Z is pyridinyl optionally substituted by two or three groups chosen from alkyl, haloalkyl, and amino.

5. The compound of claim 3, or a salt thereof, wherein Z is isoquinolinyl optionally substituted by three groups chosen from fluoro, alkynyl, hydroxyl, and amino.

6. The compound of claim 1, or a salt thereof, wherein Z is chosen from 2-amino- 3-cyano-7-fluorobenzo[b]thiophene, 2-amino-3-cyano-4,5,6,7- tetrahydrobenzo[b]thiophene, 1H-benzo[f]indazolyl, 3-amino-8-ethynyl-7- fluoroisoquinolinyl, 6-methyl-5-(trifluoromethyl)2-aminopyridinyl, 4-methyl-5- (trifluoromethyl)2-aminopyridinyl, and 5-(trifluoromethyl)2-aminopyridinyl.

7. The compound of claim 1, or a salt thereof, wherein.

8. The compound of claim 7, or a salt thereof, wherein each R12is independently chosen from fluoro, bromo, and alkynyl.

9. The compound of claim 7, or a salt thereof, wherein m is 1.

10. The compound of claim 7, or a salt thereof, wherein m is 2.

11. The compound of claim 7, or a salt thereof, wherein m is 3.

12. The compound of claim 7, or a salt thereof, wherein Z is chosen from 5-ethynyl- 6-fluoronaphthalen-2-ol, 5-ethynyl-8-fluoronaphthalen-2-ol, 5- ethynylnaphthalen-2-ol, 5-bromo-6-fluoronaphthalen-2-ol, 5-bromonaphthalen- 2-ol, and 2-amino-3-fluoronaphthalenyl.

13. The compound of any one of claims 1 to 12, or a salt thereof, wherein Q is14. The compound of claim 13, wherein15. The compound of claim 1, having a structure of Formula I:salt thereof.

16. The compound of any one of claims 1 to 15, or a salt thereof, wherein J1is CCl.

17. The compound of any one of claims 1 to 15, or a salt thereof, wherein J1is N.

18. The compound of any one of claims 1 to 17, wherein R1is OH.

19. The compound of any one of claims 1 to 17, wherein R1is NH2.

20. The compound of any one of claims 1 to 19, or a salt thereof, wherein R2is H.

21. The compound of any one of claims 1 to 19, or a salt thereof, wherein R2is fluoro.

22. The compound of any one of the preceding claims, or a salt thereof, wherein R3is H.

23. The compound of any one of claims 1 to 21, or a salt thereof, wherein R3is OCH3.

24. The compound of any one of the preceding claims, or a salt thereof, wherein R6is chosen from H and oxetanylmethyl.

25. The compound of claim 24, or a salt thereof, wherein R6is H.

26. The compound of any one of the preceding claims, or a salt thereof, wherein X is -CH2CH2-.

27. The compound of any one of claims 1 to 25, or a salt thereof, wherein X is - CH=CH-.

28. The compound of any one of claims 1 to 25, or a salt thereof, wherein X is - CH2-O-CH2-.

29. The compound of any one of the preceding claims, or a salt thereof, wherein n is 1.

30. The compound of claim 29, or a salt thereof, wherein R8is hydroxyl.

31. The compound of claim 29, or a salt thereof, wherein R8is methyl.

32. The compound of claim 29, or a salt thereof, wherein R8is fluoro.

33. The compound of claim 29, or a salt thereof, wherein R8is cyano.

34. The compound of claim 29, or a salt thereof, wherein R8is -CH2OH.

35. The compound of any one of the preceding claims, or a salt thereof, wherein A is -OCH2-.

36. The compound of any one of claims 1 to 34, or a salt thereof, wherein A is - OCH2CH2-.

37. The compound of any one of claims 1 to 34, or a salt thereof, wherein A is - OC(CH3)CH-.

38. The compound of any one of claims 1 to 34, or a salt thereof, wherein A is a bond.

39. The compound of any one of the preceding claims, or a salt thereof, wherein R4is chosen from H, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkoxy, 5- to 7-membered heteroaryl, cyano, fluoro, chloro, - C(O)OCH3, C1-5alkyl, C2-6alkynyl, C3-7cycloalkoxy, C-amido, N-amido, and C3-7 cycloalkyl, wherein 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkoxy, 5- to 7-membered heteroaryl, C1-5alkyl, C3-7cycloalkoxy, C- amido, N-amido, and C3-7 cycloalkyl may be optionally substituted by one, two, or three R5.

40. The compound of claim 39, or a salt thereof, wherein R4is chosen from H, methyl, propyl, butyl, isobutyl, isopentyl, chloro, cyano, cyclopropyl, cyclobutyl, ethynyl, azetidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, pyridinyl, oxetanyl, and oxazolyl, wherein methyl, propyl, isopropyl, butyl, isobutyl, isopentyl, cyclopropyl, cyclobutyl, ethynyl, azetidinyl, pyrrolidinyl, pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, imidazolyl, piperazinyl, piperidinyl, pyridinyl, oxetanyl and oxazolyl, any of which may be optionally substituted by one, two, or three R5.

41. The compound of claim 39, or a salt thereof, wherein R4isoptionally substituted by one, two, or three R5.

42. The compound of any one of claims 1 to 34, wherein A, R4, and R7form a 5- membered heterocycloalkyl chosen from dihydropyrrole, dihydrofuran, either of which may be optionally substituted by one, two, or three R5.

43. The compound of any one of the preceding claims, or a salt thereof, wherein each R5is independently chosen from methyl, phenyl, pyridinyl, -NH2, - C(O)OCH3, -C(O)OCH2CH3, cyano, trifluoroalkoxy, fluoromethylene, dimethylamino, morpholinyl, oxo, hydroxyl, and fluoro, or two R5may combine to form cyclopropyl, oxetanyl, or 2-azaspiro[3.3]heptanyl.

44. The compound of any one of the preceding claims, or a salt thereof, wherein R7is chosen from C1-5alkyl, C3-7cycloalkyl, cyano, halo, amino, and C2-6alkynyl, wherein C1-5 alkyl, C3-7 cycloalkyl, and C2-6 alkynyl may be optionally substituted by one, two, or three R9.

45. The compound of claim 44, or a salt thereof, wherein R7is methyl, optionally substituted by one, two, or three R9.

46. The compound of claim 44, or a salt thereof, wherein R7is cyano.

47. The compound of claim 44, or a salt thereof, wherein R7is cyclopropyl, optionally substituted by one or two R9.

48. The compound of claim 44, or a salt thereof, wherein R7is ethynyl, optionally substituted by one R9.

49. The compound of any one of claims 44 to 48, or a salt thereof, wherein each R9is independently chosen from deuterium, hydroxyl and fluoro.

50. The compound of claim 44, or a salt thereof, wherein R7is chosen from chloro, bromo, and iodo.

51. The compound of any one of the preceding claims, or a salt thereof, wherein R11is fluoro.

52. The compound of any one of claims 1 to 43, or a salt thereof, wherein R7and R11combine to form a pyran.

53. The compound of any one of the preceding claims, or a salt thereof, wherein R10is H.

54. The compound of any one of claims 1 to 52, or a salt thereof, wherein R10is methyl or ethyl.

55. The compound of claim 1, or a salt thereof, wherein the compound is chosen fromH;5or a salt thereof, wherein J1is chosen from N and CR6; J2is chosen from N and CR7; Q is chosen fromZ is chosen fromX is chosen from -CH2CH2-, -CH2-O-CH2-, and -CH=CH-, any of which may be optionally substituted with one or more R8;R1is chosen from -OH, alkoxy, and amino; R2is alkyl; R3is chosen from H, alkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, heteroaryloxy, halo, alkylthio, and alkyl sulfonyl; R4is chosen from H, halo, alkyl, alkoxy, and benzyloxy; R5is chosen from H and halo; R6is chosen from H, cyano, halo, and alkyl; R7is chosen from H and halo; each R8is independently chosen from alkyl, cyano, halo, hydroxyl, and - CH2OH; and n is chosen from 0, 1, or 2.

57. The compound of claim 56, or a salt thereof, wherein.

58. The compound of claim 56 or 57, or a salt thereof, wherein X is -CH2CH2-.

59. The compound of claim 56 or 57, or a salt thereof, wherein X is -CH=CH-.

60. The compound of claim 56 or 57, or a salt thereof, wherein X is -CH2-O-CH2-.

61. The compound of claim 56 or 57, or a salt thereof, wherein n is 0.

62. The compound of claim 56, or a salt thereof, wherein.

63. The compound of claim 56, having the structure of Formula II:salt thereof.

64. The compound of any one of claims 56 to 63, or a salt thereof, wherein J1is N.

65. The compound of any one of claims 56 to 63, or a salt thereof, wherein J1is CR6.

66. The compound of claim 65, or a salt thereof, wherein R6is chosen from H, cyano, chloro, and methyl.

67. The compound of claim 65, or a salt thereof, wherein R6is H.

68. The compound of any one of claims 56 to 67, or a salt thereof, wherein J2is N.

69. The compound of any one of claims 56 to 67, or a salt thereof, wherein J2is CR7.

70. The compound of claim 69, or a salt thereof, wherein R7is chosen from H, fluoro, and bromo.

71. The compound of any one of claims 56 to 70, or a salt thereof, wherein R1is chosen from -OH, methoxy, and -NH2.

72. The compound of any one of claims 56 to 70, or a salt thereof, wherein R1is - OH.

73. The compound of any one of claims 56 to 70, or a salt thereof, wherein R2is methyl.

74. The compound of any one of claims 56 to 70, or a salt thereof, wherein R2is ethyl.

75. The compound of any one of claims 56 to 74, or a salt thereof, wherein R3is chosen from H, cyclobutoxy, cyclopropoxy, cyclopentoxy, methoxy, ethoxy, isopropoxy, isopropylthio, phenoxy, pyridinyloxy, trifluoromethoxy, methyl sulfonyl, methyl, chloro, and fluoro.

76. The compound of claim 75, or a salt thereof, wherein R3is H.

77. The compound of any one of claims 56 to 76, or a salt thereof, wherein R4is chosen from H and fluoro.

78. The compound of any one of claims 56 to 77, or a salt thereof, wherein R5is chosen from H and fluoro.

79. The compound of claim 56, or a salt thereof, wherein the compound is chosen from; ; ;.

80. A pharmaceutical composition comprising a compound as recited in any one of claims 1 to 79, or a salt thereof, together with a pharmaceutically acceptable carrier.

81. The pharmaceutical composition as recited in claim 80, formulated for oral administration.

82. The pharmaceutical composition as recited in claim 80 or 81, additionally comprising another therapeutic agent.

83. A method of inhibition of NRAS G12D, comprising contacting NRAS G12D with a compound as recited in any one of claims 1 to 79, or a salt thereof, or a pharmaceutical composition as recited in any one of claims 80 to 82.

84. A method of treatment of an NRAS G12D-mediated disease, comprising the administration of a therapeutically effective amount of a compound as recited in any one of claims 1 to 79, or a salt thereof, or a pharmaceutical composition as recited in any one of claims 80 to 82, to a patient in need thereof.

85. The method as recited in claim 84, wherein the NRAS G12D-mediated disease is cancer.

86. The method as recited in claim 85, wherein the cancer is chosen from Melanoma, Malignant Solid Tumors, Colorectal Carcinoma, Non-Small Cell Lung Carcinoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes,Chronic Myelomonocytic Leukemia, Colorectal Adenocarcinoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Pancreatic Carcinoma, Cutaneous Melanoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Acute Lymphoblastic Leukemia, Thyroid Gland Carcinoma, Glioma, Neurofibromatosis, Poorly Differentiated Thyroid Gland Carcinoma, Myelodysplastic Syndrome With Excess Blasts, Juvenile Myelomonocytic Leukemia, Histiocytic And Dendritic Cell Neoplasm, Head And Neck Squamous Cell Carcinoma, Small Cell Lung Carcinoma, Low Grade Glioma, Squamous Cell Lung Carcinoma, Breast Carcinoma, Chronic Myelomonocytic Leukemia, Thyroid Gland Undifferentiated (Anaplastic) Carcinoma, Embryonal Rhabdomyosarcoma, Thyroid Gland Follicular Carcinoma, T-Cell Acute Lymphoblastic Leukemia, Mucosal Melanoma, Low Grade Ovarian Serous Adenocarcinoma, Thyroid Gland Papillary Carcinoma, Refractory Anemia With Excess Blasts, Myeloid Neoplasm, Myelodysplastic / Myeloproliferative Neoplasm, Rectal Carcinoma, Colon Carcinoma, Malignant Peripheral Nerve Sheath Tumor, Cholangiocarcinoma, Endometrial Carcinoma, Mantle Cell Lymphoma, Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome, Lymphoma, Neuronal And Mixed Neuronal-Glial Tumors, Ganglioglioma, Soft Tissue Sarcoma, Bladder Carcinoma, Esophageal Carcinoma, Sarcoma, Thymic Carcinoma, Lung Adenocarcinoma, Lung Carcinoma, Uveal Melanoma, Head And Neck Carcinoma, Diffuse Glioma, Squamous Cell Carcinoma, Chronic Myeloid Leukemia, Adenocarcinoma of the Gastroesophageal Junction, Glioblastoma, Neuroblastoma, Astrocytic Tumor, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Anaplastic Astrocytoma, Gastric Adenocarcinoma, Gastric Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, B-Cell Acute Lymphoblastic Leukemia, Double-Hit Lymphoma, Dysembryoplastic Neuroepithelial Tumor, Gangliocytoma, Low-Grade Neuroepithelial Tumor, Peripheral T-Cell Lymphoma, Pilocytic Astrocytoma, Pilomyxoid Astrocytoma, Rhabdoid Tumor, and Schwannoma.

Citation Information

Patent Citations

  • Hetero-bicyclic inhibitors of kras

    US20220389033A1

  • KRAS inhibitors for treating cancers

    WO2021169990A1

  • HTT modulators for treating huntington's disease

    WO2021231571A1

  • Bridged compounds as KRAS g12d inhibitor and degrader and the use thereof

    WO2022148421A1

  • KRAS inhibitors and their use

    WO2023173014A1